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CHAPTER 1: Introduction 
Acute respiratory infections (ARIs) remain the leading cause of both morbidity and 
mortality throughout the world, causing approximately 4.25 million worldwide deaths each year 
and contributing to 6% of the world’s disability and death.1,2 These infections affect a wide range 
of the population, including healthy adults as well as immunocompromised individuals, children, 
and the elderly.1 The past ten years has seen a rise in the emergence of ARIs including the 
SARS outbreak of 2002-2003, the surge in multi-drug resistant tuberculosis in 2008, and the 
2009 H1N1 influenza pandemic (Table 1.1).  
Influenza is a key respiratory pathogen that contributes up to 500,000 deaths annually. 2 
Influenza A, specifically, can be more problematic when compared to influenza B and C due to 
its increased mutation rate.1 While all influenza viruses go through antigenic drift, or slow 
changes in epitope presentation due to point mutations and error-prone RNA polymerases, 
influenza A is the only class capable of antigenic shift, or re-assortment of the virus.1,2 The 
reservoir of influenza A is waterfowl; however, the viruses have been known to infect humans, 
swine, and other mammals.1, 2 Re-assortment of the virus, typically in swine susceptible to both 
avian and human influenza strains, leads to antigenic shift and possibly creates influenza 
pandemics in a naïve human population.   
Avian influenza A H5N1 is rapidly gaining the potential to be the next influenza pandemic 
threat.3-5 Human cases of H5N1 have proven to be approximately 60% fatal with a growing 
number of strains becoming resistant to medical treatments such as oseltamivir (Tamiflu).6,7 Due 
to the severe pathology associated with H5N1 influenza and its resistance to treatment, it has 
been referred to as highly pathogenic avian influenza (HPAI). 
Currently, the infection of HPAI is mainly spread from avian species to humans and 
rarely from human to human. However, due to the HPAI strain’s ability to achieve viral mutations 
at an extremely rapid rate and ability to be weaponized, many scientists believe that human-to-
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human transmission of the virus is imminent, unleashing a possible influenza pandemic across 
the globe.3-5 If such a pandemic occurs, scientists predict that the H5N1 influenza will cause an 
estimated 50 million deaths and a ten-year lifespan reduction in the U.S. alone.6 Therefore, 
there is a strong need for new research developments for both the prevention and treatment of 
HPAI.  
While the treatment of influenza is important, prevention of the disease through 
vaccination is critical especially in the event of a pandemic. The overall goal of the research 
described in this thesis is to create a safe, efficacious vaccine against H5N1 avian influenza. 
This was achieved by encapsulating H5N1 hemagglutinin (HA) antigen into a novel delivery 
platform composed of polyanhydride nanoparticles. Polyanhydrides have been known to 
possess many beneficial characteristics as vaccine adjuvants/delivery vehicles, including 
sustained antigen release, antigen stabilization, immune cell activation, and immunomodulation 
to achieve protection against infection.8,9 The thesis describes both in vitro and in vivo studies 
that are focused on the development of a next generation nanoparticle-based vaccine against 
HPAI H5N1. 
 
 
Table 1.1: ARI occurrences  in the past decade1,10-13 
  
Respiratory Infection 
 
Annual Occurrence 
Cases/year (deaths/year) 
Symptoms 
 
Pneumonia 
 
 
156 million (1.6 million) 
 
 
Cough, fever, rapid breathing, 
chest pain 
  
Influenza 
 
 
Up to 2 billion (up to 500,000) 
 
Cough, fever, runny nose, 
body aches 
 
Respiratory 
Syncytial Virus 
 
3.4 million (up to 199,000) 
Cough, fever, sneezing, 
wheezing 
 
Tuberculosis 
 
 
9 million (2 million) 
 
Cough (with blood), fever, 
sweating, chest pain 
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CHAPTER 2: Literature Review 
 As previously discussed, H5N1 avian influenza has the potential to become the next 
influenza pandemic and thus, research efforts to prevent influenza are critical. Often times, 
alternative vaccine approaches utilizing viral proteins are safer; however these proteins are 
poorly immunogenic and require the use of adjuvants to boost immunity. This chapter will begin 
by focusing on the different adjuvant strategies that have been explored in vaccine design and 
development, including the novel polyanhydride nanoparticle adjuvant/delivery platform used in 
this work (Section 2.1). Section 2.2 will discuss intranasal vaccination, which is an important 
factor in mucosal immunity and the route of immunization for this work. Section 2.3 will cover 
the molecular characteristics of H5N1 and the protective and pathogenic immune responses 
that have been observed to date. Finally, Section 2.4 will describe the current research in the 
field of influenza vaccination, covering both traditional/seasonal vaccines and the novel 
approaches used for developing pandemic vaccines.  
 
2.1.  VACCINE ADJUVANTS 
2.1.1.  Introduction 
Traditional vaccines, such as killed or live attenuated vaccines, are fairly immunogenic 
on their own.1,2 Killed vaccines consist of entire pathogens inactivated by heat or chemicals. In 
these vaccines, the pathogen cannot replicate and often has a prolonged shelf life.2 However, 
killed vaccines have several drawbacks including inflammation at the injection site, the need for 
multiple doses or “boosters” to achieve protection, and a lack of cell-mediated immunity. Live 
attenuated vaccines, although more immunogenic, also have several pitfalls with the most 
serious being replication and disease in immunocompromised patients. In a goal to increase 
safety of vaccination, many researchers have turned to DNA or subunit vaccines. These 
vaccines encode for or contain a purified protein of the pathogen, or simply put, one small piece 
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of the pathogen.1-4 While side effects due to chemical inactivators, whole, or live pathogens are 
eliminated with purified proteins, subunit vaccines are often poorly immunogenic requiring the 
use of adjuvants to achieve protection.2,4,5 
Adjuvants are materials that non-specifically enhance immune responses. When 
coupled with an antigen, adjuvants can enhance the immune response towards the desired 
protein and increase the efficacy of the vaccine.2,6,7 Adjuvants accomplish this enhancement in 
immunogenicity by performing three main functions: creating an antigen depot for sustained 
release, targeting the antigen towards antigen presenting cells (APCs), and modulating the type 
of immune responses initiated.2,6 Aside from these three functions, adjuvants can provide other 
attributes, including antigen stabilization, targeting of cellular organelles or vesicles, and 
enhancing memory recall.3,8 
Although adjuvants have been utilized for many decades, there are relatively few that 
have been approved for human use. For example, aluminum salts, often termed Alum, are one 
of two adjuvants approved for use in the United States.2,3,9 Surprisingly, even after over 70 
years of use, the adjuvanticity mechanism of Alum is just beginning to be understood. Alum 
forms a depot by adsorbing antigen to charged aluminum particles, which in turn promotes 
uptake via phagocytosis.1,10 Although studies have also suggested that Alum activates the 
inflammasome, it is a relatively weak adjuvant, producing only humoral responses.3,11 A more 
potent adjuvant, MF59 (approved in Europe), is an oil-in-water emulsion that forms small 
droplets readily internalized by APCs.4,9 Although the mechanism of MF59 is largely unclear, it 
is known to increase cross reactivity and antibody titers in seasonal influenza vaccines.1,5 MF59 
has also been known to increase early CD4+ T cell responses and to induce cytokines at the 
injection site.3 Another adjuvant, monophosphoryl lipid A (MPLA), has been recently approved 
for use with Alum in a human papilloma virus vaccine.3,9 MPLA is a non-toxic derivative of 
lipopolysaccharide (LPS), a Toll-like receptor (TLR)-4 ligand and provides immune stimulation 
through the production of the cytokines, IL-1β, IL-12, and IFN-γ.1,2 
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Although Alum, MF59, and MPLA have been shown to be useful in enhancing vaccine 
efficacy, they are by no means suitable for all vaccine applications. For example, while Alum 
has been shown to boost humoral antibody responses, it fails to stimulate cell-mediated 
immunity, an important factor in vaccines against intracellular pathogens.1,5 Thus, it is important 
for vaccine research to shift from a “one-adjuvant-fits-all” philosophy to an approach of rationally 
designing appropriate adjuvants to match the desired antigen. The size and stability of the 
antigen, route of administration, target cells, and desired immune response must be considered 
when developing new adjuvants. To fulfill these requirements, there has been a lot of attention 
devoted to the development of novel adjuvants. Despite the large number of excipients and 
immunostimulatory materials being examined, such as TLR-9 agonists and virus-like particles, 
this section will focus on biodegradable polymeric particles for use as vaccine adjuvants and 
delivery vehicles. These particles have been extensively studied as carriers for drugs, proteins, 
and vaccines, and present some compelling advantages to other adjuvant candidates.2 Table 
2.1 summarizes the various classes of biodegradable polymers that have been studies and the 
performance of these materials is discussed below.  
 
2.1.2.  Poly(esters)  
Poly(esters) are class of biodegradable polymers that have been extensively studied for 
drug delivery applications. These materials are typically composed of lactic acid, glycolic acid, 
copolymers thereof (PLGA), and poly(ε-caprolactone) (PCL). Poly(esters) can be easily formed 
into most shapes and sizes, leading to applications in degradable sutures, bone implants and 
screws, tissue scaffolds, and drug delivery.12,13 Poly(esters) are also FDA-approved for a 
number of human applications due to their lengthy safety record. 
PLGA hydrolyzes into well tolerated degradation products: lactic and glycolic acids. 
Lactic and glycolic acid are naturally found in vivo, and easily metabolized and eliminated via 
the citric acid cycle.13 Studies have also shown that lactic and glycolic acid produced from 
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degraded poly(esters) have no effect on cell function and result in minimal systemic toxicity.13,14 
Although the degradation of poly(esters) may be favorable in terms of biocompatibility, their 
mechanism of hydrolysis, bulk erosion, can attribute to challenges when encapsulating sensitive 
cargos like protein antigens.  
The bulk erosion mechanism, in which water diffusion occurs more rapidly than cleavage 
of the polymer chain, allows water penetration throughout the material before payload release, 
affecting both the release and stability of encapsulated proteins.15 Typically, the release kinetics 
of the cargo is dictated by the erosion kinetics of the polymer. In the case of poly(esters) such 
as PLGA, degradation of the polymer has been successful at sustaining release up to four 
months, and longer for the more hydrophobic PCL.12,14 Release from poly(esters) is also 
typically characterized by an initial “burst,” or large release of cargo, which signifies less control 
over both rate of release and sustained release.16  Although the rate of degradation can be 
controlled by both polymer molecular weight and copolymer composition, poly(esters) may not 
be suitable for long-term vaccine and drug delivery. 
While bulk erosion may be successful in short-term applications, the process can be 
detrimental to the payload stability. As mentioned previously, bulk erosion allows for interactions 
between water and proteins before release.  Often times, water can create instability by 
aggregating proteins, but what may be more detrimental is the acidic microenvironment created 
by polymer degradation products.12,14 Both lactic and glycolic acid are fairly acidic (pH ~2-3) and 
can cause degradation and denaturation of encapsulated proteins, thus affecting the activity and 
epitope availability of protein antigens.12,14 Additives such as amino acids and bases have been 
proposed for co-encapsulation to improve aggregation and pH respectively.12 However, the 
encapsulation of these components may be undesirable in terms of safety or other interactions. 
Despite the challenges in bulk erosion, poly(esters) have been successfully used in 
many drug delivery platforms. PCL, for example, lacks the extreme pH of other poly(esters) and 
has been successful at stabilizing the structure and immunogenicity of hemagglutinin (HA), an 
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influenza antigen.17 Encapsulation into poly(esters) also protects antigens from proteolytic 
cleavage, as well as endosomal degradation. Other adjuvant properties exemplified by 
poly(esters) include enhanced delivery to APCs, internalization, endosomal escape, and cross 
presentation.13-18  Though some studies have noted that the immune response to poly(esters) is 
similar to that of Alum, it may not be as useful in vaccine platforms and dependent on the type 
of antigen. For example, during a study encapsulating the model antigen ovalbumin (OVA), it 
was found that PLGA microparticles were not stimulatory enough for primary immunizations, but 
suitable for booster immunizations.19 Other experiments, on the other hand, have shown 
protective immunity by encapsulating tetanus toxoid.13 However, despite this variability, 
poly(esters) are good candidates for surface modification for targeting (APC vaccine, cancer 
cell drug delivery) and co-encapsulation of innate stimulators such as TLR ligands.14,15,20  
 Despite these challenges, poly(esters) remain one of the front runners in the field of 
biodegradable materials. Their enhanced immunogenicity is well suited for acid-stabilized 
antigens to survive the denaturing microenvironment created by bulk erosion. Likewise, their 
extensive safety profile and FDA approval allow for the successful application of poly(esters) to 
numerous applications ranging from degradable sutures to cancer vaccines. 
 
2.1.3.  Acid-Catalyzed Polymers 
Although poly(esters) such as PLGA are one of the most widely studied biodegradable 
polymers, it was recognized in the early 1970s that there was room for improvement in drug 
delivery vehicles.21 A new class of biodegradable materials, termed acid-catalyzed polymers, 
was developed to enable controlled drug release kinetics, targeting of intracellular components 
such as endosomes, and stabilization of payloads. Examples of acid-catalyzed polymers include 
poly(ketals), poly(acetals), poly(urethanes), and poly(ortho esters). The last category will be 
further discussed in this section. 
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 Poly(ortho esters), one of the most well-known acid-catalyzed polymers, were developed 
in the early 1970s out of a need for biodegradable materials other than PLA, PGA, and their 
copolymer, PLGA. While PLGA was making strides in terms of its applicability in sutures and 
other surgical techniques, it was recognized that PLGA may not be the ideal polymer for drug 
delivery vehicles.21 For example, the bulk erosion mechanism of PLGA allows for little control 
over release kinetics and can create microenvironments with a pH as low as 1.5, a challenge for 
acid-sensitive payloads such as proteins or DNA.22 Thus, poly(ortho esters) were developed in 
an effort to sustain drug release via surface erosion as well as to protect encapsulated cargos. 
 Poly(ortho esters) were developed in four major classes, viz. POE I, II, III, and IV.21,23 
The first attempts at synthesis involved a transesterification process under high vacuum and 
high temperature conditions. However, these reactions required long periods of time and 
resulted in relatively low molecular weights. Often, these reactions allowed for little control over 
molecular weight and the process was abandoned for commercial scale.21,23 POE IV synthesis 
has since transitioned to addition polymerization of diols to cyclic diketene acetals.21,23 These 
poly(ortho esters) integrate glycolic or lactic acid segments into the polymer backbone for 
additional control over hydrolysis, and therefore, drug release.21 Further control over release 
kinetics have been observed in copolymerization of poly(ortho esters) with poly(ethylene glycol), 
poly(acetal), and amides.23,24  
 In contrast to poly(esters) such as PLGA, acid-catalyzed polymers tend to degrade 
through surface erosion instead of bulk erosion, increasing control over cargo release kinetics 
(Figure 2.1). Hydrolysis, for example in POE IV, begins with the hydrolysis of lactic or glycolic 
acid components within the polymer backbone, leaving behind a carboxylic end group.21 This 
reduces the pH of the local environment and thus, catalyzes the ortho ester hydrolysis. This 
acid-induced mechanism, while allowing for sustained release, can also target the payload 
vehicle.25,26 For example, antigen presentation through MHC I molecules is an important factor 
when activating cell mediated immune cells such as cytotoxic T lymphocytes (CTLs).26 Acid-
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labile delivery vehicles, such as microparticles encapsulating a vaccine antigen, can provide 
protein protection at neutral pH where very little polymer degradation occurs. However, once 
internalized into mildly acidic endosomes the polymer quickly erodes, swiftly releasing the 
antigen.26 In fact, in a vaccine platform composed of CpG DNA encapsulated in an acetal-cross-
linked hydrogel, less than 10% of the DNA was released at neutral pH after several hours. Upon 
placing the same construct in a mild acidic buffer, 100% of the encapsulated DNA was released 
after two hours.26 In another study, acid-degradable polyurethane formulations most sensitive to 
degradation at pH 5 enhanced MHC I presentation and CTL activation.27 Aside from targeting 
intracellular compartments, the acid-induced degradation of poly(acetals) and poly(ketals) has 
also been applied for cancer treatment.25 In many cases, the tumor pH is more acidic than the 
surrounding tissue, resulting in drug containment during circulation at neutral pH, and release 
locally at the tumor site.25 
 Although surface erosion permits beneficial control over the release of proteins and 
other small molecules, degradation products can lead to detrimental effects on payload stability 
or the surrounding tissue. In the case of PLGA, degradation products induce a highly acidic 
microenvironment that can quickly disrupt protein stability. On the other hand, acid-catalyzed 
polyurethane degrades into diols and acetone that do not cause detrimental acidic environments 
and have similar cytotoxicity to the FDA-approved PLGA.27 Other acid-catalyzed polymers such 
as poly(ortho ester amides), poly(acetals), and poly(ketals) have shown no significant effects on 
microenvironment pH, as well as excellent compatibility with fibroblasts in vitro,23 stability of 
encapsulated DNA,22 and have been used in orthopedic implants.25  
 Acid-degradable microparticles have shown increased phagocytosis by macrophages, 
up to 10 times more than soluble protein alone in 24 hours.28 These materials can be used for 
targeting of endosomes and enhancement of cell-mediated immunity through MHC I and CTL 
activation after particle vaccination.27 These immune enhancing properties are critical in 
designing polymer adjuvants for efficacious vaccines. Acid-catalyzed polymers have also been 
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extensively studied as thermogels for parenteral drug delivery. Many thermogels, such as 
Pluronic block copolymers and PLGA-g-PEG copolymers, are either non-degradable (Pluronic) 
or lack controlled release (PLGA-g-PEG).23,24 In contrast, poly(ortho ester amides) have shown 
fully reversible soluble-gel transitions in water and are completely degradable.23 Likewise, 
thermogels consisting of graft copolymers with PEG, poly(acetal) and/or poly(ortho ester) have 
shown controllable erosion kinetics from very short (a few days) to long (100 days) time periods, 
permitting thermogel drug release to be adjusted for each therapeutic application.15 
Acid catalyzed polymers, mainly poly(ortho esters), are considered to be more 
biologically inert than other classes of polymers, such as poly(esters) and polyanhydrides.25 
Although this is very beneficial in cases of drug delivery or implants, vaccine adjuvants may 
need to exhibit more immunostimulatory properties such as mild inflammation. In this case, 
polyanhydrides may be excellent alternative candidates for both sustained released via surface 
erosion and adjuvanticity in vaccine delivery applications.  
 
2.1.4.  Polyanhydrides 
Polyanhydrides are a unique class of biodegradable polymers possessing qualities well 
suited for both vaccine and drug delivery. Although PLGA remains one of the most extensively 
studied polymers for drug delivery, its bulk eroding mechanism can be unfavorable for the 
delivery and stabilization of sensitive payloads by allowing interactions with water before 
release. Polyanhydrides, however, eliminate many of these challenges via a surface erosion 
mechanism which protects antigens and pharmaceuticals while controlling release. 
 Polyanhydrides are composed of diacid monomers linked by anhydride bonds. While the 
anhydride bonds are hydrolytically labile, the diacid monomers themselves are hydrophobic and 
exclude water from penetrating into the bulk of the material contributing to the surface erosion 
mechanism.29,30 Although release kinetics can be affected by polymer-payload interactions, 
release of proteins from polyanhydrides is highly correlated to the surface degradation of the 
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polymer. This surface erosion, and consequently release of payload, is easily tailored by varying 
the copolymer composition of polyanhydrides, allowing the manipulation of release from several 
days to years.29,31,32 For example, a copolymer composed of the two polyanhydrides, 1,6-bis (p-
carboxyphenoxy) hexane (CPH) and sebacic acid (SA), will contain CPH-CPH bonds that 
undergo hydrolysis relatively slowly, SA-SA bonds that hydrolyze more quickly, and CPH-SA 
bonds. By synthesizing CPH:SA copolymers that are SA-rich or CPH-rich, degradation times of 
these copolymers can be tuned to weeks, months, or anything in between.29  
 Surface erosion is an important factor not only for sustained release, but for the stability 
of the encapsulated antigen or drug. Exposure to water in bulk eroding polymers can lead to 
instability of proteins due to, for example, water-induced aggregation.33 Bulk erosion also 
confines unreleased protein in the presence of polymer degradation products. These 
degradation products, for example, lactic and glycolic acid in PLGA, create a highly acidic 
microenvironment that causes protein degradation and denaturation.33,34 Proteins encapsulated 
in surface eroding polyanhydrides are only exposed to water at the uppermost surface and 
proteins are not exposed to water or degradation products until release. The degradation 
products of polyanhydrides, which are dicarboxylic acids, are much less acidic, maintaining a 
microenvironment close to neutral pH.30,31 Although it is possible that the hydrophobicity of 
polyanhydrides can lead to protein aggregation, polyanhydrides can be designed to create more 
amphiphilic, favorable environments for protein stability. One such example, 1,8-bis (p-
carboxyphenoxy)-3,6-dioxaoctane (CPTEG), was developed in the Narasimhan laboratory by 
incorporating oligomeric ethylene glycols into the backbone of CPH.33 The CPTEG and CPH 
monomers can be copolymerized to result in an amphiphilic polyanhydride that has been shown 
to sustain the release of stable antigens.33 
 The degradation products of polyanhydrides have been shown to be biocompatible.30,31 
As the polymer degrades, aromatic monomers are simply eliminated with no further need for 
metabolization. Aliphatic monomers, on the other hand, typically take part in the β-oxidation 
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pathway. The monomers are further eliminated through exhaled carbon dioxide, urine, or feces, 
while any small, insoluble fragments are cleared by macrophages and other inflammatory 
cells.29-31 Increased recruitment of these inflammatory cells is often correlated with injection site 
reactions such as pain and swelling; however, Huntimer et al. have recently demonstrated that 
even 10-fold doses of polyanhydride nanoparticles are less inflammatory than traditional 
adjuvants such as Alum or MPLA.35 In contrast with Alum, polyanhydride nanoparticles 
displayed minimal cell infiltration and resulted in normal kidney and liver function.35 
 The promising biocompatibility of polyanhydrides has led to their use in many drug 
delivery applications. One of the best successes of polyanhydrides is the FDA-approved 
Gliadel® wafer, a poly(1,3-bis(p-carboxyphenoxy)propane-co-sebacic acid) (CPP:SA) wafer 
encapsulating the nitrosourea oncolytic agent, carmustine. After tumor resection, the wafer is 
placed directly into the surgical cavity sustaining carmustine release.36 The CPP:SA formulation 
has also been used in the form of microspheres to deliver insulin for diabetic patients.29 In 
contrast to a typical regimen of multiple insulin injections per day, a single dose of CPP:SA 
microspheres released insulin for up to 35 days and maintained basal insulin levels in vivo.29 
 Aside from drug delivery, polyanhydrides have been investigated in vaccine delivery 
applications. Studies by Kipper et al. have shown that polyanhydride microparticles possess 
immunomodulatory capabilities, allowing the stimulation and targeting of specific arms of the 
immune system—which is beneficial for designing customized vaccine platforms for both 
extracellular and intracellular pathogens.37 The hydrophobicity of polyanhydrides is theorized to 
provide foreign danger signals to the immune system, leading to polyanhydride particles being 
more readily phagocytized by APCs, which is an important mechanism for vaccine efficacy.38 
Recent studies have shown that polyanhydride microparticles possess dose sparing 
capabilities, producing antibody titers similar to 64-fold higher doses of antigen alone.39 
Polyanhydride particles can also be surface modified to achieve pathogen-mimicking properties. 
For example, polyanhydride nanoparticles can be functionalized with carbohydrates that are 
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typically found on pathogens.40 This surface modification increases particle uptake by and 
activation of APCs.40 Additionally, the morphometric properties and persistence of 
polyanhydride nanoparticles intracellularly is similar to the internalization and replication of 
microbial pathogens.41 Ultimately, a single intranasal dose of antigen-containing pathogen-
mimicking nanoparticles resulted in 100% protection of mice against a live bacterial challenge 
40 weeks post-vaccination.41 The success of polyanhydride nanoparticles in sustained release, 
protein stabilization, biocompatibility, and immune activation make them an excellent platform 
for subunit vaccine and drug delivery. 
 
2.2. INTRANASAL VACCINATION 
2.2.1.  Pulmonary Immunology 
 The mucosal immune responses within the pulmonary system are unique, complex, and 
highly regulated processes. The lung is constantly exposed to airborne particulates in the 
external environment, and therefore must interact with foreign materials without producing 
inflammation that may damage the fragile air-capillary interfaces.42,43 Thus, the pulmonary 
system is composed of layered innate immune pathways to control and process antigen without 
stimulating adaptive immunity until real danger, such as bacteria or viruses, is present.43 
  As with the rest of the body, the innate immunity in the lung begins with physical 
barriers. While most particulates become stuck within the mucociliary escalator and swallowed, 
there still remains a small percentage of foreign entities that reach the underlying epithelium 
(Figure 2.2).43,44 The epithelium plays a major role in regulating immune responses. For 
example, through expression of surface receptors and chemokines the epithelium cells control 
which leukocytes enter and respond to antigens within the lung. Epithelial cells also secrete 
antimicrobials, interferons, and complement components.44  
 In addition to the epithelium, the lung contains many other innate cells that contribute to 
pulmonary immunity. For example, the epithelium contains specialized sampling cells called 
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nonciliated macro-fold cells. These cells pass antigens from the lumen of the lung to underlying 
APCs, such as dendritic cells (DCs) and alveolar macrophages (AMØs).17 The DCs of the lungs 
also extend dendrites into the lumen and sample antigens as well. Once activated, the DCs 
travel to the lymph node to stimulate and proliferate T cells.42,43,45 Perhaps more interesting are 
the alveolar macrophages, which traffic antigens to lymph nodes. Originally, it was generally 
believed that only DCs would migrate to lymph nodes, however, there is evidence now 
suggesting that within the pulmonary system AMØs may be, in fact, more important than DCs.46 
AMØs have been shown to be steadily migrating from the lung to lymph nodes even in naïve 
mice, and once exposed to antigen, transport it to draining lymph nodes within two hours before 
DCs.43,46 AMØs also have immunosuppressive capabilities on T cells, contributing to the lung’s 
ability to tightly regulate inflammatory responses.43 Neutrophils also are key players in 
pulmonary immunity, phagocytizing antigen missed by AMØs.43 Although neutrophil infiltration 
into the lung tissues is highly restricted, they line the walls of pulmonary capillaries filtering 
materials from systemic circulation.43,44 
 Adaptive immunity composed of T and B cell responses also have several distinct 
characteristics exclusive to the pulmonary system. T cells recruited to the lungs are thought to 
be hypo-responsive, again minimizing inflammatory damage to sensitive lung surfaces.43 B cells 
secrete IgA, a unique antibody to mucosal surfaces, neutralizing pathogens before entry into 
epithelial cells. While IgG can also be induced systemically, it is much more specific than IgA. 
Therefore, IgA can maintain cross reactivity against drifting pathogens, for example, the change 
in epitopes of seasonal influenza.44  
 Pulmonary immunity is indeed a distinctive and highly regulated system. However, as 
many pathogens, such as influenza, commonly enter the body through the lungs, eliciting 
mucosal immunity is essential for protection. Since most routes of vaccination stimulate 
systemic but not mucosal immunity, intranasal vaccination provides a pathway of inducing 
appropriate responses for respiratory pathogens. 
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2.2.2.  Advantages of Intranasal Vaccination 
 Vaccine formulations with “pathogen mimicking” characteristics are often the most 
successful at eliciting protective responses. With most pathogens entering the body at mucosal 
surfaces, intranasal vaccination has many advantages by inducing mucosal immunity.47 Most 
importantly, if mucosal immunity is desired then mucosal immunization must be used.48,49 Many 
other routes of immunization such as subcutaneous or intramuscular only induce systemic 
immunity that may not be protective against mucosal pathogens. Immunization at a mucosal 
site, however, has been found to induce both local and systemic immunity towards the 
antigen.48,49  
 Antigen availability is an important part of intranasal immunization that leads to both 
pulmonary and systemic immunity. By administering the vaccine formulation to the lungs, 
antigens avoid degradation in the first pass metabolism, often caused by enzymatic activity and 
the extreme pH of the stomach.17,48-50 The increased availability of antigen works to the 
advantage of systemic immunity with the large permeable and adsorptive surface area of the 
lungs.17,48,49 However, local immunity is also induced by the many immune-reactive sites of the 
lungs which are more enriched in with T cells, B cells, and plasma cells than systemic 
circulation.50   
 Delivery of free antigen intranasally is often not sufficient for protective immunity due to 
the mucosal barrier and clearance by the lungs.17 Therefore, carriers and/or adjuvants such as 
polymeric particles are often used to administer antigen successfully. As discussed previously, 
hydrophobic polymers enhance antigen uptake by APCs, but incorporation of hydrophilic groups 
can also assist penetration through the mucus layer.50 Manipulating the charge of particles, for 
example by modifying the surface for positive charge, allows the association and persistence of 
antigen at the negatively charged epithelial layer.50 Finally, immunomodulatory stimulants can 
be co-delivered with antigens to target the expansive innate immune pathways present in the 
lungs. Ligands for TLRs are often used to induce type I interferons, bridging the innate and 
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adaptive immune responses.51 By taking advantage of the unique innate pulmonary immune 
responses, efficacious vaccines can be designed for intranasal delivery. 
 
2.3.  H5N1 AVIAN INFLUENZA 
2.3.1.  Introduction 
Influenza A virus is a single strand negative sense RNA virus of the Orthomyxoviridae 
family.  The genome of influenza contains eight segmented RNA strands encoding for the 
glycoproteins hemagglutinin (HA) and neuramindase (NA), matrix proteins (M), and ion 
channels (Figure 2.3). The segmented genome also allows for re-assortment of the segments to 
take place between different viruses infecting the same host cell, leading to genetic shift.52 
Genetic shift is the basis for the sub-classification of the influenza virus based on the sixteen 
subtypes of hemagglutinin (HA) surface proteins and the nine subtypes of neuraminidase (NA) 
surface proteins, allowing for a possible 144 unique influenza strains.  These surface proteins 
are the antigens towards which host antibody responses are directed, each of which maintains a 
unique function.  The HA proteins are responsible for attaching the virus to epithelial surfaces, 
such as the lungs, by binding sialic acid receptors. Once attached, HA facilitates the fusion of 
the viral envelope with the cell membrane, allowing the virus entrance to the target cell.53 The 
NA protein is involved in preventing clumping during virus release, promoting the spread of 
infection to other cells. Both HA and NA perform their functions by binding and cleaving sialic 
acid on cell surfaces. In the H5N1 strain, both protein subunits have several cleavage sites 
instead of just one, increasing the rapid spread of infection from cell to cell, and therefore, 
pathogenicity.54,55 
A major concern with respect to H5N1 is the possibility of human-to-human transmission 
through antigenic shift and drift. During antigenic shift, two or more viruses reassort to form a 
new virus type, containing epitopes of both viruses.54-56 For example, it has been observed that 
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pigs co-infected with both avian and human flu types become a melting pot for the viral 
genome.55 The swine respiratory tract contains both α 2-3(avian) and α 2-6 (human) sialic acid 
linkages, making the pig a potential mixing vessel for genetic re-assortment.57 Because of the 
ability of influenza to mutate very quickly, there are concerns that the mutations needed to 
change binding preferences of sialic acid linkages from the avian α 2-3 to the human α 2-6 
could lead to a global pandemic, similar to the 2009 H1N1 pandemic.58 Recent work with serial 
passage of the wild type virus in ferrets, the preferred animal model for recapitulating human 
responses to influenza because of sialic acid receptor distribution and pathological similarities, 
has demonstrated that the virus will adapt to airborne transmission albeit with a loss in 
pathogenicity.59-61  These studies, while generating controversy within the scientific community, 
are essential to the understanding of the virus and the capabilities of the HPAI H5N1 to evolve 
and adapt to human-to-human transmission. 
H5N1 is a highly pathogenic form of influenza affecting its host systemically as well as 
locally.58 The easy cleavage of HA and NA proteins, as well as the large gene re-assortment 
through shift and drift, allows H5N1 to infect a host very quickly resulting in symptoms such as 
fever, sore throat, coughing, and in severe cases pneumonia. Further insight into the 
mechanisms that manifest flu symptoms in both protective (full recovery by the patient) and 
pathogenic (poor) immune response will be discussed in later sections of this chapter. 
 
2.3.2.  H5N1 Pathogenesis  
H5N1 is most commonly transmitted through aerosol droplets, infecting through 
sneezing or coughing. The most common symptoms of H5N1 influenza are fever, cough, throat 
congestion, and sore throat. Often times, pneumonia can develop as a result of inflammation 
causing the release and buildup of fluid in the lungs, or secondary bacterial infections. In such 
cases, hospitalization is needed for medical treatment (using anti-viral drugs) and careful 
monitoring is performed via chest exams and cell counts.62-63 Usually the duration of H5N1 flu 
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lasts seven to ten days in patients that recover and achieve protection. However, in pathological 
cases, H5N1 has been known to cause death within 1 to 3 days.62-64 
Recent studies have shown that the highly pathogenic H5N1 rapidly infects epithelial 
cells as well as important immune cells, including DCs, macrophages, and other APCs.65 In this 
case, cytokine production is inhibited due to the increasing apoptosis and disabling of virally 
infected APCs. Through this mechanism, both the innate and adaptive arms of the immune 
system lack the encouragement and signaling they need, leading to mortality.  
More common, however, is the theory of a “cytokine storm,” or hypercytokinemia.66,67 In 
this case, the rapid spread of the virus elicits a strong, systemic response. A flood of immune 
cells, including DCs, macrophages, and NK cells, rush toward the infected areas, in this case 
the lungs, releasing large amounts of cytokines including TNF-α, IL-6, IL-1β, IL-10, and IFN α 
and β and the chemokines RANTES, MCP-1, MCP-3, MIP-1α, and MIP-1β.68-70  In vitro infection 
of bronchial alveolar epithelial cells showed an increase in IFN-β, RANTES, and CXCL10 early 
in infection as compared to a seasonal H1N1 virus.71 Additionally, mutations in the HA viral 
sequence leading to multiple basic amino acids at the HA cleavage site of HPAI viruses skew 
the ability of the virus to replicate in multiple tissue sites as compared to other influenza viruses 
associated with the respiratory tract.72,73 The ubiquitous distribution of replicating HPAI virus 
contributes to an overabundant antiviral immune response. Normal immune responses regulate 
cytokine production, enabling cells to turn off production after some time. However, for reasons 
yet unknown, the production of cytokines is out of control and unregulated during H5N1 
infection. This large overproduction of cytokines often causes more injury than help, for 
example, inflammatory responses lead to pneumonia and the accumulation of fluid in the lungs 
blocking of airways.66,67 In studies on hypercytokinemia, normal mice infected with H5N1 were 
compared to mice whose cytokine regulators had been knocked out. Both sets of mice reacted 
similarly to H5N1, with no survival after ten days.67 Researchers concluded that 
hypercytokinemia plays a major role in the pathology of H5N1 influenza, increasing damage to 
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the lungs.67,74 The theory of the cytokine storm is important in understanding the fine balance of 
our immune system. Cytokines play an important role in activating immune cells, such as Th1 
and CTLs, to combat infections. However, if not carefully controlled and regulated, the immune 
system can be more detrimental than helpful.  
The cytokine storm is not the only process that mediates pathogenic responses to H5N1. 
Studies have shown that inhibition of cytokine production does not aid in protection.74 The role 
of cell receptors, such as TLRs, can also increase the lethality of H5N1. TLRs are pattern 
recognition receptors and found on a wide range of immune cells, binding non-specifically to an 
assortment of pathogens.75 The elusive H5N1 binds few TLRs during infection, limiting immune 
recognition and response.75 However, studies have shown that cross-linking of several 
combinations of TLRs promotes immune responses by increasing the avidity of T cell effector 
functions.75 TLRs are an increasing subject of H5N1 studies and many preventive methods, 
such as vaccines, depend upon the role of TLR binding during viral infection. 
 Macrophages commonly have C-type lectin receptors (CLRs) that bind to the 
hemagglutinin portion of viruses.76 Through this receptor, the virus gains entry into the cell and 
begins its process of replication. In influenza, the macrophage receptors have weak interactions 
with viral particles and limited entry is gained.76 Due to the limitation of infecting cells, and the 
cytokines released by macrophages, the virus is normally cleared. H5N1 virions are different in 
that they have high affinity for macrophage receptors.76 Strong interactions allow virions to gain 
easy access to macrophages, inducing large production of cytokines while inhibiting the 
regulators previously discussed in hypercytokinemia. 
 Another receptor, chemokine receptor 6 (CCR6), is found on DCs, B cells, and effector T 
cells. CCR6 is responsible for binding a pro-inflammatory chemokine and stimulating the 
immune system.77 H5N1 and other respiratory viruses are known to block CCR6 by an unknown 
pathway and disturb immune recruitment.77 By blocking CCR6 signaling, studies have found 
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that viral infection increases pathology of the lungs and diminishes important cell-mediated 
responses involving dendritic cells and CTLs.77 
 
2.3.3.  Immune Response to Orthomyxoviruses 
 The innate immune response consists of protection we are born with. It is the first 
defense against pathogens, responding very quickly. Although innate immunity often is not 
enough to completely clear infection, it can hold it at bay until the slower, but stronger adaptive 
response arrives. 
 Important cytokines are released during viral infection via APCs such as macrophages. 
Inflammatory cytokines, such as IL-1, IL-6, and TNF-α, raise the body temperature to a fever 
and slow the replication of the virus.78,79 These cytokines are also responsible for encouraging 
complement pathways to bind released virus molecules in an immune complex that will be 
cleared by macrophages.78 Cytokines also provide a chemical gradient to recruit immune cells 
by a process called chemotaxis and allow cells to hone to the infected tissues.78,79 Finally, 
cytokines such as IL-2 and IL-4 encourage the adaptive immune response to help combat 
infection. 
 Virus-infected cells also produce the interferons, IFN-α and IFN-β. Both of these 
molecules inhibit viral replication, increase MHC class I expression (antigen presentation to 
immune cells), and activate natural killer (NK) cells.78,79 NK cells are large lymphocytes that 
circulate in the blood and migrate into tissue, carrying cytotoxic granules within their cytoplasm. 
When stimulated by IFN-α and IFN-β, NK cells release their granules to kill targeted cells. When 
stimulated by IL-12, NK cells produce cytokines, including IFN-γ, which increases activity of NK 
cells as well as activated macrophages. Macrophages will in turn activate T cells of the adaptive 
immune system through cytokines of their own.78,79 As T cells activate, proliferate, and 
differentiate into CTLs, they take over the production of IFN-γ and turn off NK cells through the 
production of IL-10.79 Through this process, the innate immune system quickly responds and 
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activates the adaptive immune response while controlling infection, and then steps aside, 
leaving adaptive immunity to completely clear the virus. 
 During the adaptive immune response, T cells travel to the lymph nodes and check 
APCs for their specific antigen. Once T cells bind to its specific antigen, in this case a viral 
epitope, they activate, proliferate, and differentiate into effector T helper (CD4+) and cytotoxic T 
(CD8+) cells.78,79  
Effector T helper cells are influenced by the presence of cytokines. For example, during 
viral infection NK cell production of IL-12 and IFN-γ mediate the production of Th1 cells. Th1 
cells are responsible for the stimulation of both macrophages and cytotoxic T cells through the 
cytokines previously discussed, such as IFN-γ.78,79 Although Th2 cells can be sometimes 
involved in antiviral responses, they commonly stimulate B cells and the production of 
antibodies against extracellular pathogens.79 In most cases of viral infection, pathways towards 
cell-mediated immunity are influenced by the cytokine signals of macrophages and NK cells, 
leading to a biased response of Th1 cells. 
Effector CD8+ cells, or activated CTLs, take over for the innate NK cells by killing 
infected cells. CTLs target virally infected cells and bind to them, locally releasing cytotoxins 
such as perforin, granzymes, and granulysin, thus inducing cell death by apoptosis.78,79 
Following the clearance of the virus and infected cells, some of these T cells develop into 
memory cells, scanning the body for future infection(s) of the virus.78,79 In this way, the adaptive 
immune system learns how to deal with the virus and can respond quickly to future infections. 
 
2.3.4.  Protective responses to H5N1 
When 60% of all H5N1 cases result in mortality, it is puzzling to researchers as to why 
some patients survive and others, unfortunately, do not.63 Currently, influenza pandemics affect 
mainly the young and healthy, as opposed to seasonal flu, where the elderly are most affected. 
Many researchers believe that today’s pandemics are variations of old flu strains, such as those 
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in the 1918 Spanish flu pandemic and the Asian flu pandemics of 1957 and 1968.55 New 
pandemic strains are usually the result of an antigenic shift, crossing a species barrier (i.e., bird 
to human) and presenting several new epitopes. Researchers believe that because the H5N1 
strain is similar to earlier pandemics, previously exposed populations such as the elderly, may 
be protected against infection.55 
Other facets of protection are understood even less. In some cases H5N1 replicates 
faster or sometimes, a patient’s immune system responds faster. Highly pathogenic influenza 
strains, such as H5N1, have most commonly been found to have weak cytokine production in 
immune responses. However, when a patient experiences a robust cytokine response and is 
able to activate both the innate and adaptive branches of the immune system, protective 
immunity can be achieved.62-64 
Another important part of protective immunity is medical intervention, which will be 
discussed later in the chapter. Briefly, in cases when H5N1 can be identified early, anti-viral 
treatment, such as the popular oseltamivir (Tamiflu), can be administered in twice daily doses of 
75 mg to reduce symptoms. Hospitalized patients can also be monitored for low white blood cell 
and platelet counts, a sign of severe infection, as well as pneumonia, which commonly presents 
itself with respiratory pathogenic H5N1.62,63  
Aside from treatment, prevention is beginning to be a focus in protective immunity. 
Current vaccinations for H5N1 are poorly immunogenic, but at least provide exposure to the 
H5N1 antigen.55,80 Some scientists believe that limited responses occur in all the new vaccines, 
such as the vaccines based on H5 HA protein, and large doses are needed to secure even a 
little protection, despite the lack of understanding of these mechanisms.66 However, H5N1 
vaccination is a fast growing research area, working towards goals of increased immunogenicity 
and long term protection of patients. 
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2.3.5. Treatment of H5N1 
The treatment of H5N1 is limited by the small selection of antiviral drugs available. In 
contrast to antibiotics, the development of antiviral medications has not been as successful. 
However, two treatments are capable in reducing the infection of H5N1 by inhibiting either the 
HA or NA proteins.  
Oseltamivir, also known as Tamiflu, is an antiviral drug commonly used to treat 
influenza. When given within 48 hours of the first symptoms, oseltamivir can drastically reduce 
both the duration and severity of viral infection, and is safe and effective for patients over one 
year of age.81 The course of treatment is administration in 75 mg doses, with three doses the 
first day and twice daily for the following five days. In most cases, oseltamivir is paired with an 
antibiotic to protect against secondary bacterial infections that affect weakened patients, such 
as those with pneumonia.81 Oseltamivir is a neuraminidase inhibitor, preventing the release and 
spread of viral particles from one cell to another. First, the administered phosphate form is 
cleaved by esterase enzymes in the liver.82 Once converted into a carboxylate form, oseltamivir 
can bind and inhibit the NA protein of the viral envelope.82 With the NA protein inhibited, virus 
particles clump together and prevent their release to other cells.53,82 
Recent studies, however, show a rising disadvantage: new oseltamivir-resistant H5N1 
strains. During treatment, an amino acid mutation in the NA portion of the virus allows the 
resistance to oseltamivir. In the study by de Jong et al., only 50% of H5N1 patients survived 
during treatment and had no H5N1 mutations.82 Initial treatments identified the current H5N1 
strain in all patients, however, all the lethal cases showed mutation to the oseltamivir-resistant 
H5N1 strain.82 
Ion channel inhibitors such amantadine and rimantidine are viable options for anti-viral 
treatment in pandemic HPAI situations.  Amantadine and rimantidine form a barrier at the M2 
influenza viral protein that functions to enable the entry of H+ ions.83  HA relies on an acidic 
environment for conformational changes and goes through to fuse the viral envelope with a cell 
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membrane.53 By modifying the pH, the virus cannot gain entry into the cell. Rimantadine has 
also experienced H5N1 resistance, but in this case, alterations are made to the HA instead of 
the NA protein.53 Oseltamivir still remains the most common treatment for influenza because it 
reduces symptoms and the spread of infection.  
 Corticosteroids have been used for decades in the treatment of influenza.84 The use of 
corticosteroids reduces inflammation by down-regulating the production of cytokines such as IL-
2, TNF-α, and IFN-γ.84 Through this, corticosteroids control and reduce the effects of 
hypercytokinemia. It is important to note that corticosteroids do not clear the virus, but only help 
to control the immune response towards the virus. In the case of H5N1, it is necessary to use 
antiviral drugs, such as oseltamivir or rimantadine, to fully clear infection.84 
 
2.4.  CURRENT VACCINE APPROACHES TO H5N1  
The severe pathology of H5N1 infection in humans, the increased risk of secondary 
infections, as well as the high frequency of mutation of influenza which could lead to human to 
human transmission, have motivated research in the realm of preventive therapeutic 
approaches against HPAI. In 2007, the FDA approved the first H5N1 vaccine in the United 
States. The current H5N1 vaccine uses two 90 μg doses administered 28 days apart.85 
However, the vaccine is generally poorly immunogenic. In fact, FDA studies show that only 45% 
of patients receiving the vaccine had antibody titers suitable for protection.85 Generally, many 
vaccines follow a Th2 route of immune response, creating antibodies against a pathogen. 
However, H5N1 is a virus, and hence an intracellular infection, and Th1 or cell-mediated 
responses may be important to clear the virus. Future research towards the development of a 
H5N1 vaccine (described below) needs to focus on inducing both cell-mediated responses and 
antibody production to promote immunogenicity and protection. In addition, new vaccine 
development strategies must take into account both the safety and potency of the formulation, 
which is often challenging when safer vaccines are typically less potent (Table 2.2).  This 
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section will focus on the traditional seasonal influenza vaccines and the possibility of using 
those for pandemic preparedness to H5N1 as well as on emerging vaccine and anti-viral 
technologies which may enable pandemic preparedness (Figure 2.4). 
 
2.4.1.  Inactivated Viral Vaccines 
The traditional seasonal influenza vaccine consists of formaldehyde or β-propiolactone 
inactivated virus propagated in embryonated hen eggs,86 and more recently, propagation of 
influenza virus in Vero cell cultures to replace hen egg propagation.87 The antigenic components 
of the vaccine are either administered as whole inactivated virion, purified subunit of surface 
glycoproteins, or chemically split virus vaccine. These aspects of the seasonal influenza vaccine 
may therefore be applied towards stockpiling H5N1-specific vaccines for pandemic 
preparedness. Seasonal influenza vaccine protection profiles are based on a close antigenic 
match and previous exposure to influenza.88 The previous exposure to the HPAI H5N1 will be 
absent due to the fact that the seasonal influenza A virus contains H1 and H3 (and not H5) 
HA.89 Inactivated influenza virus vaccines can result in rubor and tumor at injection sites with 
frequency of incidence dictated by age but no differences from placebo were observed.90-92 
People with egg albumin allergies cannot be administered the traditional mass-produced 
inactivated vaccines because of hen egg virus propagation. The main conundrum of using 
traditional seasonal inactivated influenza virus techniques to produce pandemic vaccines is the 
time needed for the manufacture and production of the virus. Typical mass production timelines 
are estimated to be 6-9 months.93 However, a dominant pandemic strain would need to be 
identified prior to production delaying when the vaccine could make it to clinics.    
The immune response induced by inactivated influenza virus vaccines is predominately 
humoral. Antibody responses are typically directed towards the surface glycoproteins HA and 
NA. Systemic antibody specific for HA and NA is predominately IgG1 with some IgM and IgA 
being identified with protective antibody responses elicited within two weeks post-vaccination.94  
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IgG and IgA specific antibody secreting cells have been identified in peripheral blood following 
vaccination.95 The isotype switch associated with these humoral responses can be attributed to 
the prime/boost effect of the previous year’s vaccinations.96 Combinations of antiviral NA 
inhibitors with inactivated virus vaccines may also be an effective regimen during a pandemic 
due to little interference with the humoral response kinetics in clinical studies.97 Inactivated viral 
vaccines can also elicit stronger influenza antigen specific proliferative responses of T cells 
found in the palatine tonsils and peripheral blood, although this may also be attributed to the 
prime/boost response of either natural seasonal influenza infection or previous vaccinations.94,98-
100 
Studies with inactivated HPAI H5N1 prepared and administered similarly to licensed 
seasonal vaccines still present the most viable option for pandemic formulations due to the 
vaccine not having to undergo licensure but rather be considered a new strain of influenza 
added to an existing licensed product to alleviate regulatory delays. Inactivated subvirion H5N1 
virus vaccines were shown to provide virus neutralization titers in 54 percent of individuals 
receiving two doses of 90 μg of HA which is approximately six times the dose of seasonal 
influenza vaccines.101,102 A TLR7 dependent mechanism associated with increased 
immunogenicity of inactivated H5N1 vaccines because of residual viral RNA in the preparation 
has been identified.103 Aluminum salt adjuvanted inactivated split virion H5N1 vaccines were 
able to elicit 67% HA inhibition in patients after two doses of 30 μg HA.104 Post vaccination, 
immunological responses to split virion H5N1 were greater in infants and children.105 
Additionally, whole virion inactivated H5N1 vaccines were able to produce 78% seropositivity 
when administered in a two dose regimen with aluminum salts at a dosage of 10 μg of HA.106  
Vero cell derived inactivated H5N1 vaccines show similar moderate humoral immune responses 
with and without Al(OH)3 adjuvant.
107 
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2.4.2.  Cold adapted attenuated viral vaccines 
The field of influenza vaccinology was expanded by the licensure of a cold adapted live 
seasonal influenza vaccine (Flumist®, MedImmune, Gaithersburg, MD) in 2003. Cold adapted 
live influenza viruses are based on the master strain A/Ann Arbor/6/60 (H2N2) being attenuated 
by passaging the virus through decreasing temperatures in embryonated hen eggs. The 
continuous passage through decreasing temperatures allows for mutational adaptations in the 
polymerase (PA), PB1, PB2, and M genes of influenza leading to the cold adapted phenotype in 
which replication is restricted to 33°C in the upper respiratory tract.108 The cold adapted virus 
expressing the HA and NA of interest, either the seasonal influenza strains or pandemic strains, 
is produced by genetic reassortment.109 The modified live cold adapted influenza virus allows for 
an intranasal vaccination that mimics the natural infection in both site and mode of infection, but 
under the virus replicative constraints of the upper respiratory tract. The upper respiratory 
replication of the virus allows for lower doses of influenza antigen.   
The cold adapted influenza virus seasonal vaccines have shown cross-reactive immune 
responses to other antigenically drifted H1N1 and H3N2 strains.110-112 This cross reactivity could 
prove extremely beneficial in the stockpiling of pandemic influenza vaccines because prediction 
of the antigenically drifted strain of influenza will be difficult.113 The intranasal route also allows 
for ease of administration by individuals with minimal professional training during a pandemic.   
Cold adapted H5N1 virus vaccines were able to provide incomplete protection after 
single dose vaccinations with homologous and heterologous viral challenge but two dose 
regimens provided heterologous cross protection in laboratory models.114 Safety and 
toxicological profiles of the cold adapted H5N1 vaccines were favorable in the ferret model.115  
Clinical evaluations of a cold adapted influenza vaccine containing the H5 and N1 outer 
glycoproteins of two H5N1 isotypes A/Vietnam/1203/2004 and A/Hong Kong/213/2003 on the 
A/Ann Arbor/6/60 show limited viral replication leading to nominal neutralizing humoral immune 
response.113 Immune responses were elicited using a low pathogenicity avian influenza 
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A/Duck/Potsdam/1402-6/86 (H5N2) genetically reassorted to a cold adapted 
A/Leningrad/134/17/57(H2N2) that show cross reactivity to an H5N1 strain in a HA inhibition 
test.116 Interestingly, a cold adapted vaccine consisting of HA and NA of the 2009 pandemic 
H1N1 strain was able to protect mice from lethal H5N1 challenge.117,118 
 
2.4.3.  Reverse Genetics Derived Virus 
The traditional method of genetic re-assortment of influenza virus for vaccines in 
embryonated hen eggs can be inefficient and variable. Recent advances in molecular biological 
techniques have allowed for the formation of infectious influenza A virus completely from 
plasmid cDNA expression of the viral RNA segments transfected in human embryonic kidney 
cells (293T) or Madin-Darby canine kidney (MDCK) cells.119,120 The reverse genetics system of 
creation and propagation of influenza virus allows for molecular manipulation of the genetic 
elements to decrease pathogenicity, a more targeted approach for creation of genetically 
reassorted viruses, and alleviation of propagation validation issues associated with production 
of virus for vaccine purposes.   
The initial reverse genetics systems demonstrated the rescue of seasonal influenza 
variants containing the HA and NA of A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 
(H3N2), A/teal/HK/W312 (H6N1), and A/quail/HK/G1/97 (H9N2) and the six internal genes of 
PR8, a high growth lab strain of influenza.121 Subsequently, reverse genetics derived strains 
containing the HA and NA of H5N1 were created122,123 and adapted for expression in Vero cells, 
which have been previously validated for the production of polio vaccine.124-126 The reverse 
genetics derived system for production of re-assorted viruses verified the decreased timeline 
needed for reverse genetics derivation compared to the traditional embryonated hen egg re-
assortment method. Vero cells present difficulties in transfection efficiency compared to non-
production validated cell lines such as 293T cells. Adenovirus vectors that, when transduced in 
Vero cells, produce the viral RNA needed for creation of the viral ribonucleoprotein complex by 
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transfecting the same cells with plasmids encoding the PB1, PB2, and PA subunits of the viral 
polymerase increased the viral production efficiency from the traditional eight plasmid 
method.127 
An inactivated reverse genetics virus was used for immunization and elicited cross 
neutralization to several H5N1 strains isolated from human infections in a guinea pig model and 
protection from challenge with three different H5N1 viruses in mice vaccinated with a two dose 
regimen.128 An H5N3 reverse genetics derived virus was used for an inactivated vaccination 
challenge model in ducks and chickens that provided protection in a two dose and a single dose 
regimen.129 Finally, a formalin inactivated reverse genetics derived H5N1 oil emulsion vaccine 
also showed protection 43 weeks post vaccination in chickens.130   
The reverse genetics platform allows for a more targeted approach towards generation 
of cold adapted influenza virus with the A/Ann Arbor/6/60 (H2N2) backbone and the H5N1 
glycoproteins of HPAI H5N1. Reverse genetics derivation of cold adapted influenza virus for 
modified live vaccines have shown potential in two dose intranasal administrations in reducing 
wild type virus replication.131 Protection from homologous and heterologous virus challenge in 
mice, ferrets, and macaques has also been reported when boosted with a second 
immunization.114,132   
 
2.4.4.  DNA Vaccines 
Viral infections are good candidates for DNA vaccination because infection of the host 
cells hijacks the cellular machinery for viral replication.  DNA vaccination, in general, refers to 
the initiation of an immune response against an antigen introduced via purified DNA in 
supercoiled plasmids that encode for the antigen (poly)peptide sequence.133 The plasmid DNA 
incorporates into the host cells via direct gene transfer and the host cells produce the protein 
antigen. Mass production of plasmid DNA is less labor intensive than protein antigens and DNA 
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storage conditions are less intense when proper techniques are used, providing advantages in 
stockpiling pandemic vaccines.134   
The immune response elicited to DNA vaccines is primarily skewed to the Th1 type of 
immune response, in which cell-mediated immunity (CMI) to the DNA encoded antigen is more 
prevalent with IFN-γ and IL-12 being the predominant cytokines being reported in the vaccine 
response.133 Although the entirety of the plasmid DNA in the vaccine is non-immunogenic, the 
plasmid DNA can be a non-specific immunostimulatory component through pattern recognition 
receptors (PRRs) thus providing an innate adjuvant response.135,136 The proposed mechanism 
of DNA vaccines mimics the cellular pathogenesis of viruses. The post transcriptional and 
translational proteins are split into smaller peptides by intracellular proteosomes of either 
muscle cells, epithelial cells, or APCs.137,138 The peptides are presented by MHC class I 
molecules after trafficking through the endoplasmic reticulum of the host cell. The MHC class I 
molecule containing the peptide then elicits the appropriate CD8+ T cell responses.  
The stability and ease of manipulation of plasmid DNA allows for encoding of additional 
immunostimulatory components to be transcribed and translated by the host cell. Some 
components that have been encoded to be co-expressed with the antigen of interest include the 
cytokines IFN-γ, IL-2, IL-12 and GM-CSF, co-stimulatory molecules such as B7 (CD80 and 
CD86) and CTLA4-Ig, as well as DNA sequences that are specifically immunostimulatory.139-144    
The molecular techniques developed in the last decades and the antigenic drift 
associated with influenza have provided resources to enable fast production of a pandemic 
H5N1 vaccine. Protection from lethal challenge of heterologous strains of H5N1 influenza with 
DNA vaccines encoding HA proteins as well as protection from homologous strains encoding for 
NA, NP, or M2 have been demonstrated.145-147 Dependency on the HA protein needing to be 
encoded in the formulation for humoral and cellular immunity is evident when combinations of all 
the antigenic targets are used.148-150 Addition of a virus induced signaling adaptor (VISA) 
molecule in the DNA antigenic preparation of an H5 HA peptide was able to convey protection 
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from lethal challenge in a mouse model.151 Heterotypic immunity against different clades of 
HPAI viruses has been reported making thus validating the approach.152 Clinical trials of H5N1 
DNA vaccines have begun.153 
 
2.4.5.  Virus Like Particles (VLPs) 
Responding to the need for enhanced immunity and novel approaches for potential 
pandemics, VLPs present viral antigens in a more native and therefore immunogenic 
fashion.154,155 VLPs are self-assembled membranes (a virion shell) containing relevant viral 
proteins such as HA, NA, nucleoprotein (NP), and matrix protein 1 and 2 (M1, M2).156-158 The 
presented proteins are active and remain in their native structures similar to live virions.  
VLPs are immunogenic due to their ability to mimic live virions at the cellular level.156 
Due to the lack of the viral genome, VLPs are non-replicating and non-infectious and therefore, 
remain immunogenic and safe to those in high-risk groups such as the elderly, even after 
several administrations.154,156,157,159 Immunogenicity of VLPs can be further enhanced due to the 
particle’s adjuvant properties to stimulate both humoral and cellular immune responses, 
including cross-reactive antibodies that protect against the variability of influenza 
strains.154,157,158,160 
VLP proteins are commonly recombinant based, produced by the baculovirus system in 
yeast, insect, or mammalian cells.155,156,158 Independence from egg-derived vaccines is 
especially important for an avian influenza vaccine, due to the limited egg supply and the 
H5N1’s ability to kill egg embryos.160 Egg independence also eliminates the need for live viruses 
during production and manufacturing, and is therefore very favorable for production without the 
need for chemical inactivation or biosafety containment. 
VLPs against H5N1 have been successful in eliciting cross-reactive responses between 
subtypes.154,155,160,161 H1N1 VLP intranasal vaccinations in mice and ferrets induced high levels 
of cross-reactive IgG and IgA and had two to three fold greater amounts of IL-2, IL-9, IL-10, and 
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IL-17 than other vaccinations, while remaining protective against a heterologous H5N1 
challenge.154 VLPs using HA and NA surface proteins, while internalizing the conserved 
epitopes of the M1 protein, stimulated the activation and proliferation of CD8+ T cells that 
increased production of IFN-γ, TNF-α, and IL-2 when compared to recombinant protein subunit 
vaccines.155,159 Although the HA protein is mainly responsible for inducing H5N1 specific 
antibodies, the M1 protein’s conserved epitopes are generally accountable for cellular immunity 
and cross-protection.155,159 This increase in cellular immunity was also apparent in the ratios of 
antibodies found with H5N1 VLP vaccine responses. Post-vaccination, IgG2a and IgG2b titers 
were largely increased resulting in a balanced IgG1:IgG2 ratio.160,162 H5N1 vaccines using VLP 
technology showed long lasting memory responses in challenge with single does as low as 0.4 
μg155,163 and utilized needle-free technologies for inoculation.155,162-164 Protective efficacy of VLP 
vaccines against H5N1 have been shown in poultry and a computationally optimized broadly 
reactive antigen (COBRA) H5 VLP vaccine showed protection from challenge in a non-human 
primate model challenged with clade 2.2 A/Whooper Swan/Mongolia/244/05 (WS/05).165,166 
 
2.4.6.  Subunit Vaccines  
Recombinant subunit protein-based vaccines using a single protein antigen have also 
been examined due to the increased purity and safety profiles.156,167-169 Using this system, 
individual viral proteins, most commonly HA and NA, are recombinantly synthesized in 
mammalian cells or cells that support post-translational modifications such as glycosylation, 
allowing the production of correctly folded proteins.156,168-170  
While the baculovirus technology allows rapid production of recombinant proteins, there 
is some debate on using insect or mammalian cultures.156,167-169 During translation of 
recombinant H5 HA protein, mammalian cells commonly produced a high-molecular weight 
oligomer or trimer form of HA.167-169 Insect cells have been more likely to produce cleaved or 
monomer forms of the HA protein, although some studies have shown stable production of 
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trimer HA in insect cultures.167-169 In most cases, the immunogenicity of the H5 HA protein was 
highly dependent on its oligomer and trimer forms showing that in a weakly immunogenic 
protein it is optimal to present it in its natural trimeric state.167-169 
Besides the challenges associated with protein production, subunit antigens like H5 HA 
are a weak immunogens. Therefore, several large doses (up to 90 μg) are needed to achieve 
suitable protection. However, with the help of novel adjuvants and/or protein carriers, the 
immunogenicity of HA can be greatly improved to reduce both the number and size of vaccine 
doses.165,168,171,172 H5 HA has been shown to be the only protein inducing H5N1 specific 
neutralizing antibodies. While other proteins, such as NA, are also included in protein-based 
vaccinations, they have not been shown to be protective on their own. When used in tandem 
with HA protein, NA enhanced cross-reactive protection between H5N1 clades.167,168,170,171 
Like DNA vaccines and VLPs, recombinant proteins can be produced quickly in mass 
quantities without the dependence on a limited egg supply.167,169 Large scale production of 
recombinant proteins is feasible because no live viruses are required, eliminating the need for 
bio-containment facilities.167,169 Novel recombinant production techniques that use plant-based 
systems are being developed for influenza HA antigens.173 Likewise, recombinant proteins can 
be highly purified and don’t utilize chemical inactivators, reducing contamination and adverse 
effects on patients.167   
Oral and intranasal vaccinations of baculovirus produced H5 HA led to effective, long-
lived production of IgA in mucosal tissues, as well as protection in mice.169,171 Likewise, H5N1 
proteins such as M2, NP, and NA have also been used to induce cross-protection between 
clades of avian influenza.170,174,175 As mentioned previously, HA is the primary antigen that 
stimulates neutralizing antibody in H5N1.174 However, by using more conserved proteins, 
studies have shown an increase in HA-specific neutralizing antibodies, as well as IFN-γ 
producing CD8+ T cells, especially in the presence of an adjuvant.170,174-176 Recombinant 
production of HA proteins of H5 allows for manipulation of the antigen, specifically in the 
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creation of stabilized trimeric forms of the antigen that increase the immunogenicity of the 
protein.177-179 Licensure of a recombinant HA vaccine, FluBlok, grown in insect cells has been a 
recent advancement in this area.180 
 
2.4.7.  Immune Refocusing  
Immune refocusing, also termed as deceptive imprinting or epitope masking, is a new 
advance in influenza vaccine technology. Immune refocusing targets class II pathogens, such 
as influenza, or pathogens that have immune responses to strain specific epitopes, yet high 
rates of mutation within these epitopes.181 Tobin et al. theorize that pathogens, such as H5N1 
avian influenza, have immunodominant epitopes, such as the globular head of the HA trimer, 
and subdominant epitopes, or more conserved proteins.181 These dominant epitopes are 
distractions to obstruct the immune system from recognizing and manufacturing antibodies 
against more protective or cross-reactive epitopes.182 This concept arises from the theory of 
original antigenic sin.183 For example, a secondary influenza infection containing epitopes 
previously recognized from a former strain as well as new epitopes will only produce antibodies 
against the previous epitopes, eliminating the infection quickly during a memory response.183 
However, in the cases of HPAI, strain specific epitopes dominate the immune response and 
block reactions to epitopes that appear from strain to strain. In this case, the immune system 
must respond to each infection as a primary infection, with no memory response.186 
Recent evidence has identified wide cross reaction of the influenza HA immune 
responses by constructing a headless HA molecule that retains the correct conformation of the 
stalk structure.184 The HA protein has two subunits: the globular head and immunodominant 
HA1 and the more conserved and cross-reactive HA2.91 By removing a portion of the HA1 
globular head, the most variable and strain specific subunit, the remaining portion of HA1 and 
conserved HA2 is retained and exposed to the immune response allowing cross-reactive 
antibodies to form.184 Immunizations with the headless HA allowed complete protection and 
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partial prevention of weight loss during a lethal homologous challenge and cross-reactive 
antibodies to different HA subtypes. This advancement could be exploited for a prospective 
pandemic platform for cross-reactive influenza vaccines.184 
 
2.4.8.  Vectors 
An increasing focus on utilizing vectors (i.e., bacteria or viruses) to deliver antigen to the 
appropriate cellular compartments has been identified with emphasis on production in poultry 
medicine.185,186 A commercially available fowlpox vectored avian influenza vaccine administered 
parenterally has demonstrated extensive efficacy in poultry against HPAI although 
administration requires handling of each individual bird.185,186 Subsequent studies focused on 
improving efficacy by overcoming immune suppressive effects of the fowlpox vector by including 
genes encoding for the cytokine IL-18.187 Modified Vaccinia virus Ankara (MVA) encoding H5 
HA showed protective efficacy in mice.188 Vaccinia virus, smallpox and fowlpox viral vector 
vaccines encoding A/chicken/Indonesia/7/03 H5 hemagglutinin were examined in a swine model 
of vaccination and elicited protection from challenge with low pathogenic H5N1 virus.189 
Replication defective human adenovirus vectors effectively delivered DNA encoding influenza 
antigens to host cells while being well tolerated in human trials.190  The adenovirus technology 
ensures a targeted approach towards delivery of the H5 HA DNA over the intramuscular 
injection of DNA discussed earlier and demonstrated protection in mouse and poultry models of 
HPAI challenge.191-193 A poultry specific attenuated live vaccine strain of Newcastle Disease 
Virus (NDV) was genetically modified to express HA of HPAI and showed protection from lethal 
challenge of both HPAI and NDV in poultry.194 Wang et al. demonstrated that a common poultry 
Lactobacillus that colonizes the gut of poultry delivered H5 antigen to mucosal tissues and 
elicited specific IgA and cell mediated immune responses.195  
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2.4.9.  Adjuvants 
HPAI vaccines present the same problems that hinder seasonal influenza vaccines in 
that the immunogenicity of the antigens is mediocre.196 Adjuvanting vaccines with 
immunostimulatory compounds has long been a proven technique for increasing the immune 
response towards the antigens of interest.196 However, adjuvants present safety concerns as 
vaccinologists and immunologists attempt to balance between sufficiently engaging the immune 
system to mount a response without crossing the line into a deleterious immune event. Adverse 
events associated with adjuvants have led to very few vaccines containing adjuvants being 
approved for use in humans.197,198 Seasonal as well as pandemic influenza vaccine research 
has led to significant advances in adjuvant development, leading to novel adjuvants like MF59, 
an oil-in-water emulsion adjuvant, being approved for human use in the European Union.199   
As mentioned in the earlier sections, many possible pandemic formulations for HPAI 
contain adjuvants.  Here we highlight the advances in adjuvant research in the context of HPAI 
vaccines.  Alum remains the principal adjuvant studied because of its approval for human use 
while maintaining favorable safety profiles.200-202 MF59 and AS03 (another oil-in-water emulsion) 
appear to increase efficacy as compared to Alum, although vaccines using these adjuvants are 
limited in their approval for use world-wide.203-207 Evidence has pointed to the spreading of the 
epitopes that the immune response recognizes in the context of individuals vaccinated with 
MF59 adjuvanted H5N1 vaccines versus un-adjuvanted vaccines providing insight into the 
mechanisms of efficacy.208   
The pandemic possibility of HPAI has pushed other avenues of adjuvant research.  
Inactivated whole virus adjuvanted with CoVaccine HTTM, a mixture of squalene, polysorbate 80, 
sucrose fatty acid sulphate ester in water, demonstrated favorable HA inhibition titers in ferrets 
and macaques with a single dose regimen.209,210 A purified derivative of the saponin from 
Quillaja saponaria, QS-21, has been identified as another potential adjuvant in pandemic HPAI 
vaccines.132 Addition of QS-21 with Alum adjuvanted vaccines greatly increased antibody 
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responses to the M2 protein of HPAI in rhesus monkeys.132 Immune stimulating complexes 
(ISCOMs) are 40 nm structures containing glycosides from Quillaja saponaria and lipids for 
which immunogens can attach via hydrophobic interactions. These compounds have shown 
promising protection data upon lethal challenge in avian models.211,212 Platycodin D, another 
saponin derived from Platycodon grandiflorum, has shown adjuvant potential with recombinantly 
produced H5.213 
Recent advances in molecular and structural biology have led to targeted approaches to 
stimulate innate immune cells through PRRs such as TLRs, RIG-1-like receptors, NOD-like 
receptors, and CLRs.214,215 Stimulating PRRs with ligands in conjunction with delivering antigens 
provides an adjuvanting mechanism.216 Stimulation of endosomal TLR3 and TLR9 with Poly 
ICLC or CpG, respectively, during HPAI infections led to protection and viral clearance.217 The 
adjuvant effect of TLR3 ligands was also demonstrated in intranasal HPAI vaccines in 
primates.218 Intranasal administration of Poly I:C with H5N1 HA as well as chitin microparticles 
delivered concurrently with Poly I:C led to protection upon lethal challenge.219,220 PIKA, a dsRNA 
analog that functions through ligation of TLR3, showed adjuvant effects to subunit H5N1 
vaccines administered intranasally in mice as well as protection from heterologous challenge.221 
Incorporation of monophosphoryl lipid A (MPLA), a non-toxic derivative of LPS that signals 
through TLR4, combined with Alum showed higher HAI responses and balanced IgG1 and 
IgG2a isotypes with a 3.8 μg HA dose of a split virion vaccine.222  
Cholera toxin (CT) has demonstrated mucosal adjuvant capabilities that appear to be 
STAT3 signaling dependent.223 Recombinant CT demonstrated more favorable safety profiles 
due to engineering the absence of the catalytic subunit.224 Recombinant CT adjuvanted 
inactivated H5N1 viral vaccines showed similar antibody titers to other adjuvanted inactivated 
H5N1 vaccines but with diminished protection.225 Another bacterial derivative adjuvant, a patch 
containing heat labile enterotoxin from E. coli (LT) administered over the injection site, proved to 
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be safe and provided enhanced mean HA inhibition titer in a randomized clinical trial in a prime 
boost immunization regimen.226 
Combinations of adjuvants, as alluded to earlier with MPLA and Alum, are an exciting 
avenue of HPAI vaccine research. A synthetic bioresorbable diblock tri-component copolymer 
poly(ethylene glycol)-block-poly(lactide-co-ε-caprolactone) (PEG-b-PLACL) was used to create 
a novel emulsion delivery system (PELC) that when combined with CpG, a TLR9 agonist, 
induced higher antibody responses in single dose applications using inactivated H5N1 virus and 
elicited cross reactive antibodies to heterologous virus.227,228 The increased immune response 
with a particulate adjuvant as well as other studies using micelle-based carriers administered 
orally229 indicate the importance of size and shape in designing adjuvants.230  
 
2.5.  CONCLUSIONS 
 H5N1 influenza is a growing concern for public health officials all over the world. This 
rapidly mutating virus has the potential to become the next influenza pandemic devastating the 
global population with a 60% mortality rate. With this in mind, there is an urgent need for 
research on the prevention of H5N1 through vaccination. Many vaccination strategies have 
been studied, including DNA plasmids and VLPs, but perhaps the safest vaccine is a 
formulation of highly purified protein or subunits. The purified proteins, which are non-infectious, 
will minimize side effects from vaccination. However, these proteins are generally poorly 
immunogenic and require the use of an adjuvant. Among the various classes of adjuvants that 
have been studied as described in this chapter, polyanhydride nanoparticles have many 
advantages: sustained protein release, preservation of protein antigenicity, activation of immune 
cells, and immunomodulation. These nanoparticles also have pathogen mimicking properties 
that take advantage of unique pulmonary immunity leading to the design of safe, efficacious 
vaccines. 
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2.6.  TABLES 
Table 2.1 Biodegradable Polymers as Vaccine Adjuvants and Delivery Vehicles 
Poly(esters) PLGA 
 
 PCL 
 
Acid-Catalyzed 
Polymers 
Poly(acetal) 
 
 Poly(ketal) 
 
 Poly(ortho ester) 
 
Polyanhydrides CPP 
 
 CPH 
 
 CPTEG 
 
 SA 
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Table 2.2: Considerations for Pandemic Vaccines 
Vaccine Potency 
Production 
Speed 
Purity Safety 
 
Inactivated Viral 
 
** * * * 
Cold Adapted 
Attenuated Viral 
** * ** * 
Reverse 
Genetics 
Derived 
** ** * * 
 
DNA 
 
** *** *** ** 
Virus Like 
Particles 
*** ** ** ** 
 
Subunit 
 
* ** *** *** 
Immune 
Refocusing 
* ** *** *** 
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2.7.  FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1. Bulk and surface erosion of biodegradable polymers. Poly(esters) exhibit bulk 
erosion mechanisms allowing water penetration into the bulk of the material (top). Surface 
eroding polymers, such as acid catalyzed polymers or polyanhydrides, only allow water 
penetration at the surface and erode layer by layer (bottom). 
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Figure 2.2. Features of the pulmonary immune system. The pulmonary immune system has 
several unique aspects that provide mucosal protection from foreign particles. The lung is lined 
with a mucosal escalator that traps particulates and moves them upward to be swallowed 
(upper right). Macro-fold cells sample antigens from the lumen and pass them to underlying 
APCs such as alveolar macrophages and dendritic cells (lower right). Finally, neutrophils line 
the pulmonary capillaries to catch antigen missed by other APCs (lower left). 
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Figure 2.3. The H5N1 virion capsid encloses an eight segmented, negative sense RNA 
genome. The virion also contains a lipid envelope with several major glycoproteins: 
hemagglutinin (HA), neuraminidase (NA), and ion channels. 
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Figure 2.4. A simplified overview of the immune responses generated from the different 
antigens used in the vaccines discussed in this chapter.  Arrows are indicative of the route 
of administration being used for these vaccines.     
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CHAPTER 3: 
Research Objectives and Thesis Organization 
 
 The overall objective of this research is to design a synthetic nanoparticle-based 
intranasal vaccine against respiratory pathogens, specifically H5N1 influenza. In order to 
accomplish this objective, the deposition and internalization of intranasal nanoparticle vaccines 
were studied at early time points with an eye towards examining the role of the initial fate of 
these particles on the induction of long-lasting memory responses and protective immunity. 
These studies were followed by an examination of the long-term persistence of nanoparticle-
based vaccines. Furthermore, the long-lasting memory responses of particle-based vaccines 
were examined by utilizing an adoptive transfer model of antigen-specific CD8+ T cells and a 
model antigen (ovalbumin). Next, the stability and release kinetics of a nanoparticle-
encapsulated H5 hemagglutinin trimer (H53) were investigated to rationally determine the 
optimal polyanhydride chemistries suitable for protein stabilization. The insights gained from all 
these studies were utilized to perform in vivo experiments in a rodent model to define the 
immune responses to H53-containing polyanhydride nanovaccine formulations and protection 
was evaluated against live viral challenge. 
 
The specific goals (SGs) of this research are to: 
SG1: Characterize the deposition, internalization, and persistence characteristics of 
          intranasally delivered polyanhydride nanoparticles; 
SG2: Assess the cell-mediated long-term memory responses induced by polyanhydride 
         nanoparticle vaccine formulations using an adoptive transfer model of antigen 
         specific CD8+ T cells; 
SG3: Evaluate the structural and functional stability and release kinetics of H53 
         hemagglutinin antigen encapsulated within polyanhydride nanoparticles; and 
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SG4: Investigate the efficacy of H53-containing polyanhydride nanoparticle formulations 
         in a murine model. 
 
 The following four chapters in the thesis address these specific goals. The first specific 
goal is addressed in Chapters 4 and 5, which discuss the initial (i.e., within 48 h) deposition and 
cellular internalization of polyanhydride nanoparticles within the lungs as well as effects of long-
term antigen persistence. Chapter 6 focuses on SG2, investigating the expansion, contraction, 
and phenotypes of CD8+ T cells after administration of polyanhydride nanoparticles. Chapter 7 
is focused on rationally determining the optimal polyanhydride chemistries for encapsulating H53 
through examination of protein structure and function upon release from nanoparticles. Finally, 
Chapter 8 addresses SG4 by investigating the humoral and cell-mediated responses to H53-
loaded nanoparticles in vivo and the ability of those responses to protect against a live viral 
challenge. 
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CHAPTER 4: 
Lung Deposition and Cellular Uptake Behavior of Pathogen-mimicking 
Nanovaccines in the First 48 Hours 
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Abstract 
Pulmonary immunization poses the unique challenge of balancing vaccine efficacy with 
minimizing inflammation in the respiratory tract. While previous studies have shown that mice 
immunized intranasally with F1-V-loaded polyanhydride nanoparticles were protected from a 
lethal challenge with Yersinia pestis, little is known about the initial interaction between the 
nanoparticles and immune cells following intranasal administration. Herein, the deposition within 
the lung and internalization by phagocytic cells of polyanhydride nanovaccines encapsulating 
F1-V are compared to that of soluble F1-V alone or F1-V adjuvanted with monophosphoryl lipid 
A (MPLA). Encapsulation of F1-V into polyanhydride nanoparticles prolonged its presence while 
F1-V administered with MPLA was undetectable within 48 hours. The inflammation induced by 
the polyanhydride nanovaccine was mild compared to the marked inflammation induced by the 
MPLA-adjuvanted F1-V. Even though F1-V delivered with saline was detected in the lung 48 
hours after administration, it is known that this regimen does not elicit a protective immune 
response. The prolonged F1-V presence in the lung in concert with the mild inflammatory 
response provided by the nanovaccine provides new insights into the development of protective 
1
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2
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immune responses with a single intranasal dose.  
 
4.1. INTRODUCTION 
Many pathogens enter the body through mucosal surfaces, especially those of the 
gastrointestinal and respiratory tracts. When designing vaccines against respiratory pathogens, 
mucosal immunization (e.g., oral, intranasal, pulmonary, intrarectal, conjunctival) will likely 
provide both systemic and mucosal immunity.1,2 Delivery to the lungs also increases the 
bioavailability of the antigen by avoiding first pass metabolism and by enabling high adsorption 
because of the large, permeable surface area.1-4 The lungs encounter many airborne particles 
and must differentiate between innocuous particles and pathogens, only initiating a response 
when true danger is present.5,6 Therefore, an ideal delivery system for a subunit vaccine must 
enhance antibody and/or T cell responses to often weakly immunogenic proteins without 
disrupting homeostasis within the respiratory tract.  
Polyanhydride nanoparticles comprised of 1,6-bis(p-carboxyphenoxy)hexane (CPH), 1,8-
bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG), and copolymers thereof are well suited for 
pulmonary administration because of their favorable safety profile, mild inflammatory response, 
and their ability to enhance the immune response.7,8 However, compared to an approved 
adjuvant such as alum, polyanhydride nanoparticles are markedly less phlogistic.8 Induction of a 
mild inflammatory response may be especially important when designing vaccine formulations 
to deliver antigens to the lungs, which are sensitive to inflammation. Additionally, polyanhydride 
nanovaccines provide pathogen-mimicking capabilities that enhance the activation of antigen 
presenting cells (APCs).8, 9, 10 These nanovaccines induce robust immune responses and 
provide protective immunity without the damaging effects of disease.7 A recent study utilizing 
F1-V, a recombinant antigen derived from Yersinia pestis, showed that a single dose of 
intranasally administered polyanhydride nanovaccine induced full protection against a 
subsequent lethal challenge.7, 10 
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While it has been demonstrated that intranasally administered polyanhydride 
nanovaccines provide long-lasting protective immunity,7, 10 the role of deposition within the lung 
and internalization by phagocytic cells of nanoparticles on the induction of immune responses 
after delivery is largely unknown. The initial interactions between antigen and the immune 
system are often critical to the establishment of long-lasting protective immunity. For example, 
studies with nano-sized viral particles such as influenza virions have demonstrated pathogen 
deposition and infection in the lower respiratory tract.11 Likewise, vaccines that deposit within 
the same area of the respiratory tract would be ideal candidates for prevention of influenza. 
Such vaccines have demonstrated increased residence time and prolonged contact with APCs 
resulting in enhanced cell-mediated responses.12 It is known that dendritic cells (DCs) that 
reside within lymph nodes and injection-site DCs play important roles during the first 50 hours 
post-infection.13 This study by Jenkins and co-workers demonstrated that while many resident 
DCs acquired antigen in the draining lymph nodes and presented peptide-MHC II complexes 
within 30 minutes of injection of a soluble antigen, the interactions between these DCs and 
naïve CD4+ T cells were relatively short-lived. Injection-site DCs that migrated to the lymph 
node, however, interacted with CD4+ T cells for extended periods of time, inducing T cell 
proliferation despite arriving at the lymph nodes 18 hours post-injection.13 It was also observed 
that sustained exposure of antigen enriched these interactions and enhanced T cell activation.13 
Based on these results, a reasonable hypothesis is that vaccine delivery vehicles that prolong 
the presence of antigen may enhance the immune response. 
This work focuses on the initial (i.e., the first 48 hours) deposition within the lung and 
internalization by phagocytic cells of intranasally administered polyanhydride nanovaccines. 
Using fluorescently labeled F1-V antigen, the kinetics of soluble and encapsulated F1-V 
distribution within the lungs and its uptake by APCs were investigated. This work demonstrates 
key differences in antigen presence and inflammation when administered as part of a 
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polyanhydride nanovaccine compared to that associated with monophosphoryl lipid A (MPLA), 
providing new insights into the protective capabilities of pathogen-mimicking nanovaccines. 
 
4.2. METHODS AND MATERIALS 
4.2.1. Materials 
 Compounds for polymer synthesis included 1,6-dibromohexane, 1-methyl-2-
pyrrolidinone, hydroxybenzoic acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene 
glycol (Sigma Aldrich, St. Louis, MO). Acetic acid, acetic anhydride, acetone, acetonitrile, 
chloroform, dimethyl formamide, ethyl ether, hexane, methylene chloride, pentane, petroleum 
ether, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were purchased from 
Fisher Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile was obtained from Apollo Scientific 
(Cheshire, UK). F1-V fusion protein was obtained from BEI Resources (Manassas, VA) and 
fluorescently labeled with Vivo Tag 680 according to manufacturer instructions (Vivo Tag 680, 
Perkin Elmer, Waltham, MA). The inflammatory probe ProSense® 750 FAST was also 
purchased from Perkin Elmer. Flow cytometric analysis utilized anti-mouse antibodies and their 
respective isotypes for PerCP-Cy5.5 labeled anti-CD11c, Biotinylated anti-CD324, Streptavidin-
conjugated eFluor 710 (eBioscience, San Diego, CA), PE-CF594 labeled anti-CD11b (BD 
Bioscience, San Jose, CA), and PE-Cy7 labeled anti-F4/80 (BioLegend, San Diego, CA). 
 
4.2.2. Polymer synthesis and characterization 
 The anhydride monomers, CPH and CPTEG, and the 50:50 CPTEG:CPH copolymer 
were synthesized as previously described.18,19 Copolymer composition, purity, and molecular 
weight (Mw~5100 Da, PDI = 1.5) were determined by 
1H nuclear magnetic resonance 
spectroscopy (VXR 300 MHz, Varian, Palo Alto, CA) and found to be consistent with previously 
published results.19 
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4.2.3. Nanoparticle synthesis 
 F1-V was conjugated to Vivo Tag 680 per the manufacturer’s instructions (Perkin Elmer). 
50:50 CPTEG:CPH nanoparticles loaded with 2% (w/w) Vivo Tag 680-conjugated F1-V were 
fabricated by nanoprecipitation as described previously.7 Briefly, 20 mg/mL polymer with 0.2 mg 
lyophilized F1-V was dissolved in methylene chloride and sonicated to ensure uniform protein 
distribution. The solution was then poured into chilled pentane (at a solvent:non-solvent ratio of 
1:250) to precipitate the nanoparticles. Particles were collected using vacuum filtration and their 
morphology and size (mean diameter of 180 ± 57 nm) were characterized with scanning 
electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR). 
 
4.2.4. Intranasal immunization 
 Female C57BL/6 mice were purchased from Harlan (Haslett, MI). Mice were housed 
under specific pathogen-free conditions where all bedding, caging, water, and feed were 
sterilized prior to use. All studies were conducted with the approval of the Iowa State University 
Institutional Animal Care and Use Committee. There were five separate treatment groups of 
mice that were intranasally administered following administration of 100 µL of 20 mg/mL 
ketamine with 1 mg/mL xylazine anesthesia with either i) 10 μg of F1-V encapsulated within 500 
μg of 50:50 CPTEG:CPH nanoparticles, ii) 50 μg of soluble F1-V and 10 μg encapsulated within 
500 μg of 50:50 CPTEG:CPH nanoparticles, iii) 50 μg of soluble F1-V adjuvanted with 10 μg 
MPLA, iv) 50 μg of soluble F1-V alone, or v) saline (Figure 4.1). These groups were chosen 
based upon previous studies by Ulery et al.7, 10 All formulations were administered in 50 μL 
sterile phosphate buffered saline (PBS). Six mice per group were used and two independent 
experiments were performed. 
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4.2.5. Ex vivo imaging of antigen distribution in lung tissue 
 Animals were euthanized 2 and 48 hours post-immunization. After perfusing the lungs 
with 5 mL sterile PBS, the lungs were excised and imaged to detect the distribution of the Vivo 
Tag 680-conjugated antigen within the lung using an in vivo imaging system (Carestream 
Multispectral FX, Rochester, NY). Images were captured using a white light image with a 2 
second exposure followed by a fluorescent image with a 10 second exposure with an excitation 
wavelength of 670 nm and a 750 nm emission filter. All images were analyzed with ImageJ 
software (Version 1.46r, NIH, Bethesda, MD). To calculate MFI, regions of interest were 
selected around each fluorescent lung image to obtain a MFI value for each sample. To obtain 
ex vivo fluorescent lung images (Figure 4.1), the false-color look-up table “fire” was applied to 
the fluorescent image and an overlay was created with the white light and fluorescent images.   
 
4.2.6. Inflammatory response of adjuvants 
 The pulmonary inflammation was measured using ProSense® 750 FAST (Perkin Elmer, 
Waltham, MA), a fluorescent probe activated by cathepsins. ProSense® 750 FAST was 
prepared according to manufacturer instructions and administered via tail vein injection six 
hours prior to imaging. Mice (n = 3) received intranasal administrations with 500 µg of blank 
50:50 CPTEG:CPH nanoparticles or 10 µg MPLA in 50 µL, and euthanized at 6, 24, and 48 
hours post-administration. Perfused lung tissue was excised from each mouse and imaged for 
the presence of activated ProSense® 750 FAST. Images were captured as described above 
using a white light image with a 2 second exposure followed by a fluorescent image with a 10 
second exposure with an excitation wavelength of 750 nm and an 830 nm emission filter. 
Regions of interest were selected around each fluorescent lung image and the background was 
subtracted using a rolling ball radius of 40 to obtain a MFI value for each sample. To obtain ex 
vivo fluorescent lung images (Figure 4.1), the false-color look-up table “fire” was applied to the 
fluorescent image and an overlay was created using the white light and fluorescent images.   
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4.2.7. High-throughput multi-spectral imaging flow cytometry 
 Excised lungs were incubated in Hank’s balanced salt solution with 1 mg/mL 
collagenase D and 60 U/mL DNase II for 20 minutes at 37°C. Single cell suspensions were 
prepared using a gentleMACSTM dissociator (Miltenyi Biotec, Cambridge, MA). Debris was 
removed by passing the tissue homogenate through a 40 μm cell filter and red blood cells were 
lysed with ACK lysis buffer (150 mM ammonium chloride, 10 mM potassium bicarbonate, 0.1 
mM EDTA). The cells (2.5 x 106 cells/mL) were washed with 2% heat inactivated fetal bovine 
serum and 0.1% sodium azide in PBS and re-suspended in 50 μL 1% paraformaldehyde in 
PBS. Cell samples were analyzed using multi-spectral imaging flow cytometry (ImageStreamX, 
Amnis, Seattle, WA) by exciting the samples with a 658 nm laser and collecting emission 
spectra using a 600-745 nm filter. Internalization of F1-V antigen was determined following the 
manufacturer’s instructions using IDEAS® software (Amnis). 
 
4.2.8. Flow cytometry 
 Single cell suspensions were prepared as described above. Cell suspensions (2.5 x 106 
cells/mL) were subsequently blocked for non-specific antibody binding using 0.1 mg/mL rat IgG 
and 10μg/mL mouse anti-CD16/32. Cells were surface-stained for CD11c, CD11b, CD324, and 
F4/80. All samples were fixed with stabilizing fixative (BD Biosciences) and analyzed using a 
FACS Canto flow cytometer (BD Biosciences, San Jose, CA) and data analysis was performed 
with FlowJo software (Treestar, Inc., Ashland, OR). 
 
4.2.9. Statistics 
 The statistical tests were performed in MiniTab software (Minitab Inc, State College, PA). 
Significant differences between two indicated groups were evaluated by Student's t-test. The 
level of significance was set at p < 0.05, unless otherwise stated. 
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4.3. RESULTS AND DISCUSSION 
4.3.1. Encapsulation prolongs antigen presence 
Mice received an intranasal administration of the vaccine formulations shown in Figure 
4.1. After 2 and 48 hours post-administration, separate groups of animals were euthanized and 
their lungs were excised to visualize and quantify the distribution of fluorescently labeled F1-V 
antigen. The lungs of all mice showed a uniform spatial distribution of F1-V at 2 and 48 hours 
post-administration, regardless of the formulation (Figure 4.1). Ex vivo analysis of lung tissues 
showed that the mice administered the nanovaccine formulation showed prolonged presence of 
antigen. Figure 4.1 shows the percentage loss in fluorescence in the lung between 2 and 48 
hours for each formulation administered. Statistically significant decreases in fluorescence 
intensity, i.e., statistically significant differences in mean fluorescence intensity (MFI) values at 2 
and 48 hours post-immunization, were observed in the lungs of mice that received soluble F1-V 
or F1-V adjuvanted with MPLA (Figure 4.1) while that of mice that received only nanoparticle-
encapsulated F1-V (i.e., no soluble antigen) displayed stable fluorescence intensity (i.e., no 
statistical significance between MFI values at 2 and 48 hours). The lungs of the mice that 
received the soluble F1-V + nanoparticle-encapsulated F1-V also showed a marked decrease in 
fluorescence between 2 and 48 hours. In this formulation, 80% of the antigen was delivered 
solubly and thus cleared quickly, accounting for the decreased fluorescence. However, the 
nanoparticles prolonged the presence of F1-V in the lungs, as noted by the stable fluorescence 
intensity between 2 and 48 hours in the lungs of the mice that received only the F1-V 
encapsulated nanoparticles (i.e., without any soluble antigen). In order to make comparisons 
with the formulations tested in previous work,7 the “encapsulated only” formulation contained 10 
µg of antigen, while the soluble protein formulation contained 50 µg, and the “soluble + 
encapsulated” group received 60 µg of F1-V. Therefore, it is important to note that only 
differences between 2 and 48 hours within each group are being compared, because the actual 
MFI may vary between groups.  
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4.3.2. Reduced pulmonary inflammation after deposition of polyanhydride nanovaccine 
Because inflammation may affect the disappearance of antigen from the site of 
deposition, the inflammatory response induced by MPLA and the nanovaccine was evaluated. It 
is known that MPLA induces a marked inflammatory response16 and recruits inflammatory cells 
to the site of antigen administration, which aids in the clearance of antigen. While 
subcutaneously administered polyanhydride nanoparticles have previously been shown to 
induce less inflammation in comparison to alum,8 the inflammation induced by intranasally 
delivered polyanhydride nanovaccines is unknown. Mice that were previously administered 
polyanhydride nanoparticles or MPLA intranasally were injected with ProSense® 750 FAST, a 
fluorescent imaging agent that is activated by cathepsins produced by inflammatory cells such 
as monocytes and macrophages.20 While both polyanhydride nanovaccines and MPLA 
displayed similar magnitudes of inflammation at 6 hours post-administration (Figure 4.2), by 48 
hours the level of cathepsin-activated fluorescent probe detected in the lungs of mice treated 
with MPLA was double that of the mice that received nanoparticles. We hypothesize that the 
increased inflammation induced by MPLA led to a greater recruitment of macrophages that 
enabled the more rapid clearance of F1-V depicted in Figure 4.1.  
Thus far, our data indicate that polyanhydride nanovaccines prolonged the presence of 
F1-V in the lungs (Figure 4.1) while inducing mild inflammation (Figure 4.2). The prolonged F1-V 
presence in the lung in concert with the mild inflammatory response provided by the 
nanovaccine suggests a novel paradigm related to the development of the long-lasting 
protective immune response following the administration of a single intranasal dose as 
previously observed.7 It is instructive to note that F1-V delivered with MPLA induced a relatively 
higher level of inflammation, and was cleared from the lung by 48 hours. F1-V delivered alone 
does remain in the lung for up to 48 hours, but failed to elicit a measurable immune response in 
previous studies.7, 10 An important benefit of the F1-V nanovaccine formulation is to enhance the 
stimulation of the immune system through the induction of an inflammatory response (albeit mild 
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in comparison to MPLA), while simultaneously prolonging the presence of antigen within the 
lung, potentially leading to increased interactions with T cells and enhanced immune 
activation.13  
 
4.3.3. Cellular internalization of antigen is sustained by polyanhydride nanovaccine 
It is known that continual exposure of antigen to APCs at the site of administration 
increases APC-T cell interactions and T cell proliferation in the draining lymph nodes.13 These 
enhanced cellular interactions suggest that vaccine delivery regimens which provide a sustained 
presence of antigen in the lungs would better enable the induction of long-lasting immunity. In 
this work, high-throughput multi-spectral imaging flow cytometry was used to detect APCs that 
had internalized F1-V. At 48 hours post-administration, cells recovered from the lungs of mice 
that received soluble and/or nanovaccine formulations were positive for internalized F1-V. In 
addition, there was a marked decrease (from 2 to 48 hours) in the percentage of cells containing 
F1-V from the mice that had been administered F1-V adjuvanted with MPLA (Figure 4.3). This 
observation is consistent with the results in Figure 4.1. While soluble F1-V is rapidly internalized 
by APCs, the nanovaccine formulations continue to release antigen that can be continually 
internalized by both resident as well as recruited APCs. In contrast, the mice treated with MPLA-
adjuvanted F1-V demonstrated a significant decrease in both tissue fluorescence and cellular 
internalization within 48 hours after immunization.  
It is important to recognize that the cellular population at the administration site is 
dynamic and involves both resident and recruited APCs. While the inflammatory responses 
induced by MPLA (Figure 4.2) recruits APCs that can internalize foreign antigen, the antigen 
may be rapidly exported to the lymph node and/or degraded, resulting in little antigen remaining 
in the lungs to interact with newly recruited cells. In contrast, more F1-V positive cells were 
present at 48 hours in the lungs of mice that received the polyanhydride nanovaccines. This 
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suggests that APCs recruited to the lung were able to internalize F1-V released from the 
nanovaccine.  
Although soluble antigen is still present within the lung at 48 hours, it was previously 
demonstrated that soluble F1-V antigen alone did not elicit a protective immune response.7, 10 
Because soluble F1-V alone likely failed to induce an inflammatory response, it is conceivable 
that fewer APCs were recruited to the lungs that resulted in less clearance of the F1-V by 48 
hours. This poses an additional consideration to the above argument. While presence (i.e., dose 
and time) of antigen is necessary for the induction of an immune response, soluble F1-V 
delivered alone was not sufficient to initiate an immune reponse.7 Therefore, an appropriate 
adjuvant is necessary to prolong the presence of the antigen within the lung for internalization 
by and activation of recruited APCs. As demonstrated in this work, polyanhydride nanovaccines 
are able to bridge this shortfall by prolonging the presence of antigen at the site of 
administration coupled with a mild inflammatory immunological stimulation that may explain the 
ability of the nanovaccines to induce long-lasting protective immunity.7 
 
4.3.4. Cellular uptake prolonged by polyanhydride nanovaccines 
 To ascertain the specific cell types interacting with antigen, flow cytometry was used to 
characterize cellular populations of F1-V+ cells. In these analyses, all F1-V+ cells were gated 
first before using the following cell surface marker combinations to characterize the cellular 
populations: DCs: CD11c+ CD11b-; alveolar macrophages (aMØs): CD11c- CD11b+ F4/80+; and 
epithelial cells: CD11c- CD11b- CD324+ (Figure 4.4A). While the percentage of different cellular 
populations associated with antigen was independent of formulation (Figure 4.4B), the MFI or 
amount of F1-V within the cell populations varied among the different treatment groups (Figure 
4.4C). Consistent with the data presented in Figures 4.1 and 4.3, the amount of antigen in the 
F1-V+ DCs and aMØs was reduced significantly to background by 48 hours for cells recovered 
from mice administered MPLA-adjuvanted F1-V (Figure 4.4C). This is likely associated with the 
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more rapid clearance of antigen (Figure 4.1) induced by inflammation (Figure 4.2). In contrast, 
mice administered nanovaccines or soluble antigen alone displayed stable or increased MFI of 
antigen associated with DCs or aMØs and was comparable to cells recovered from mice that 
received only the soluble antigen (Figure 4.4C). It is likely that the previously identified protective 
nanovaccine formulation,7 consisting of both soluble and nanoparticle-encapsulated antigen, 
demonstrated superior performance because of the initial priming of the immune response by 
soluble protein and the maturation of the serum antibody response (e.g., titer and avidity) 
facilitated by the prolonged presence of F1-V provided by the nanovaccines. 
 
4.4. CONCLUSIONS 
These studies provide confirmatory evidence relating to the ability of the pathogen 
mimicking 50:50 CPTEG:CPH nanovaccine to induce prolonged APC uptake of antigen in 
concert with a mild inflammatory response. Furthermore, the nanovaccine was able to 
overcome limitations associated with the MPLA and soluble dose formulations in its ability to 
bridge the gap between prolonged antigen presence and activation of APCs. These 
characteristics of polyanhydride nanovaccines suggest a novel paradigm related to the 
development of the long-lasting protective immune response following the administration of a 
single intranasal dose as previously observed. Together with their low phlogistic potential and 
their capacity to prolong antigen presence at the site of administration, polyanhydride 
nanovaccines are excellent candidates for pulmonary vaccination. 
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4.5 FIGURES 
 
 
 
 
 
 
 
 
Figure 4.1. Ex vivo detection of F1-V in the lungs of mice following intranasal 
administration. Images of excised lungs show presence of fluorescently labeled F1-V at 2 and 
48 hours after administration. The table on the right depicts the different treatment groups with 
the respective dose of F1-V administered per mouse. The table also includes the percent 
decrease in mean fluorescence intensity (MFI) of the labeled-F1-V from the 2 to 48 hour time 
point for each group ± standard error of mean. * indicates statistical significance between the 
MFI values at 2 and 48 hours for that treatment at p < 0.05. Six mice per group were used from 
two independent experiments. 
 
 
Percent  
Decrease 
in MFI 
Total  
F1-V 
(µg) 
Soluble  
F1-V 
(µg) 
Encapsulated 
F1-V 
(µg) 
Soluble 
Alone 
52.4 ± 7.9* 50 50 0 
MPLA 85.9 ± 4.3* 50 50 0 
Encapsulated 32.1 ± 13.0 10 0 10 
Soluble + 
Encapsulated 
68.4 ± 7.6* 60 50 10 
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Figure 4.2. Comparison of the pulmonary inflammation induced following intranasal 
administration of 50:50 CPTEG:CPH nanoparticles compared to that induced by MPLA. 
ProSense® 750 FAST, a cathepsin activated fluorescent probe, was used to detect 
inflammation. Mean fluorescence intensity, represented on the y-axis, corresponds to the level 
of inflammation present at the indicated time points after administration. Error bars represent 
standard error of the mean (SEM) and n=3. * indicates statistical significance between 50:50 
CPTEG:CPH and MPLA at the indicated time point (p < 0.05). Background levels of 
inflammation observed at 6 hours in the mice administered saline, n=2, had an average MFI of 
63.8. 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Assessment of internalized F1-V by lung cells using multispectral imaging 
flow cytometry. All error bars represent SEM with n=6. One thousand events per sample were 
acquired and analyzed as described in Materials and Methods. * indicates statistical significance 
between 2 and 48 hours for that treatment at p < 0.05. “Encap“ is an abbreviation for 
“Encapsulated“. 
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Figure 4.4. Use of flow cytometry to assess the pulmonary cellular populations of F1-V+ 
cells. (A) Representative contour plots demonstrate the gating used to determine dendritic 
(CD11c+ CD11b-), macrophage (CD11c- CD11b+ F4/80+), and epithelial (CD11c- CD11b- 
CD324+) cell types. (B) Percent of each cell type within the F1-V+ population and (C) MFI of F1-
V associated with dendritic cells (top), macrophages (middle), and epithelial cells (bottom). All 
error bars represent SEM and n=6. Ten thousand events per sample were collected. * indicates 
statistical significance between 2 and 48 hours for that treatment at p < 0.0001. 
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Abstract 
 Acute respiratory infections represent a significant portion of global morbidity and 
mortality annually. There is a need for highly effective vaccines against respiratory pathogens. 
When designing a vaccine against respiratory diseases, pulmonary delivery is an attractive 
route as it mimics the route of natural infection and may confer both systemic and mucosal 
immunity. We have previously demonstrated that single dose, intranasal vaccines based on 
polyanhydride nanoparticles elicit a protective immune response up to 40 weeks after 
immunization. Herein we investigate the effect of nanoparticle chemistry on in vivo antigen 
persistence, antigen release kinetics, and the humoral immune response. We demonstrate that 
a tunable antigen persistence profile in vivo can be achieved based on nanoparticle chemistry, 
sustained antigen internalization by antigen presenting cells, and the development of avid 
antibodies towards protective epitopes over time. These studies shed new light on the role of 
prolonged antigen presence in vivo in inducing protective immunity and have important 
implications for the rational design of efficacious single dose vaccines against respiratory 
pathogens. 
1
 Department of Chemical and Biological Engineering, Iowa State University, Ames, Iowa 50011 
2
 Department of Veterinary Microbiology and Preventive Medicine, Iowa State University, Ames, Iowa 50011 
 
82 
 
 
 
5.1. INTRODUCTION 
 Acute respiratory infections represent a significant portion of global morbidity and 
mortality annually.1, 2 With the increasing prevalence of multi-drug resistant pathogens and the 
threat of aerosolized bioterrorism agents, there is an urgent need for highly effective vaccines 
against respiratory pathogens.3, 4 When designing vaccines against respiratory diseases, 
intranasal and pulmonary delivery are attractive routes because intranasal or inhaled vaccines 
can confer both systemic and mucosal immunity, deliver antigen to highly immunoreactive sites 
within the lung, and lead to increased protection.5, 6 Recombinant protein technology has led to 
the development of protective antigens against many respiratory pathogens, often based on 
surface proteins of viruses and bacteria. It is often noted, however, that antigen delivered alone 
intranasally does not induce a protective immune response, and therefore, requires the use of 
adjuvants.7, 8  
 Polyanhydride nanoparticle-based vaccines (i.e., nanovaccines) have previously been 
demonstrated to be a safe and efficacious delivery platform for protein antigens against multiple 
pathogens.3, 9, 10 These biodegradable polymers demonstrate pathogen-mimicking properties 
that adjuvant poorly immunogenic subunit proteins to enhance the immune response.11 
Additionally, particle chemistry may be tailored to stabilize fragile proteins as well as the protein 
release profile.10 A polyanhydride nanovaccine based on F1-V, a recombinant fusion protein 
that has been shown to be a protective antigen against pneumonic plague,12 has been 
demonstrated to provide protective immunity up to 40 weeks after vaccination.13   
 Previously, we have described the deposition, distribution, and prolonged presence of 
antigen delivered with polyanhydride nanovaccines at early time points after administration (i.e., 
48 hours), which enhances internalization by antigen presenting cells (APCs).14 While the initial 
interactions between antigen and APCs are important in laying a foundation for vaccine efficacy, 
the role of the nanovaccine formulation (i.e., the chemistry of the nanoparticle carrier) on the 
persistence of antigen in vivo is critical for the continual recruitment of antigen-internalizing 
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APCs and the development of high antibody titers with increased avidity. In this work, we follow 
the persistence of antigen encapsulated into polyanhydride nanoparticles over nine weeks and 
provide an in-depth analysis of the effect of nanoparticle chemistry on pulmonary persistence of 
antigen, sustained internalization of antigen by immune cells, and the humoral immune 
response. 
 
5.2. MATERIALS AND METHODS 
5.2.1. Materials 
 The materials used for monomer synthesis include sodium hydroxide, hydrobenzoic 
acid, dibromohexane, 1-methyl-2-pyrrolidinone, triethylene glycol, and sebacic acid (Sigma 
Aldrich, St. Louis, MO). Acetone, sulfuric acid, potassium carbonate, dimethyl formamide, 
toluene, acetonitrile, N,N-dimethylacetamide, and acetic acid were purchased from Fisher 
Scientific (Fairlawn, NJ). 4-p-fluorobenzonitrile used in the synthesis of CPTEG monomer was 
purchased from Apollo Scientific (Cheshire, UK). Acetic anhydride, ethyl ether, petroleum ether, 
chloroform, methylene chloride, and hexane used in acetylation and polymerization were 
purchased from Fisher Scientific. Deuterated chloroform and dimethyl sulfoxide were used in 1H 
NMR analysis of the polymers and monomers (Cambridge Isotope Laboratories, Andover, MA). 
Pentane and methylene chloride used in nanoparticle fabrication were purchased from Fisher 
Scientific. 
 F1-V fusion protein (BEI Resources, Manassas, VA) was conjugated to the fluorescent 
label Vivo Tag 680 (Perkin Elmer, Waltham, MA). Flow cytometry utilized anti-mouse antibodies 
and their respective isotypes for PerCP-Cy5.5 CD11c, Biotin CD324, Streptavidin eFluor 710 
(eBioscience, San Diego, CA), PE-CF594 CD11b (BD Bioscience, San Jose, CA), and PE-Cy7 
F4/80 (BioLegend, San Diego, CA). 
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5.2.2. Polymer Synthesis 
 The CPH and CPTEG monomers were fabricated as described previously.15-17 Pre-
polymers of CPH and SA were synthesized from monomers as described previously.16, 17 
Polymers and co-polymers of CPH, CPTEG and SA were synthesized using melt condensation 
as described by Kipper et al. and Torres et al.15, 16 Polymer purity and molecular weight were 
determined using 1H NMR (Varian VXR300). 
 
5.2.3. Nanoparticle Fabrication 
 The F1-V fusion protein was conjugated to VivoTag 680 fluorescent label according to 
manufacturer instructions (Perkin Elmer). Briefly, 10 µL VivoTag 680 was added per mg of F1-V 
and incubated at room temperature for 1 h. Excess unconjugated VivoTag 680 was then 
removed using a 5 kDa MWCO dialysis microcentrifuge tube. The protein was lyophilized 
overnight at -40˚C under vacuum. The F1-V loaded polyanhydride nanoparticles were 
formulated using an anti-solvent precipitation method as previously described.13 Polymer and 
2% (w/w) F1-V were dissolved in methylene chloride at a concentration of 20 mg/mL. The 
solution was sonicated (Vibra-CellTM, Sonics & Materials, Newton, CT) at an output of 40 Hz to 
ensure a homogenized mixture. The resulting solution was rapidly poured into pentane at a ratio 
of 1:250 at room temperature for CPH:SA and poly(SA) formulations or at -40°C for the 
CPTEG:CPH polymers due to the lower glass transition temperature for these polymers.15 
Nanoparticles were collected via vacuum filtration and characterized using scanning electron 
microscopy (FEI Quanta SEM, Hillsboro, OR). Particle size distribution was determined from 
resultant images using ImageJ (Version 1.46r, NIH, Bethesda, MD) software and found to be 
consistent with previous work.18, 19 
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5.2.4. Mice 
 C57BL/6 mice purchased at 5-6 weeks of age were used (Harlan, Haslett, MI). Mice 
were housed under specific pathogen-free conditions where all bedding, caging, water, and feed 
were sterilized prior to use. All studies were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. 
 
5.2.5. Immunization Protocol 
 Mice (between 7 and 9 weeks of age) were anesthetized with 100 µL of 20 mg/mL 
ketamine and 1 mg/mL xylazine and immunized intranasally. Experimental groups consisted of 
10 µg of F1-V encapsulated into 500 µg of 50:50 CPTEG:CPH, 20:80 CPTEG:CPH, 20:80 
CPH:SA, or poly(SA) nanoparticles with 40 µg soluble F1-V delivered concurrently in 50 µL 
PBS, 50 µg F1-V delivered with 10 µg MPLA derived from Salmonella enterica serotype 
Minnesota Re 595 (Sigma Aldrich), or 50 µg F1-V alone. Sterile PBS was used for control 
animals. Mice were euthanized at 14, 36, and 63 days post-immunization. Four mice were used 
per group per time point and the experiment was repeated for a total of 8 mice per group. The 
soluble protein alone and control groups were administered to half the number of animals as the 
treatment groups. 
 
5.2.6. Ex vivo Lung Imaging 
 Mice were euthanized to quantify protein remaining in the lung at 14, 36, and 63 days 
after immunization. A lung perfusion with 5 mL of sterile PBS was performed to reduce 
background from autofluorescence of red blood cells and the lungs were excised. An in vivo 
imaging system (Carestream Multispectral FX, Rochester NY) was used to measure the 
fluorescence of antigen remaining in the lungs. A white light image (2 s exposure) followed by a 
fluorescent image (60 s exposure) with an excitation of 670 nm and a 750 nm emission filter 
was used. 
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 Images were analyzed using ImageJ software. Mean fluorescence intensity (MFI) was 
calculated using the fluorescent lung images. A region of interest was drawn around the 
fluorescent image and the mean was recorded. Background was then subtracted from each 
sample and a MFI value was obtained. For the ex vivo lung images (Figure 5.1), background 
was subtracted from the fluorescent images with a rolling ball radius of 40, the images were 
smoothed, and the false-color look-up table “fire” was applied. White light images were adjusted 
to have the same minimum and maximum values and a z-projection of the two images was 
created. 
 
5.2.7. Multi-spectral Imaging Flow Cytometry 
 After imaging, lung samples were incubated in Hank’s balanced salt solution (HBSS) 
with 1 mg/mL collagenase D and 60 U/mL DNase II for 20 min at 37°C. Tissue was then 
homogenized to a single cell suspension using a gentleMACSTM dissociator (Miltenyi Biotec, 
Cambridge, MA). The cell suspensions were centrifuged at 250 rcf for 30 seconds to remove 
large debris. The supernatants were then passed through a 40 µm cell filter and centrifuged at 
250 rcf for 10 min at 4˚C to collect the cell pellet. Remaining red blood cells in the lung samples 
were lysed with ACK lysis buffer (150 mM ammonium chloride, 10 mM potassium bicarbonate, 
0.1 mM EDTA), and cells were centrifuged once more before enumeration using a Coulter 
counter (Beckman Coulter, Indianapolis, IN). Cells were washed once in buffer (2% heat 
inactivated fetal bovine serum and 0.1% sodium azide in PBS) and re-suspended in 60 μL 1% 
paraformaldehyde (PFA) in PBS. Samples were analyzed using an ImageStreamX (Amnis, 
Seattle, WA) with a 658 nm laser and 600-745 nm emission filter. Internalization of F1-V was 
determined using IDEAS® software following the manufacturer’s instructions (Amnis). 
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5.2.8. Flow Cytometry 
 Single cell suspensions were prepared as described above. Cell solutions were 
incubated with 0.1 mg/mL rat IgG and 10 μg/mL mouse anti-CD16/32 to prevent non-specific 
binding of fluorescent antibodies. Cell suspensions were surface-stained for CD11c, CD11b, 
CD324, and F4/80 for 30 min. After washing, the stained cell samples were re-suspended in 
100 μL stabilizing fixative (BD Biosciences) and analyzed using a FACS Canto flow cytometer 
(BD Biosciences, San Jose, CA). Analysis of the flow cytometric data was performed with 
FlowJo software (Treestar, Inc., Ashland, OR). 
 
5.2.9. Anti-F1-V Serum Antibody Titers and Avidity Assays 
 Antibody titers were determined using an enzyme-linked immunosorbent assay (ELISA) 
as described elsewhere.13 Briefly, high-binding microtiter plates were coated with 100 μL of F1-
V (0.5 µg/mL) in PBS and incubated overnight at 4˚C. F1-V coated microtiter plates were 
incubated with blocking buffer (0.05 M PBS with 0.05% Tween 20 (PBS-T) supplemented with 
2.5% powdered skim milk) for 2 h at room temperature before washing three times with PBS-T. 
Serum from immunized mice was added to the first well at a 1:200 dilution in PBS containing 
1% goat serum and serially diluted at a three-fold ratio per well. After incubating at 4˚C 
overnight, plates were washed three times with PBS-T. Alkaline phosphatase-conjugated goat 
anti-mouse IgG (heavy and light chain) (Jackson ImmunoResearch, West Grove, PA) was 
added at a concentration of 1 µg/mL and incubated for 2 h at room temperature. Plates were 
washed again and 1 mg/mL alkaline phosphatase substrate (Fisher Scientific, Pittsburgh, PA) 
dissolved in 50 mM sodium carbonate, 2 mM magnesium chloride buffer (pH 9.3) was added for 
colormetric development. The optical density (OD) was recorded after 30 min at 405 nm. All the 
samples were tested in technical replicates of two. Herein, we define titer as the serum dilution 
value that produced an OD greater than twice that of the saline group.  
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 Avidity assays were performed as described above for ELISA. After overnight incubation 
with 100 µL per well serum at a 1:200 dilution, a 5 M solution of sodium thiocyanate (NaSCN) in 
a 0.1 M sodium phosphate buffer was added to the first well and serially diluted two-fold five 
times. Six control wells were used per sample and received sodium phosphate buffer alone. 
Solution was incubated for 15 min before washing thoroughly. The remainder of the assay 
follows the steps described above for ELISA. Avidity indices were calculated by determining the 
concentration of sodium thiocyanate at which the OD is 50% of that of the control wells.  
 
5.2.10. Peptide Array Assay 
 In order to measure the immune response to specific F1-V epitopes an overlapping 
peptide array (BEI Resources) assay was performed. High-binding microtiter plates were coated 
with individual F1-V peptides at a concentration of 5 µg/mL in PBS. The ELISA protocol 
described above was followed with a single serum dilution of 1:200 used for each sample. The 
optical density (OD) was recorded at 405 nm after incubating for 2 h at room temperature. 
 
5.2.11. Statistics 
 Statistical significance using the Graph Pad Prism software (Version 6.01, Graph Pad 
Software, Inc., La Jolla, CA) was determined by one-way analysis of variance (ANOVA) 
followed by Tukey's post-test. P-values less than or equal to 0.05 were considered significant. 
 
5.3. RESULTS 
5.3.1. Immunization with polyanhydride nanovaccines induced prolonged presence of 
antigen within the lung up to 63 days after administration 
 In order to compare the pulmonary persistence and immune response across different 
nanoparticle chemistries, a 50 µg dose of the protein F1-V was used, with 40 µg delivered as 
soluble protein and 10 µg encapsulated into 500 µg of polyanhydride nanoparticles. This 
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formulation has been demonstrated previously to protect against lethal challenge with Yersinia 
pestis with 50:50 CPTEG:CPH nanoparticles.11, 13 The F1-V antigen was tagged with the 
fluorescent label Vivo Tag 680 in order to track the persistence of encapsulated protein. 
Anesthetized C57B/6 mice were administered a single dose vaccine formulation intranasally 
and were euthanized at 14, 36, and 63 days in order to quantify the remaining fluorescence in 
the lungs and characterize antigen uptake by lung cells.  
 Figure 5.1 demonstrates the persistence of polyanhydride nanoparticles within the lung 
and the effect that nanoparticle chemistry has on the persistence of encapsulated antigen. 
Consistent with our previous work,14 protein adjuvanted with MPLA was cleared rapidly from the 
lung, with less than 0.4% of the original fluorescence (which was observed 2 h after 
immunization) remaining 14 days after administration. In contrast, the nanovaccine formulations 
continued to persist in the lung and released antigen as a function of the nanoparticle chemistry. 
The nanoparticles based on the CPH-rich chemistries, i.e., 20:80 CPTEG:CPH and 50:50 
CPTEG:CPH, maintained visible and measurable fluorescence for at least 63 days after 
immunization, indicating the prolonged presence of antigen within the lung. In contrast, 
nanoparticles based on the SA-rich chemistries, poly(SA) and 20:80 CPH:SA, showed a marked 
decrease in fluorescence within the lung 36 days after immunization and returned to baseline 
levels by 63 days. 
 
5.3.2. Nanoparticle chemistry influences antigen internalization and association 
 The quantification of antigen internalization within the lung demonstrates the combined 
effects of nanoparticle chemistry and persistence. SA-rich chemistries have been demonstrated 
previously to be the most readily internalized by APCs.18, 20, 21 Consistent with this observation, 
Figure 5.2 shows that 14 days after administration, antigen internalization is highest in mice 
immunized with the 20:80 CPH:SA nanovaccine. However, 36 days post-immunization, the 
percent of cells internalizing the 20:80 CPH:SA nanovaccine formulation decreased 
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dramatically. This decrease can be attributed to the fast erosion of 20:80 CPH:SA,22 which 
therefore, reduces antigen availability. In contrast, the hydrophobic 20:80 CPTEG:CPH 
nanovaccine shows comparatively modest internalization at day 14, but continues to be 
internalized above background for at least 63 days. This observation can be attributed to the 
slow erosion profile of CPH-rich chemistries,22 which enabled sustained release of antigen.   
 Additionally, flow cytometric analysis (Figure 5.3) showed increased cellular association 
of F1-V with dendritic cells (CD11c+) in mice that were administered the poly(SA) nanovaccine 
compared to that in saline-administered animals and the animals that received F1-V alone 14 
days after administration. Although macrophage association (CD11b+) did show some increase 
over the saline background, the differences between the various nanovaccine formulations were 
less pronounced. After 14 days, the fluorescence was no longer detectable.   
 
5.3.3. Polyanhydride nanovaccines elicit sustained high titer antibody responses 
 The data in Figures 5.1-3 provide evidence regarding the persistence and sustained 
release of antigen within the lung facilitated by intranasal immunization with polyanhydride 
nanovaccines. These data also suggest that antigen is continuously being internalized by lung 
cells. Next, new insights are presented on the combined effects of polymer chemistry and 
nanoparticle persistence on the immune response to the antigen. Figure 5.4 shows that 
antibody titer is a strong function of adjuvant chemistry, while antigen persistence has less of an 
impact on the antibody titer over time. The mice administered the highly persistent 20:80 
CPTEG:CPH nanovaccine demonstrated the highest serum antibody titers over the course of 
the nine week study. However, the titers appear to be trending downward by day 63. In contrast, 
the mice that received the 50:50 CPTEG:CPH nanovaccine showed increasing serum antibody 
levels through nine weeks. This is consistent with previously published work demonstrating that 
the 50:50 CPTEG:CPH nanovaccine contains pathogen-mimicking abilities,11 which may have 
led to a sustained immune response similar to that induced by the microbially-derived MPLA. It 
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is interesting to note that although the soluble protein alone persisted in the lung and continued 
being internalized by cells for 14 days, the animals that received this treatment did not show 
demonstrable antibody titers.  
 
5.3.4. Antigen persistence and release kinetics affects antibody avidity 
 The release kinetics of antigen, which is controlled by the chemistry of the biodegradable 
nano-carrier, affects the quality of antibody response, as measured by antibody avidity (Figure 
5.5). Nanovaccines based on 20:80 CPTEG:CPH, 20:80 CPH:SA, and poly(SA) nanoparticles 
induced highly avid antibodies which are sustained for nine weeks. In contrast, the serum of 
mice that received the amphiphilic 50:50 CPTEG:CPH nanovaccine showed an increasingly 
avid IgG antibody with time. These differences in avidity may be attributed in part to the 
differences in the protein release kinetics from these polymers.10, 15, 22 The poly(SA) and 20:80 
CPH:SA nanoparticles release antigen too rapidly to stimulate a sustained immune response 
which is important for high maturation affinity (i.e., highly avid) antibody. The most hydrophobic 
20:80 CPTEG:CPH nanoparticles release antigen so slowly that there may not be sufficient 
stimuli to elicit a sustained response. In contrast, the 50:50 CPTEG:CPH nanoparticles exhibit 
the appropriate release rate of antigen to induce a sustained immune response that favors the 
production of highly avid antibody. This finding is consistent with the antibody titer data in Figure 
5.4.  
 
5.3.5. Polyanhydride nanovaccines result in a focused epitope response 
 A peptide map of the F1-V antigen was used to determine how the nanovaccine 
formulation, delivery method, and protein release kinetics affected the immune response to 
specific regions of the protein. As shown in Figure 5.6A, F1-V delivered alone (i.e., without any 
adjuvant) generated antibodies to a broad spectrum of epitopes, but at relatively weak optical 
densities. In contrast, F1-V delivered either in the context of polyanhydride nanoparticles or 
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MPLA elicited a more specific antibody response towards a few dominant epitopes. Consistent 
with the antibody and avidity responses discussed in Figures 5.4 and 5.5, the responses to 
specific epitopes were highly dependent upon the nanoparticle chemistry and the kinetics of 
antigen release. The 20:80 CPTEG:CPH and 20:80 CPH:SA nanovaccines responded by day 
14 to the V1 and V2 epitopes, which have been shown to be important for protection.23, 24 
However, this response waned over the nine-week duration of the study, likely due to the 
clearance of soluble protein, and the too slow (20:80 CPTEG:CPH) or too fast (20:80 CPH:SA) 
release of the encapsulated antigen. In contrast, the 50:50 CPTEG:CPH nanovaccine enhanced 
its response to this region over 63 days. Similar responses were observed for the F18 epitope, 
noting that the addition of responses to the F1 antigen enhances the protection provided by the 
V antigen.12 The data in Figure 5.6B compares the immune response to the dominant epitope 
F18, V1, and V2 in response to each of the formulations. The immune response to these 
dominant epitopes induced by the 50:50 CPTEG:CPH nanovaccine exhibits a time dependent 
evolution to the V1 and V2 epitopes. In this case, the optical density increases steadily over the 
course of the study as the immune response narrows to these epitopes. This type of kinetics 
was not observed with any of the other nanovaccine formulations of with MPLA. 
 
5.4. DISCUSSION 
 In this work, polyanhydride nanoparticle formulations representing a range of 
hydrophobicity, amphiphilicity, and degradation kinetics were examined for their effect in vivo on 
antigen persistence, antigen release kinetics, and the resultant immune response phenotype. 
The most hydrophobic of the anhydride chemistries studied is CPH, which has the slowest rate 
of degradation (of the order of several months).15 Therefore, CPH-rich chemistries maintain a 
sustained release of payload over long periods of time and persist longer in vivo. In contrast, 
CPTEG, which has ethylene glycol moieties incorporated into the polymer backbone, has been 
shown to be pathogen-mimicking, based on its backbone oxygen moieties, presence of hydroxyl 
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end groups, etc.11, 15, 20 CPTEG-based polymers degrade the fastest among the formulations 
studied and exhibit bulk erosion.15 The degradation rate of poly(SA) is in between that of 
CPTEG and CPH.25 
 While all the formulations tested produced similar levels of antibody, the immune 
response to F1-V is altered when delivered in the context of different polymer nanovaccine 
formulations, presumably because the antigen release kinetics are strongly affected by the 
nano-carrier chemistry. Previous work has demonstrated that poly(SA) and 20:80 CPH:SA 
nanoparticles provide the fastest antigen release kinetics in vitro of the four nanoparticle 
formulations tested, with a majority of the antigen released in one month.26, 27 Consistent with 
these studies, the amount of antigen in vivo is almost completely cleared from the lung 36 days 
post-immunization (Figure 5.1). In contrast, the two CPH-rich chemistries (i.e., 20:80 
CPTEG:CPH and 50:50 CPTEG:CPH), which have slower antigen release kinetics,15 prolonged 
the presence of antigen in the lung for up to 63 days as shown in Figure 5.1. Together, these 
data raise an important question on the effect of persistent antigen and nanoparticle presence 
on the generation and sustenance of immune responses over time. 
 To answer this question, the antigen release kinetics from 50:50 CPTEG:CPH 
nanoparticles needs to be carefully considered. The antigen internalization data presented in 
Figure 5.2 displays a unique balance between antigen release and persistence of the 50:50 
CPTEG:CPH nanovaccine. Consistent with previous work, SA-rich chemistries are rapidly 
internalized by dendritic cells and macrophages18, 20, 21 (Figures 5.2 and 5.3). However, most of 
the antigen is cleared by 14 days post-immunization, leading to the decline in antibody 
responses discussed below. Despite the fact that CPH-rich chemistries are less readily 
internalized by cells, the 50:50 CPTEG:CPH formulation enables antigen release kinetics that 
provides sustained antigen presence for internalization, and thus, maturation of the immune 
response.  
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 Figure 5.4 demonstrates that the antibody titers induced in mice that received 50:50 
CPTEG:CPH nanovaccine steadily increased over time. The evidence that the levels of 
circulating antibody increased between 36 and 63 days after immunization for the mice that 
received the 50:50 CPTEG:CPH nanovaccine formulation suggests that the immune response 
is being driven by the continuous presence of the right amounts of antigen released from this 
formulation. The F1-V antigen release kinetics from this formulation is “just right”, neither too 
slow nor too fast, enabling both increased antibody titers as well as highly avid antibody over 
time as shown in Figure 5.5. In contrast, the remaining nanovaccine formulations and MPLA 
show similar profiles for the development of anti-F1-V antibody titers that peak or plateau 
between day 36 and 63. The release kinetics of antigen from these formulations is either too 
fast (i.e., MPLA, poly(SA), 20:80 CPH:SA) or too slow (i.e., 20:80 CPTEG:CPH) and resulted in 
titers that peaked between 36 and 63 days and induced antibody that is not highly avid. 
Together, these data suggest that the presence of antigen alone is not sufficient to stimulate the 
immune response. The chemistry of the nano-adjuvant must be selected carefully to interact 
with immune cells and enable sustained antigen release at an appropriate rate to generate long-
lived antibody titers. 
 It may be possible that differences in antibody titer profiles are a result of plasma cell 
development.28 Perhaps nanovaccine formulations that sustain antigen presence (and hence re-
expose B cells to antigen over time) lead to the development of long-lived plasma cells, 
accounting for the increase in antibody titers between 36 and 63 days. In contrast, formulations 
that induce the production of short-lived plasma cells, which have a half-life of only seven 
days,28 may account for the plateau or decreasing antibody titers at day 63. In addition, 
repeated antigen exposure (and therefore generation of long-lived plasma cells) typically leads 
to the maturation of antibody responses over time. In this work, the avidity of antibodies in 
response to 50:50 CPTEG:CPH nanovaccine immunization increased over time, while the other 
formulations did not (Figure 5.5). There are a number of factors to consider when analyzing this 
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observation. CPTEG-rich polymers have lower glass transition temperatures compared to the 
other polyanhydrides studied herein.15 This may induce more agglomeration of these particles 
within the lung, leading to a reduced surface area to volume ratio and result in slower release of 
antigen, thereby prolonging antigen release kinetics optimally.15, 16 Additionally, the pattern 
provided by 50:50 CPTEG:CPH formulations may imitate a replicating pathogen, or a 
replication-competent vaccine, as suggested previously based on demonstration of protective 
immunity 40 weeks after a single intranasal immunization,11, 13 leading to memory development.  
 Furthermore, the selection of protective epitopes by nanovaccine formulations provides 
additional evidence of antibody maturation, and therefore, the presence of long-lived plasma 
cells (Figure 5.6). Consistent with the increasing antibody titers and avidity, the 50:50 
CPTEG:CPH nanovaccine formulation led to a more focused epitope spread over nine weeks 
as shown in the peptide heat map in Figure 5.6A. The gradual development of an immune 
response to the V1 and V2 epitopes (Figure 5.6B) over time indicates that the release rate of 
antigen is sufficient to maintain B cell maturation, leading to the production of antibodies 
towards specialized epitopes. It is well known that the V1 and V2 epitopes are important in Y. 
pestis pathogenesis and antibody to these epitopes is critical for protective immunity against 
infection.23, 24 In contrast, the other nanovaccine formulations (which may release antigen too 
fast or too slow) demonstrated early recognition of protective epitopes that waned over the 
course of the study. F1-V antigen delivered alone without adjuvant elicited a broad, unfocused 
response to many F1-V epitopes, indicating that while the antigen is recognized, plasma cell 
maturation and antibody refinement did not occur and this formulation failed to protect animals 
upon live challenge.13 
 While the prolonged presence of antigen in vivo may play a large role in the 
development and maturation of antibody responses, it is instructive to note that the mice 
administered the slowest eroding (and therefore, most persistent) 20:80 CPTEG:CPH 
nanovaccine formulation showed decreased antibody titers over time. Therefore, the 
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persistence of antigen alone is not enough to drive an efficacious immune response. The 
kinetics of antigen release must be appropriate and play a key role in the rational design of 
efficacious vaccines.  
 The persistence of antigen has a large impact on the development of short-lived and 
long-lived plasma cells, as well as the development of T cell memory.29-30 Short-lived plasma 
cells are quick to respond and proliferate, but often at the expense of antibody maturation.29 In 
instances where antigen is released and cleared quickly, these short-lived responses are often 
ineffective in developing protection. However, sustained antigen presence may enhance the 
development of germinal centers and long-lived plasma cells producing high avidity, high affinity 
antibodies as well as memory B cells.28, 29 Likewise, the kinetics of antigen release from 
nanovaccine formulations has a large role in the development of T cell responses. The initial 
activation and expansion of T cells is largely antigen-dependent, requiring optimal 
concentrations to successfully prime the immune response.30 Too much antigen, however, may 
lead to accelerated activation-induced cell death and short-lived immune responses.30 Similar to 
B cells, optimal concentrations of persisting antigen may lead to the development of T cell 
memory.30 The development of optimal vaccine formulations, such as 50:50 CPTEG:CPH-
based nanovaccines, which release the right amount of antigen at the right time, bring balance 
to the adaptive immune response, effectively bridging the gap between priming early expansion 
and sustaining long-lived memory through persistent antigen. 
 
5.5. CONCLUSIONS 
 We have herein demonstrated the importance of polymer chemistry in the design of 
nanovaccines. There are several important factors that influence the design of an efficacious 
intranasal vaccine, including nanoparticle interactions with immune cells and the kinetics of 
antigen release. The performance of the 50:50 CPTEG:CPH nanovaccine formulation clearly 
demonstrates the impact of sustained release of antigen on the immune response to the F1-V 
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antigen over time. The formulation delivered with this nano-carrier chemistry showed an 
increase in antibody titer throughout the duration of the experiment, indicating a continual 
addition of long-lived plasma cells to the pool of antibody-generating cells. In contrast, the other 
nanovaccine formulations as well as MPLA demonstrated a stable or decreased antibody titer at 
longer time points, suggesting a higher percentage of short-lived plasma cells. Finally, the 
maturation of antibody avidity and focus towards protective epitopes demonstrates the 
importance of persistent antigen in developing an efficacious immune response.  
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5.6. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. Polyanhydride nanovaccines persist in the lung up to 63 days. Images 
represent fluorescence of remaining labeled F1-V antigen in excised lung tissue at the indicated 
time points. Mean fluorescence intensity (MFI) is represented graphically as the average of 
eight mice per group from a total of two independent experiments (Days 14 and 36) and four 
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mice per group from one experiment (Day 63). Error bars represent the standard error of the 
mean. Letters represent statistical differences comparing experimental groups across one time 
point. Asterisks represent statistical differences across time points for one experimental 
treatment group. p ≤ 0.05. 
 
 
     
Figure 5.2. Persistence of particles leads to sustained internalization of antigen. 
Multispectral imaging flow cytometry was used to determine the internalization of F1-V by lung 
cells. Error bars represent the standard error of the mean with n = 8 from two independent 
experiments (Day 36) and n = 4 from one experiment (Days 14 and 63). One thousand events 
per sample were acquired and analyzed as described. Letters represent statistical differences 
between experimental groups at one time point.  Asterisks represent statistical differences 
across time points for one experimental treatment group. p ≤ 0.05. 
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Figure 5.3. Flow cytometric analysis indicates increased cellular association at 14 days 
after immunization for dendritic cells (CD11c+) and macrophages (CD11b+). Flow cytometry 
was used to assess the mean fluorescent intensity (MFI) of F1-V associated with dendritic cells 
and macrophages 14 day post-immunization. Ten thousand events per sample were collected. 
Error bars represent the standard error of the mean (n = 8) from two independent experiments. 
Letters represent statistical differences between experimental groups. p ≤ 0.05. 
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Figure 5.4. Polyanhydride nanovaccines induced high titer anti-F1-V antibody responses. 
Error bars represent the standard error of the mean (n = 8) from two independent experiments 
(Days 14 and 36) and n = 4 from one experiment. Letters represent statistical differences 
between experimental groups at one time point.  Asterisks represent statistical differences 
across time points for one experimental treatment group. p ≤ 0.05. 
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Figure 5.5. Polyanhydride nanovaccine formulations induced highly avid antibodies to 
F1-V. Error bars represent the standard error of the mean (n = 8) from two independent 
experiments (Days 14 and 36) and n = 4 from one experiment. Letters represent statistical 
differences between experimental groups at one time point.  Asterisks represent statistical 
differences across time points for one experimental treatment group. p ≤ 0.05. 
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  Figure 5.6. Epitope recognition of 
  antibodies induced by nanovaccine 
  formulations. A heat map of the 
responses to eighty F1-V peptides was 
evaluated by ELISA, beginning at the top 
with the amino-terminal peptide and then 
A 
B 
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moving down sequentially through the F1-V protein (A). The optical density of each peptide is 
indicated by a range of color from blue (no response) to red (maximum response). Data 
presented is the average of eight individual mice for days 14 and 36, and four individual mice for 
the day 63 time point. Graphical representation of the evolution of the immune response to the 
F18, V1, and V2 peptides as fold change over saline (B). Data was collected from groups of 
animals for days 14 and 36 from two individual experiments and from four animals for day 63 
from one experiment. Epitope recognition is considered to be 1.5-fold or higher fold change over 
saline. Dashed line represents a 1.5-fold change from saline controls for that peptide.  
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Abstract 
 Vaccination remains the most cost effective preventive intervention against disease. 
Polyanhydride nanovaccines stabilize protein antigens, provide sustained antigen release 
leading to prolonged antigen presence, enhance activation of antigen presenting cells, and elicit 
protective immunity against respiratory infections upon challenge. However, evaluation of cell-
mediated immune activation when mice are immunized with polyanhydride nanoparticles has 
not been carried out. Using a transgenic ovalbumin-specific T cell adoptive transfer model, we 
report the enhanced expansion of antigen-specific cytotoxic CD8+ T cells expressing an effector 
memory phenotype at early time points post-immunization with nanovaccine formulations. 
Furthermore, mice immunized with polyanhydride nanoparticles also showed superior ability to 
respond to tumor challenge, indicative of memory T cell generation post-immunization.  
 
6.1. INNOVATION 
 Polyanhydride nanoparticles represent a unique biodegradable platform for the delivery 
of vaccine antigens. Polyanhydride copolymers contain hydrophobic properties, which exclude 
water from the bulk of the material. This limitation of water exposure maintains the stability of 
1
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fragile protein antigens, as well as allows for sustained release kinetics. Previously, 
polyanhydride nanoparticles successfully induced long-lived humoral responses (i.e., high 
avidity, high titer antibody) that provided protection against live bacterial challenge. For many 
infectious pathogens, humoral immunity (antibody) alone will not provide complete protection 
and cell-mediated immunity is required to provide host protection. Many subunit vaccines fail to 
produce or produce weak cellular immune responses towards single protein antigens. Herein, 
we demonstrate that polyanhydride nanovaccines elicited cell-mediated immunity via expansion 
of antigen-specific T cells of memory phenotypes and enabled tumor regression. The ability of 
polyanhydride nanovaccines to induce memory CD8+ cytotoxic T cells provides proof of concept 
for this platform to be used in the development of efficacious vaccines for cancer, influenza, and 
intracellular pathogens. 
 
6.2. INTRODUCTION 
 The use of preventive vaccines remains the most effective public health intervention 
strategy to decrease the morbidity and mortality associated with infectious diseases. Challenges 
associated with design of next generation vaccines include eliciting effective cell-mediated 
immune responses from highly purified antigens and achieving long-lived immunological 
memory against the purified antigen. To date, the live attenuated yellow fever vaccine remains 
the most successful human vaccine.1-3 This efficacy is primarily due to its ability to elicit cell-
mediated (i.e., CD4+ and CD8+ T cell) responses within the first two weeks of immunization and 
subsequently a long-lived protective antibody response that can last for 45 years.1-3  
 The effectiveness of the yellow fever vaccine can be attributed to two important factors. 
First is the engagement of the innate immune system resulting in enhanced humoral and cell-
mediated immunity. Second is the ability of the attenuated virus to establish a mild sub-clinical 
infection and a low level of replication, which promotes the development of long-lived CD8+ T 
cells.1-3 Unfortunately, not all organisms can be attenuated, and adverse side effects must be 
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given careful consideration in vaccine design. Subunit (i.e., purified or recombinant proteins) 
vaccines are a safe alternative to live, attenuated pathogens; however, these proteins are often 
poorly immunogenic requiring adjuvants to enhance immune responses and induce long-lived T 
cell memory. 
 Polyanhydride nanoparticles based on 1,6-bis(p-carboxyphenoxy)hexane (CPH) and 
1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) have been shown to sustain the release 
of and enhance the immunogenicity of encapsulated subunit proteins, which promotes robust B 
cell responses with sustained antibody titers with high avidity.4-6 Furthermore, immunization with 
polyanhydride nanovaccines has induced protective responses upon live bacterial challenge.7 
However, no direct evaluation of the cell-mediated immune responses elicited by the 
polyanhydride nanovaccine platform has been reported. In this work, we sought to examine the 
CD8+ T cell responses elicited by the 20:80 CPTEG:CPH nanovaccine utilizing an adoptive 
transfer model of ovalbumin (OVA)-specific transgenic OTI CD8+ T cells to recipient mice 
receiving a vaccine regimen of soluble and encapsulated OVA, as previously described.7  
 This study demonstrates that encapsulation of antigen in 20:80 CPTEG:CPH 
nanoparticles enhanced the expansion of OTI CD8+ T cells after immunization. The subsequent 
expansion led to higher frequencies of memory precursor effector cells and central memory 
CD8+ T cells. Mice immunized with 20:80 CPTEG:CPH nanovaccine significantly expanded 
antigen-specific CD8+ memory T cells in response to challenge with OVA-secreting EG7 tumor 
cells, delaying tumor progression. Altogether, our data demonstrates that immunization with 
polyanhydride nanoparticles leads to the development of memory T cells capable of being 
recalled in response to challenge.  
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6.3. METHODS 
6.3.1. Synthesis and characterization of copolymers  
 Polyanhydrides were synthesized using the chemicals listed: 4-p-hydroxybenzoic acid, 
1,6-dibromohexane, 1-methyl-2-pyrrolidinone, N,N-dimethylacetamide, and tri-ethylene glycol. 
All these chemicals and sebacic acid (99%) were purchased from Sigma Aldrich (St. Louis, 
MO); 4-p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); potassium 
carbonate, dimethyl formamide, toluene, sulfuric acid, acetic acid, acetonitrile, acetone, acetic 
anhydride, methylene chloride, chloroform, sodium hydroxide, hexane, ethyl ether, and 
petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of CPH and 
CPTEG diacids was performed as previously described.8, 9 The 20:80 CPTEG:CPH copolymer 
was synthesized using a melt polycondensation process as described previously.8, 10 The 
molecular weight and polymer purity were determined using 1H nuclear magnetic resonance 
(NMR) spectroscopy (Varian VXR-300 MHz, Palo Alto, CA).  
 
6.3.2. Fabrication and characterization of particles  
 Nanoparticles encapsulating ovalbumin (OVA) (Sigma-Aldrich) (5.0% w/w) were 
fabricated using the anti-solvent nanoencapsulation method outlined previously.5 Briefly, the 
copolymer was dissolved in methylene chloride at a concentration of 20 mg/mL at 4˚C. 
Lyophilized OVA was added to the dissolved copolymer and the solution was sonicated for 
uniform dispersal of the protein. The OVA-loaded copolymer (OVA-loaded) or copolymer (blank) 
solution was poured into chilled pentane (-20°C) at a solvent to non-solvent ratio of 1:250 and 
vacuum filtration was used to recover the nanoparticles. The shape and size of the resulting 
nanoparticles were characterized using scanning electron microscopy (FEI Quanta 250, FEI, 
Hillsboro, OR).  
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6.3.3. Animals  
 Recipient female C57BL/6 Thy 1.1+, recipient albino C57BL/6, OTI mice were purchased 
from Jackson Laboratories (Bar Harbor, ME). C57BL/6 mice were obtained from Harlan 
Laboratories (Indianapolis, IN). T-lux mice were a kind gift from Dr. Casey Weaver of the 
University of Alabama. A T-lux breeding colony was established at Iowa State University. 
Heterozygous breeding between T-lux and OTI mice was established to produce T-lux/OTI 
offspring. Phenotyping of offspring for T cell receptor rearrangement (Vα2 Clone B20.1 Vβ5 
Clone MR9-4 (eBioscience, San Diego, CA) and luciferase-positive status was examined to 
establish which mice were the desired T cell donors (e.g., OT I+:T-Lux+). All mice were housed 
under specific pathogen-free conditions where all bedding, caging, water, and feed were 
sterilized prior to use. Animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. 
 
6.3.4. Adoptive transfer of antigen-specific T cells  
 For the in vivo imaging studies, 5 x 105 T-lux OTI CD8+ T cells were transferred into 
albino C57BL/6 recipients performed on day -1.11 For the low frequency adoptive transfer 
studies, 3 x 103 OTI Thy 1.2+ 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE) 
(Molecular Probes/Life Technologies, Grand Island, NY) labeled cells were adoptively 
transferred to each recipient mouse.  
 
6.3.5. Immunization Regimens  
 On day 0, mice were immunized with 1.75 mg of soluble OVA and 5 mg of 5% OVA-
loaded 20:80 CPTEG:CPH polyanhydride nanoparticles, 2.0 mg of soluble OVA (sOVA), or 2.0 
mg of OVA adjuvanted 1:1 with ImjectTM Alum (ThermoFisher, Rockford, IL). 
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6.3.6. Ex vivo T cell phenotype and activity assays 
 At multiple time points post-immunization, mice were euthanized and draining lymph 
nodes were excised and single cell suspensions were created using a glass homogenizer. Cell 
numbers and phenotype were quantified using flow cytometry (BD FACS Aria III, BD 
Biosciences, San Jose, CA). For the low frequency adoptive transfer experiments, positive 
selection for donor T cells was accomplished using biotinylated anti-CD90.2 (Thy 1.2 Clone 53-
2.1) (eBioscience) and streptavidin magnetic microbeads (Miltenyi Biotech, Auburn, CA). 
Positive magnetic bead selection was performed via methods outlined by Moon et al.11 
(AutoMACS Pro, Milteny Biotech). Cell suspensions were blocked for non-specific antibody 
binding using 0.1 mg/mL rat IgG (Sigma Aldrich) and 10 µg/mL mouse anti-CD16/32 
(eBioscience). For T cell assays, fluorescently conjugated antibodies specific for CD8β (APC, 
Clone eBioH35-17.2, eBioscience), CD62L (PE, Clone 2G8, eBioscience), Thy 1.2 (APC-eFluor 
780, Clone 53-2.1, eBioscience), Thy 1.1 (PerCP-Cy 5.5, Clone HIS51, eBioscience), CD197 
(eFluor 450, Clone 4B12, eBioscience), KLRG1 (PE-Texas Red, Clone 145-2C11, eBioscience), 
or CD44 (v500, clone IM7, BD, Franklin Lakes, NJ) were diluted in FACS buffer and used to 
label the cells in order to quantify donor antigen-specific cell populations. Antibodies were used 
with appropriate combinations of fluorochromes. 
 
6.3.7. In vivo imaging of T-lux cells  
 Five minutes prior to imaging for the presence of T-lux positive T cells, mice were 
administered D-luciferin (215 µg/g body weight) via intraperitoneal injection. In vivo images 
(Carestream Multispectral FX, Rochester, NY) were captured while mice were anesthetized as 
described above. Bioluminescent images were captured using 10-minute exposures with high 
amounts of binning for increasing sensitivity. All image analyses were performed using Image J 
software version 1.46.12 Raw fluorescence images were inverted and background subtracted via 
a rolling ball radius of 150 pixels. The mean luminescence intensity (MLI) of the region of 
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interest (ROI) of 0.39 mm x 0.32 mm were quantified via ImageJ and presented thereto. 
Composite images of luminescent channel, fluorescence channel, and white light image were 
created using Image J software.  
 
6.3.8. Tumor challenge 
 EG7 ovalbumin expressing tumor cells (2.5 x 106) were administered subcutaneously in 
the left rear flank on day 35 post-immunization. Tumor measurements were recorded using a 
digital caliper and tumor volume was calculated using the ellipsoid volume equation, where 
volume = (4/3)* π * length * width * height. Per criteria outlined in consultation with the attending 
veterinarian, animals were removed from the study when tumor volume reached 1000 mm3. 
Prosense® 750 was administered (2 nmol) via tail vein injection seven days post-tumor 
challenge to visualize the inflammation associated with the tumor and to quantify changes in 
tumor size. ProSense® 750 is an activatable fluorescent reagent that is optically visible when the 
dye is cleaved by degradative enzymes, including cathepsin B, L, S, or plasminogen, that are 
common at sites of tumor growth.13 After 24 h, in vivo images were captured while mice were 
kept under anesthesia using 2 % isoflurane in 100% O2 at 2.5 L/min. Images were captured 
using 30 second exposures with an excitation filter of 730 nm and an emission filter of 790 nm.  
 
6.3.9. Statistical analysis  
 Differences in mean responses among treatment groups were tested with either 
unpaired T test with Welch’s correction or one-way ANOVA F-test followed by a post-hoc 
Tukey’s t-test using GraphPad Prism version 5 (GraphPad Software, Inc., La Jolla, CA). 
Statistical tests with p values ≤ 0.05 were regarded as significant. Data was log transformed 
when variances were not equal. 
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6.4. RESULTS 
6.4.1. Polyanhydride nanovaccine enhances early expansion of OTI CD8+ T cells 
 Induction of antigen-specific cell-mediated responses to cognate antigen occurs early 
following antigen encounter.14 Upon antigen encounter, antigen-specific T cells undergo 
expansion and acquire effector function. Once antigen is cleared, about 90% of antigen-specific 
T cells will undergo apoptosis while the remaining 10% will become long-lived memory T cells.14 
In order to determine the ability of OVA-loaded 20:80 CPTEG:CPH polyanhydride nanovaccines 
to expand memory CD8+ T cells, we adoptively transferred 5 x 105 transgenic luciferase-
expressing OTI CD8+ T cells into naïve mice prior to immunization with OVA-loaded 20:80 
CPTEG:CPH nanovaccine, OVA adjuvanted with alum (Alum), soluble OVA (sOVA) or sham 
vaccine (saline). Cohorts from each treatment group were imaged at 1, 3, 5, 7, and 10 days 
post-immunization to determine the level of OTI CD8+ T cell expansion in each of the 
treatments. Based on mean fluorescence intensity (MFI) in all groups, peak T cell expansion 
occurred at 5 days post-immunization (DPI) and contraction was achieved by 10 DPI (Figure 
6.1). Mice immunized with the OVA-loaded 20:80 CPTEG:CPH nanovaccine formulation and 
alum had the highest levels of MFI, while sOVA-treated groups also induced expansion of OTI 
CD8+ T cells, albeit at a lower magnitude (Figure 6.1).   
 
6.4.2. 20:80 CPTEG:CPH nanovaccine expands memory precursor T cells 
 To better assess the expansion and phenotype of antigen-specific T cells following a 
20:80 CPTEG:CPH nanovaccine regimen, we again utilized an adoptive transfer model, as 
outlined by Moon et al.11 In this study, 3 x 103 OTI CD8+ Thy 1.2+ cells were transferred into 
naïve recipients and immunized as described before. Seven days post-immunization, draining 
lymph nodes were harvested and the antigen-specific T cell population was analyzed for 
expansion and surface phenotype. Immunization with 20:80 CPTEG:CPH nanovaccines 
resulted in a statistically significant increase not only in the frequency, but also the total 
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numbers of OTI CD8+ T cells in comparison with all the other treatment groups (both panels of 
Figure 6.2A).  
 Surface phenotype analysis indicates that following all immunizations, the antigen-
specific CD8+ T cells acquired both central memory (TCM) (CD44
high CD62Lhigh) and effector 
memory (TEM) (CD44
high CD62Llow) phenotypes (Figure 6.2B, flow cytometry panels) with a 
higher frequency of TCM generation as compared to TEM. Furthermore, 20:80 CPTEG:CPH 
nanovaccine-immunized mice showed significantly higher total numbers of TCM phenotype in 
comparison with all the other treatment groups (Figure 6.2B, graph). Further surface phenotype 
analysis demonstrated that the 20:80 CPTEG:CPH nanovaccine immunization strategy resulted 
in higher numbers of antigen-specific CD8+ T cells with a memory precursor effector cell 
(MPEC) phenotype (CD44high CD62Lhigh KLRG1low CD127high) in comparison with all the other 
immunization regimens (both panels of Figure 6.2C). 
 
6.4.3. Cytotoxic CD8+ T cells respond to tumor challenge following immunization with 
20:80 CPTEG:CPH nanovaccine 
 To determine if the 20:80 CPTEG:CPH nanovaccine was able to elicit cytotoxic CD8+ T 
cells capable of responding to challenge, albino C57BL/6 recipient mice receiving adoptive 
transfer of T-lux OTI CD8+ T cells and immunized with the regimens outlined previously were 
challenged with 2.5 x 106 OVA-expressing EG7 lymphoma cells into the right rear flank at 35 
DPI. In vivo imaging of bioluminescent OTI CD8+ T cells at seven days post-tumor challenge 
showed measurable T cell infiltrate into the tumor site in 20:80 CPTEG:CPH nanovaccine-
immunized mice compared to mice immunized with Alum or sOVA (Figure 6.3A). Quantitative 
luminescent analysis of the OTI CD8+ T cell response at the site of tumor implantation (Figure 
3B) showed more robust OTI CD8+ T cell responses in mice treated with the 20:80 CPTEG:CPH 
nanovaccine formulation in contrast to all the other treatments (Figure 6.3B).  
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 To determine if the observed CD8+ T cell infiltration had a functional effect on tumor 
progression, a protease cleavable probe, Prosense® 750, was administered to tumor-challenged 
mice. Mice immunized with the 20:80 CPTEG:CPH nanovaccine formulation showed inhibited 
tumor growth as evidenced by the decreased tumor fluorescence intensity (Figure 6.4). This 
tumor inhibition by the 20:80 CPTEG:CPH nanovaccine may be attributed to the enhanced T 
cell response observed in Figure 6.3A-B. Altogether, these data suggest that polyanhydride 
nanovaccines promote the generation of antigen-specific OTI CD8+ T cells with a long-lived 
MPEC phenotype, capable of recall effector function. 
 
6.5. DISCUSSION 
 A major obstacle in an increasingly stringent regulatory environment is the development 
of safe and efficacious vaccines with purified antigens and reduced adverse side effects. 
Another major challenge is the generation of cell-mediated immunity against vaccine antigens. 
The ability to expand cytotoxic T cells and generate memory T cells using immunization is 
largely biased towards replicating viral vectors or DNA vaccines expressing targeted antigens, 
which provide both innate viral stimulatory mechanisms as well as extended presence of 
antigen.15, 16 Targeting the small number of antigen-specific naïve T cells that would be available 
for a given T cell epitope, expanding that population of T cells, and creating stable central 
memory populations capable of responding to a subsequent infection is difficult to achieve with 
subunit immunizations.14, 17-19 Polyanhydride nanoparticles can bridge the gap between safe 
subunit vaccines and efficacy with a broad-based repertoire of immune responses because of 
their pathogen mimicking attributes such as particle size, chemical structure, and perhaps most 
importantly to the development of memory T cells, sustained release of antigen.4, 7, 20 
 The timing of antigen exposure to naïve T cells entering the draining lymph nodes is 
limited by antigen availability, making it critical in programming memory T cells.21 Short-lived 
effector cells are generated initially, while naïve T cells arrive later or during reduced antigen 
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load, and are subject to differential programming resulting in the development of T cells with a 
central memory phenotype.14, 22-24 Continued antigen presence is a key component in driving 
memory populations since naïve T cells activated as the antigen load is waning acquire more 
central memory characteristics.22, 25, 26 While the initial expansion of T cells was similar between 
Alum- and 20:80 CPTEG:CPH nanovaccine-immunized mice (Figure 6.1), the persistent release 
of antigen from 20:80 CPTEG:CPH nanoparticles27 would likely increase the duration of antigen 
availability for late-arriving naïve CD8+ T cells. Polyanhydride nanoparticles have been shown to 
persist up to 12 weeks in vivo and sustain antigen release.27  
 The expansion of OTI CD8+ T cells following 20:80 CPTEG:CPH nanovaccine 
administration resulted in higher total numbers of T cells expressing a precursor memory 
(MPEC) phenotype at 7 DPI, characterized by increased expression of CD127 (IL-7Rα and 
decreased expression of KLRG1 (Figure 6.2C). KLRG1low CD127high T cells demonstrate greater 
ability to effectively convert into central memory T cells.28, 29 These data indicate that the 
polyanhydride nanovaccine formulation elicits not only an effector immune response, but also 
promotes the development of long-lived memory CD8+ T cells.  
 Likewise, the kinetics of T cell infiltration in response to the tumor challenge (Figure 6.3) 
and the amount of OTI CD8+ T cells in the periphery (data not shown) indicated higher levels of 
memory T cells developed from polyanhydride nanovaccine immunization. The high frequency 
adoptive transfer model demonstrated the ability of 20:80 CPTEG:CPH nanovaccine 
immunization to activate OTI CD8+ T cells and showed that an effector memory CD8+ T cell 
response can be enhanced by the inclusion of polyanhydride nanovaccines.  
 Adaptive immunity is contingent on innate immune response to “foreign” antigens. 
Previous work examining the immunomodulatory potential of the polyanhydride nanovaccine 
platform indicated that CPTEG:CPH chemistries appear “pathogen-like” in their ability to induce 
innate immune functions.20 These “pathogen-like” properties most likely are a synergistic 
combination of: the nanoparticles mimicking pathogen size; sustained antigen release 
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mimicking the kinetics of replicating pathogens; and interaction of conserved innate immune 
receptors responding to the patterns of repeated polymeric units.20 The data herein demonstrate 
that the polyanhydride nanovaccine platform can be harnessed to induce cellular immunity by 
expanding antigen-specific T cells that acquire a long-lived and functional memory phenotype.  
 Particulate-adjuvanted subunit antigen is regarded as better able to access intracellular 
endosomal compartments crucial for antigen presentation via major histocompatibility complex 
(MHC) I.16 Cross-presentation or endosomal escape into the cytosol leads to MHC I antigen 
presentation critical for CD8+ T cell activation.16 This work suggests that MHC I presentation 
may be enhanced by polyanhydride nanovaccines, thus requiring future examination of antigen 
presentation pathways in APCs using these formulations. Further studies are needed to 
examine if the nanovaccine platform is capable of inducing cellular immunity to other subunit 
antigens. Memory CD8+ T cell expansion and generation against antigens typically thought of as 
humoral dominant antigens can lead to increased vaccine efficacy and cell-mediated memory.16 
The data reported herein demonstrates the polyanhydride nanovaccine platform performs as 
both an effective particulate vaccine delivery system as well as a potent immunomodulator, 
leading to enhanced CD8+ T cell immunity.  
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6.6. FIGURES 
 
 
 
Figure 6.1. 20:80 CPTEG:CPH nanovaccine immunized groups expanded OTI CD8+ T cells 
at the immunization site. (A) Representative images of albino C57BL/6 mice receiving transfer 
of T-lux OTI CD8+ T cells from immunized groups (20:80 CPTEG:CPH nanovaccine, Alum, 
sOVA, or PBS) at 1, 3, 5, 7, or 10 days post-immunization (DPI) examining bioluminescent 
CD8+ T cell activity. (B) Regions of interest of equal area were drawn at the immunization site to 
measure intensity of T cell luminescence and quantified over time. Error bars represent 
standard error of mean. 
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Figure 6.2. 20:80 CPTEG:CPH nanovaccine immunization expanded OTI CD8+ T cells 
early after immunization and promotes memory development. (A) Representative flow 
cytometric histograms of donor OTI Thy 1.2+ (y-axis) CD8+ (x-axis) T cell expansion from 
draining lymph nodes (LNs) seven days post-immunization (DPI) and total CD8+ Thy 1.2+ T cells 
recovered from the axial and brachial LNs at seven DPI . (B) Representative flow cytometric 
histograms of OTI Thy 1.2+ CD8+ T cells analyzed for expression of CD44 (y-axis) and CD62L 
(x-axis) and total numbers of CD8+ Thy 1.2+ CD44high CD62Lhigh T cells recovered from the axial 
and brachial LNs at seven DPI. (C) Representative flow cytometric histograms of gated OTI Thy 
1.2+ CD8+ T cells for surface markers CD127 (y-axis) and KLRG1 (x-axis) and total numbers of 
CD8+ Thy 1.2+ CD127low KLRG1high (MPEC) T cells recovered from the axial and brachial LNs. * 
indicates statistical difference at a p-value < 0.0001 value obtained via one-way ANOVA with 
Tukey’s post-test.  Data is from a single experiment. 
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Figure 6.3. 20:80 CPTEG:CPH nanovaccine immunized groups demonstrated cellular 
recall responses. (A) Representative images of albino C57BL/6 mice receiving transfer of T-lux 
OTI CD8+ T cells from immunized groups (20:80 CPTEG:CPH nanovaccine, Alum, sOVA, or 
PBS) challenged with EG7 tumor cells visualizing OTI CD8+ T cells. (B) Regions of interest of 
equal area were drawn at the tumor challenge site of representative mouse cohort and 
luminescent intensity of T cell luminescence was quantified post-tumor challenge (n = 4). 
 
 
122 
 
 
 
 
Figure 6.4. 20:80 CPTEG:CPH nanovaccine immunized groups demonstrated cellular 
recall responses capable of controlling tumor growth. Representative images of albino 
C57BL/6 mice receiving transfer of T-lux OTI CD8+ T cells from immunized groups (20:80 
CPTEG:CPH nanovaccine, Alum, sOVA, or PBS) challenged with EG7 tumor cells visualizing 
inflammation (ProSense® 750, Red) at the site of tumor implantation. 
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Abstract 
 
 While H5N1 avian influenza has not yet acquired the capacity to readily infect humans, 
should it do so, this viral pathogen would present an increasing threat to the immunologically 
naïve human population. Subunit vaccines based on the viral glycoprotein hemagglutinin (HA) 
can provide protective immunity against influenza. Polyanhydride nanoparticles have been 
shown to enhance efficacy of subunit vaccines, providing the dual advantages of adjuvanticity 
and sustained delivery resulting in enhanced protein stability and immunogenicity. In this work, 
a recombinant trimer of H5 (H53) was encapsulated and released from polyanhydride 
nanoparticles. Release kinetics of the encapsulated H53 were found to be dependent on 
polymer chemistry (i.e., hydrophobicity and molecular weight). Polyanhydride nanoparticles 
composed of sebacic anhydride and 1,6-bis(p-carboxyphenoxy)hexane (CPH) (that degrade 
into more acidic monomers) released structurally stable hemagglutinin H53, while H53 released 
from formulations composed of CPH and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) 
(that are amphiphilic and whose degradation products are less acidic) displayed unfolding of 
tertiary structure. However, the antigenicity of the H53 based on binding of a H5-specific 
monoclonal antibody was preserved upon release from all the formulations studied, 
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demonstrating the value of polyanhydride nanoparticles as a viable platform for hemagglutinin-
based influenza vaccines. 
 
7.1. INTRODUCTION 
 Seasonal influenza affects people of all ages and induces characteristic symptoms that 
include cough, fever, and body aches; patients typically recover in a short period of time. 
However, other strains of influenza such as H5N1 avian influenza can be much more 
devastating due to the immunological naiveté of the population and ease of spread worldwide. 
H5N1 is an influenza A virus whose host range has been primarily restricted to waterfowl 
because of the binding of the HA to sialic acid with an α2,3 linkage to galactose; however, 
cases of H5N1 influenza viral infections have occurred in humans over the last several years.1,2 
These cases, while isolated, have shown that up to 60% of human H5N1 infections are fatal 
within one to three days.3-7 While mutations are common in RNA viruses, as observed by the 
change(s) in seasonal influenza each year, the mutations in H5N1 influenza virus strains are of 
a greater concern.3,4 If the appropriate mutations occur in the HA protein, the virus would be 
efficiently transmissible among a global population of immunologically naïve individuals. With its 
high fatality rate and resistance to antiviral treatments, it is predicted that without implementing 
appropriate public health measures, an H5N1 influenza virus pandemic would cause an 
estimated 50 million deaths in the U.S. alone, indicating an urgent need for research to develop 
efficacious vaccines against this virus.3,4 
 Current manufacturing processes of viral vaccines require strictly regulated 
biocontainment facilities because of the need to generate large quantities of live virus for 
vaccine production.8-10 In contrast, subunit vaccines do not require biocontainment and have 
reduced patient side effects (i.e., pain, swelling, allergic reactions) because the proteins are 
highly purified.8-10 By using a protein-based subunit vaccine, the risks to both manufacturers and 
127 
 
 
 
patients can be largely reduced. Recently, progress has been made in the development of a 
subunit vaccine against H5N1 influenza virus.8  
 The hemagglutinin (HA) protein has been identified as a protective antigen against 
infections induced by the homologous influenza virus.8-10 HA is a trimeric membrane 
glycoprotein present on the surface of influenza virions and is responsible for binding to and 
entry of the virus into host cells.11 During infection, HA binds to host cell sialic acid receptors 
and the virion is internalized by receptor-mediated endocytosis. Once inside an acidified 
endosome a conformational change in the trimeric structure occurs, exposing a fusion peptide 
and allowing endosomal escape of the viral RNA. Due to the involvement of HA in initiating viral 
infection, HA proteins are good candidates for inducing neutralizing antibodies. 
As with most subunit vaccines, HA protein administered alone generally results in a 
weak immune response requiring multiple doses for efficacy.8-10 Therefore, adjuvants are 
needed to reduce the dosage and cost while enhancing immune stimulation and vaccine 
potency.9,12,13 Unlike traditional adjuvants (e.g., alum), polyanhydride nanoparticles can be used 
to perform the dual functions of providing sustained delivery of structurally stable and functional 
proteins, as well as enhancing the capacity to induce a robust immune response.14, 15, 16  
Polyanhydrides degrade into non-toxic, non-mutagenic carboxylic acids.17,18 The 
anhydride monomers most commonly studied include sebacic acid (SA), 1,6-bis(p-
carboxyphenoxy) hexane (CPH), and 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG). 
Polyanhydrides exhibit surface erosion, resulting in a sustained release of antigen.17,19 The 
composition of polyanhydride copolymers can be varied to modulate the release kinetics of the 
encapsulated protein, which can be tailored from days to weeks and even months.18-20 The 
sustained release kinetics of F1-V antigen from vaccine formulations based on amphiphilic 
50:50 CPTEG:CPH nanoparticles proved beneficial, by inducing high titer, high avidity antibody 
responses that correlated with protection against a lethal Yersinia pestis challenge.14 
Amphiphilic polyanhydride nanoparticles have also been shown to stabilize recombinant 
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proteins, which is an important consideration in designing subunit vaccines because many 
recombinant proteins, including HA, are functionally and immunogenically labile.17,18 In contrast 
to the acidic microenvironment created by the bulk erosion of poly(esters), which may be 
detrimental to protein function,21 polyanhydride degradation products are less water soluble and 
consequently create less acidic and more protein-friendly microenvironments. This study 
examines the structural and antigenic stability of a recombinant H5 HA trimer (H53) upon 
release from several polyanhydride nanoparticle formulations with an eye towards rationally 
determining the optimal chemistries for development of efficacious H5-based nanovaccines. 
 
7.2. MATERIALS AND METHODS 
7.2.1. Materials 
For monomer and polymer synthesis, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, 
hydroxybenzoic acid, N,N-dimethylacetamide, sebacic acid, and tri-ethylene glycol were 
purchased from Sigma Aldrich (St. Louis, MO). Acetic acid, acetic anhydride, acetone, 
acetonitrile, chloroform, dimethyl formamide, ethyl ether, hexane, methylene chloride, pentane, 
petroleum ether, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were 
purchased from Fisher Scientific (Fairlawn, NJ); 4-p-fluorobenzonitrile was obtained from Apollo 
Scientific (Cheshire, UK). Protein analysis was performed with a microBCA kit (Pierce, 
Rockford, IL), alkaline phosphatase conjugated goat anti-mouse IgG (H+L) (Jackson 
ImmunoResearch, West Grove, PA), Flamingo fluorescent gel stain, and Mini-protean TGX gels 
from Bio-Rad (Hercules, CA). Monoclonal Anti-Influenza Virus H5 Hemagglutinin (HA) Protein 
(VN04-8), A/Vietnam/1203/2004 (H5N1), (ascites, Mouse), NR-2731 was obtained through the 
NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH. 
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7.2.2. Protein production and purification 
The HA0 ectodomain of the H5N1 influenza virus (A/Whooper Swan/244/Mongolia/05) 
HA gene was cloned and expressed using the Bac-to-Bac baculovirus expression system 
(Invitrogen, Grand Island, NY). Purification was facilitated by the addition of a HIS-tag to the C-
terminus of the HA0 ectodomain, and the trimeric structure was stabilized with a GCN4pII 
trimerization module.22 Briefly, recombinant H53 baculoviruses were produced by transfecting 
insect SF9 cells with bacmid DNA. After three rounds of amplification, the recombinant 
baculovirus was titered and used to subsequently infect SF9 cells. Supernatant containing the 
expressed H53 was collected after 96 hours and affinity-purified utilizing nickel-agarose beads.  
 
7.2.3. Polymer synthesis and characterization 
CPH and CPTEG diacids were synthesized as previously described.23, 24 Pre-polymers 
of CPH and SA were then synthesized followed by melt polycondensation to synthesize 20:80 
CPH:SA, 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH copolymers.15,24,25 To determine the final 
composition, purity, and molecular weight, the polymers were dissolved in deuterated 
chloroform and characterized using 1H nuclear magnetic resonance spectroscopy (VXR 300 
MHz, Varian, Palo Alto, CA). Polymer molecular weight was also measured using gel 
permeation chromatography (Waters HPLC, Milford, MA). The number average molecular 
weight was approximately 5,100 Da for both 20:80 and 50:50 CPTEG:CPH (PDI = 1.3 and 1.5, 
respectively) and 17,400 Da for 20:80 CPH:SA (PDI = 1.4), and found to be consistent with 
previous work.24,26 
 
7.2.4. Nanoparticle fabrication 
 H53-loaded nanoparticles were synthesized by concentrating 10.5 mg H53 into 
approximately 100 μL of nanopure water utilizing 5000 Da MWCO Vivaspin centrifugal 
concentrators (Viva Products, Sartorius, Goettingen, Germany). The protein solution was added 
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to 20 mg/mL of polymer in methylene chloride and homogenized for 90 s. Following 
homogenization, the solution was poured into chilled pentane at a solvent: non-solvent ratio of 
1:250 and filtered to collect nanoparticles. Blank nanoparticles (i.e., no protein) were 
synthesized similarly without the protein/water emulsion step. Scanning electron microscopy 
(FEI Quanta 250, FEI, Hillsboro, OR) was used to determine the size and morphology of the 
nanoparticles. Image J (Version 1.46r, NIH, Bethesda, MD) analysis determined the 
nanoparticles were approximately 200 nm in diameter (Table 7.1), similar to that observed in 
previous studies.14 
 
7.2.5. H53 release from polyanhydride nanoparticles 
 Approximately 10-20 mg of 7% H53-loaded nanoparticles were incubated at 37°C in 350 
μL of PBS buffer containing 0.01% sodium azide. Periodically, the nanoparticles were 
centrifuged to the bottom of the tube and PBS buffer containing released protein was collected 
using a pipet and an equivalent amount of fresh buffer was added back to the tubes. To 
determine the release kinetics, the protein in buffer was quantified at each time point using a 
micro-bicinchoninic acid (BCA) assay. After one month of protein release, the PBS buffer was 
replaced with a 25 mM sodium hydroxide solution to rapidly degrade the particles and extract 
the remaining protein. The total amount of H53 released in the first 30 days point plus the 
amount of H53 extracted was used to calculate the encapsulation efficiency as described 
previously.21  
 
7.2.6. Structural analysis of H53 released from polyanhydride nanoparticles 
  Soluble H53 proteins were released from the nanoparticles for 1 h in PBS and analyzed 
by SDS-PAGE. Briefly, 0.19 μg of released H53 was loaded into each well of Mini-Protean TGX 
gels and electrophoresed at 150 V for 60 min at 4°C. Gels were incubated in fixative (40% 
ethanol, 10% acetic acid) for three hours and stained overnight with Flamingo fluorescent gel 
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stain (BioRad). Subsequently, images of each gel were collected using a Typhoon 9400 flatbed 
scanner (GE Healthcare, Pittsburgh, PA). 
 A blue native gel and western immunoblot was used to assess the oligomeric form of 
H53 following release. Briefly, protein samples were prepared with a sample loading buffer of 2 
mM EDTA, 20 mM NaCl, 20 mM Bis-Tris, 8% glycerol, and 0.08% CBG-250. A control of non-
encapsulated H53 to show the monomer, dimer, and trimer forms of the protein was prepared in 
sample loading buffer containing 0.5% SDS. Next, 200 ng of protein was loaded into each well 
of the blue native gel and subjected to a voltage of 100 V for 3 h. After electrophoresis, the 
separated proteins were transferred to a PVDF membrane at 100 V for 80 min. The membrane 
was blocked with 5% non-fat milk in Tris buffered saline (pH 7.2) containing 0.1% Tween 20, 
and incubated with a rabbit polyclonal anti-H5 Vietnam 03/04 antibody (Dr. Carol Weiss, FDA) 
followed by HRP-conjugated donkey anti-rabbit antibody (Jackson ImmunoResearch). The 
immunoblot was developed with ECL substrate (Thermo Scientific, Waltham, MA) and detected 
with a FOTODYNE imaging system (FOTODYNE Incorporated, Hartland, WI). 
To determine changes in tertiary structure, H53 solutions (15 μg/mL) were excited at a 
wavelength of 280 nm. The emission spectrum was analyzed over a range of 295-405 nm using 
a SpectraMax M3 fluorescent spectrometer (Molecular Devices, Sunnyvale, CA). Changes in 
the tertiary structure were qualitatively assessed by the relative peak fluorescence compared to 
a non-encapsulated H53 protein control.  
 
7.2.7. H53 antigenicity upon release from polyanhydride nanoparticles 
 The antigenicity of released H53 was analyzed by ELISA. High binding 96-well plates 
were coated with 0.5 μg/mL protein in 100 μL PBS. After incubating overnight at 4°C, each well 
was blocked for two hours at room temperature with 300 μL of 1% bovine serum albumin in PBS 
supplemented with 0.05% Tween 20 (PBS-T). The plates were washed three times with PBS-T, 
and incubated with 100 μL/well of 1:1000 anti-H5 monoclonal antibody (NR2731, BEI 
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Resources) overnight at 4°C. After washing three times with PBS-T, 100 μL/well of 1:1000 
alkaline phosphatase-conjugated goat anti-mouse was added for two hours at room 
temperature. Finally, the colorimetric reaction was developed after washing the microtiter plates 
three times with PBS-T followed by the addition of 100 μL of 1 mg/mL phosphatase substrate in 
buffer to each well. Optical density of each well was determined by measuring the absorbance 
at 405 nm after 45 min. The relative antigenicity was determined by dividing the optical density 
of the experimental sample by the optical density obtained using control H53 to coat the 
microtiter wells. 
 In addition, the presence of neutralizing epitopes on the released H53 protein was 
evaluated in a neutralization inhibition assay using an H5-pseudotyped lentivirus vector.27, 28, 29 
Influenza lentiviral pseudotyped viruses were produced in HEK293T cells by co-transfecting 5 
μg of pEV-53B which encodes a lentiviral core, 5.5 µg of the luciferase reporter plasmid 
plgSIN6.1Luc, and 1 µg of plasmid DNA expressing H53 from H5N1 influenza strain A/Whooper 
Swan/244/Mongolia/ 05 using the ProFection mammalian transfection system (Promega, 
Madison, WI). Pig anti-H5 antiserum was diluted 1:5,000 and incubated with 10-fold serial 
dilutions of H53 protein at 37°C for 30 min. The mixtures were then incubated with 50,000 RLU 
of the H5-WhooperLuc pseudovirus at 37°C for 1h, and added into 96-well plates that contained 
293T cells grown for 24 h at 2 x 104 cells per well. After 48 h, the levels of the luciferase in the 
transduced cells were evaluated using ONE-Glo luciferase assay system (Promega). 
Neutralization inhibition was calculated as the concentration of H53 that inhibited 50% 
pseudovirus neutralization (IC50) compared to non-treated pig serum 
 
7.2.8. Statistical Analysis 
 Statistical significance using the Graph Pad Prism software (Version 6.01, Graph Pad 
Software, Inc., La Jolla, CA) was determined by a one sample t-test (Figure 7.4) or one-way 
analysis of variance (ANOVA) followed by Dunnett’s post-test (Figure 7.3 & 7.5). Each sample 
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was compared to a protein only control and p-values less than or equal to 0.05 were considered 
significant. 
 
7.3. RESULTS 
7.3.1. Polyanhydride nanoparticles provide sustained release of H53 
The H5N1 hemagglutinin trimer (H53) was encapsulated into three polyanhydride 
nanoparticle formulations: 20:80 CPH:SA, 20:80 CPTEG:CPH, and 50:50 CPTEG:CPH (Figure 
7.1A-C). In this work, the water/oil/oil (w/o/o) double emulsion method was used to fabricate the 
protein-loaded nanoparticles. It is known that the w/o/o method of nanoparticle synthesis affects 
the encapsulation efficiency due to the propensity of proteins to migrate to water/organic solvent 
interfaces.30 The encapsulation efficiency was found to be chemistry-dependent with 
encapsulation efficiencies of approximately 17% for 20:80 CPH:SA, 13% for 20:80 
CPTEG:CPH, and 29% for 50:50 CPTEG:CPH nanoparticles (Table 7.1).  
The degradation products of polyanhydrides range from mildly acidic pH (4-5 for 20:80 
CPH:SA), which is a pH that has been shown to stabilize hemagglutinin,31 to neutral pH (6.5-7 
for 20:80 CPTEG:CPH and 50:50 CPTEG:CPH). These polymers also have different 
hydrophobicities and molecular weights both of which directly affect their erosion rates (and 
consequently, payload release kinetics).21, 32 Protein release kinetics from these three 
formulations was studied for one month. As shown in Figure 7.1D, all three polyanhydride 
nanoparticle formulations demonstrated near-zero order release kinetics of H53 after an initial 
burst. The initial burst of protein release (i.e., protein release within the first hour) was relatively 
small, ranging from ~1% for protein released from 20:80 CPH:SA nanoparticles up to ~20% for 
protein released from 50:50 CPTEG:CPH nanoparticles. The H53 release rate was observed to 
decrease with increasing hydrophobicity and molecular weight of the polymer. The amphiphilic 
50:50 CPTEG:CPH nanoparticles, which have the lowest hydrophobicity of the three 
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formulations tested, released H53 at the highest rate compared to the other formulations 
studied.32 In contrast, both 20:80 CPTEG:CPH and 20:80 CPH:SA provided slower release 
kinetics due to the increased hydrophobicity of the polymer. In addition, the 20:80 CPH:SA 
formulation, which had a molecular weight approximately three times higher than the other two 
polymers, displayed the slowest protein release rate with only ~4% of the protein released in 
one month. 
 
7.3.2. Polyanhydride nanoparticles release structurally stable H53 
The stability of structure and folding of the H53 protein released from the three 
polyanhydride nanoparticle formulations were examined. SDS-PAGE analysis of H53 protein 
released from all three nanoparticle formulations identified a dominant band at 66 kDa, the 
molecular size of H5 monomer, similar to the dominant band of the control indicating little 
degradation of the released protein (Figure 7.2A). While no smeared bands or low molecular 
weight proteins were observed in the gel, the decreased intensity of the bands in comparison to 
the control may indicate the presence of small amounts of degraded protein. 
To determine the effect of encapsulation and release on the oligomeric structure of H53, 
released protein was electrophoresed in a blue native gel and analyzed by immunoblot. Unlike 
SDS-PAGE, the blue native gel allows for the observation of H53 in its trimeric, dimeric, and 
monomeric states. The western blot showed that the H53 trimeric form was the predominant 
oligomeric form of H53 following release from all the polyanhydride nanoparticle formulations 
(Figure 7.2B). 
The stability of the tertiary structure of the protein was qualitatively determined using 
fluorescence spectroscopy. Emission spectra of protein solutions excited at 280 nm is 
dependent upon the presence of tryptophan and tyrosine residues.33, 34 Typically, these 
hydrophobic amino acids are buried within the protein’s tertiary structure. If the protein 
undergoes unfolding, these residues are exposed to a hydrophilic environment leading to a 
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lower fluorescence emission. In this study, the relative fluorescence intensity was determined by 
normalizing the relative fluorescent units (RFUs) of each sample emitted at 335 nm, which is a 
signature for emission by tryptophan and tyrosine residues,33, 34 with the non-encapsulated 
protein control. 
The tertiary structure of H53 was significantly perturbed upon release from both 
CPTEG:CPH nanoparticle formulations as indicated by the data shown in Figure 7.3. This 
decreased fluorescent intensity observed for the protein released from the CPTEG:CPH 
formulations indicates unfolding of the tertiary structure, while the tertiary structure of H53 
released from the 20:80 CPH:SA nanoparticles was preserved.  
 
7.3.3. Polyanhydride nanoparticles preserve H53 antigenicity and function 
An anti-H5 monoclonal antibody (NR-2731, BEI Resources, Manassas, VA) was used to 
evaluate the antigenicity of the H53 released from the polyanhydride nanoparticles. As shown in 
Figure 7.4, H53 protein released from all three nanoparticle formulations was recognized by the 
monoclonal antibody and not statistically significant from a protein only control (i.e., non-
encapsulated protein), indicating preservation of antigenic epitopes.  
The antigenicity of the released protein was further evaluated by investigating the 
preservation of neutralizing epitopes in the released H53 using a neutralizing inhibition assay. 
When the released H53 is pre-incubated with antiserum capable of neutralizing a H5 
pseudovirus, neutralizing epitopes expressed on the protein will be bound by neutralizing 
antibodies, resulting in decreased neutralization of the pseudovirus. The H53 released from all 
the nanoparticle formulations was able to inhibit the neutralizing capacity of the anti-H5 pig 
antiserum (Figure 7.5). These results indicate that the protein released from the polyanhydride 
nanoparticle formulations retained the epitopes capable of neutralizing pseudovirus. 
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7.4. DISCUSSION 
 The development of vaccines for H5N1 influenza is critical due to the ability of the H5N1 
virus to resist anti-viral treatments and its potential to become a pandemic infectious agent.3,4 
Subunit vaccines have been increasingly utilized due to their favorable safety profile.8-10 Subunit 
proteins, however, are typically weak immunogens. This is often problematic as the generation 
of recombinant protein is expensive to produce and requires adjuvants to increase the titer of 
protective (i.e. neutralizing) serum antibodies. This work is focused on testing the stability of HA 
protein following release from the multi-functional adjuvant platform of polyanhydride 
nanoparticles (with varying hydrophobicities, molecular weight, and pH of degradation products) 
to help evaluate their use for vaccine delivery.  
The data presented herein demonstrate the ability of polyanhydride nanoparticles to 
encapsulate and release structurally and antigenically stable H53. Polymer chemistry was found 
to influence the encapsulation efficiency of H53 as shown in Table 7.1. The 50:50 CPTEG:CPH 
formulation had the highest encapsulation efficiency (29%) suggesting that the glycosylated H53 
may be more compatible with amphiphilic polymers. In contrast, the 20:80 CPTEG:CPH 
formulation had the lowest encapsulation efficiency, likely due to its increased hydrophobicity. 
The hydrophobicity of the polymer, and, therefore, its rate of erosion, plays a major role in the 
release kinetics of H53 (Figure 7.1). For example, encapsulating H53 within amphiphilic 50:50 
CPTEG:CPH nanoparticles resulted in the most rapid H53 release rate among the three 
formulations tested. While hydrophobicity is an important factor to consider in tailoring the 
release kinetics of H53, polymer molecular weight also influences the release kinetics. The 
release kinetics of H53 from 20:80 CPH:SA nanoparticles was the slowest, likely because of the 
higher molecular weight of this polymer (~three times greater than that of the other two 
polymers studied). The initial burst (i.e., within the first hour) of released protein was found to be 
relatively small (ranging between 1 - 20%) for all three formulations. This is likely due to the low 
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encapsulation efficiency of H53 into the nanoparticles (Table 7.1), and is indicative of a uniform 
distribution of protein within the polymer.26 However, the differences between the initial burst 
release among the various chemistries can be attributed to variations in actual loading of H53 as 
well as the stability of H53 within each chemistry (discussed below). 
 The primary structure of H53 was largely preserved when released as observed by SDS-
PAGE, although differences in band intensity may indicate slight degradation (Figure 7.2A). 
Likewise, as shown in Figure 7.2B, the trimeric state of H53 was also preserved upon 
encapsulation and release. This preserved structure is likely to enhance the induction of 
neutralizing antibodies following immunization with the H53, as studies have suggested that H5 
monomer is not as immunogenic as the native trimeric structure.9  
 Fluorescence spectroscopy demonstrated unfolding of H53 tertiary structure when 
released from CPTEG:CPH formulations (Figure 7.3). The decreased fluorescent intensity can 
be attributed to a combination of completely unfolded protein and/or partially unfolded protein 
molecules. It is known that the degradation products of CPH:SA formulations are slightly more 
acidic (pH ~4-5) when compared to their CPTEG:CPH counterparts (pH ~6.5) .21,35 It is possible 
that the pH microenvironment may have contributed to the observed changes in the 
conformational structure of H53. 
 
Although there was no statistical significance of the relative antigenicity of the protein 
released from the different nanoparticle formulations (Figure 7.4), the small decrease in 
antigenicity of H53 released from 20:80 CPTEG:CPH nanoparticles may be attributed to the 
unfolding of tertiary structure observed in Figure 7.3. The anti-H5 antibody (NR-2731) used to 
determine antigenicity is specific for H5 as determined by hemagglutinin inhibition, suggesting 
that the antibody binds to conformational epitopes, and maintenance of conformational epitopes 
of H53, or folding, may be important. Similarly, released H53 from all three nanoparticle 
formulations was found to inhibit neutralizing serum as well as the control (Figure 7.5). 
However, it is important to note that while the H53 preparations recovered from the three 
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nanoparticle formulations were each capable of blocking the neutralizing activity of anti-H5 
antiserum, it required approximately four to five times more H53 released from the CPTEG:CPH 
formulations to achieve the same level of inhibition as the H53 released from 20:80 CPH:SA 
nanoparticles. As the conformational epitopes presented by H5 are known to be most important 
for neutralization,31, 36 the loss of tertiary structure exhibited by the H53 released from the 
CPTEG:CPH formulations (Figure 7.3) is consistent with the lesser ability to block the 
neutralizing antiserum.  
The ability of polyanhydride nanoparticles to release stable and antigenic antigen has 
many advantageous implications for vaccine design. The sustained release of antigen from 
polyanhydride nanoparticles has been shown to prolong the presence of antigen leading to 
long-lived high titer, high avidity antibody responses.14 In addition, maintaining the structural 
stability, and therefore a broad spectrum of protective epitopes, may also be beneficial in 
influenza where antigenic drift is common.1 It is also important to note that dry powder 
formulations with nanoparticles can be easy to administer with needle-free technologies (e.g., 
intranasal administration), allowing for rapid deployment in pandemic scenarios.37 Furthermore, 
encapsulating antigen into dry powder polyanhydride formulations has been shown to maintain 
antigen stability and activity even when stored for long periods of time at room temperature.38 
The ability to maintain stockpiles of easy-to-use, broadly protective vaccines would be highly 
valuable in preparation for possible influenza pandemics. 
 
7.5. CONCLUSIONS 
 The studies described herein demonstrated that polyanhydride nanoparticles provided 
sustained release of stable H53. Protein released from CPH:SA nanoparticles maintained both 
structural and antigenic stability. Despite changes in the tertiary structure of H53 released from 
CPTEG:CPH nanoparticles, the antigenicity of protein released from all the nanoparticle 
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formulations was preserved. Together, these studies demonstrated that there was release of 
stable H53 from polyanhydride nanoparticles and that this platform is a potentially useful delivery 
vehicle for efficacious HA subunit nanovaccines against influenza viruses. 
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7.6. TABLES 
Table 7.1. Properties of Polyanhydride Nanoparticle Formulations 
 
Formulation 
Molecular 
Weight 
(g * mol-1) 
Particle 
Diameter 
(nm) 
Encapsulation 
Efficiency 
Actual H53 
Loading 
20:80 
CPH:SA 
17,472 220 ± 60 17.1 ± 0.9% 1.2 ± 0.06% 
20:80 
CPTEG:CPH 
5,117 195 ± 59 13.1 ± 0.3% 0.9 ± 0.02% 
50:50 
CPTEG:CPH 
5,153 192 ± 54 28.7 ± 8.1% 2.0 ± 0.57% 
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7.7. FIGURES 
 
Figure 7.1. Encapsulation and release of H53 from polyanhydride nanoparticles. Scanning 
electron photomicrographs showing H53-loaded 20:80 CPH:SA (A), 20:80 CPTEG:CPH (B), and 
50:50 CPTEG:CPH (C) nanoparticles. Scale bar represents 1 μm. Release kinetics of H53 from 
the three polyanhydride nanoparticle formulations over 28 days (D). Error bars represent 
standard error of mean. Three replicates of each formulation were analyzed. 
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Figure 7.2. Integrity of the primary structure and oligomeric forms of H53 released from 
polyanhydride nanoparticles. SDS-PAGE analysis of H53 released from nanoparticles (A). 
Lanes represent molecular weight ladder (1), H53 control (2), H53 released from 20:80 CPH:SA 
(3), 20:80 CPTEG:CPH (4), and 50:50 CPTEG:CPH nanoparticles (5). Western blot of released 
H53 separated by blue native gel electrophoresis (B). Lanes represent non-encapsulated H53 
control in 0.5% SDS (1), H53 released from 20:80 CPH:SA (2), 20:80 CPTEG:CPH (3), and 
50:50 CPTEG:CPH nanoparticles (4). 
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Figure 7.3. Integrity of the tertiary structure of H53 released from polyanhydride 
nanoparticles. Tertiary structure of H53 released from various polyanhydride nanoparticle 
formulations was examined by fluorescent spectroscopy. The fluorescent intensity of the 
spectral peak (335 nm) was normalized to a H53 control. Three replicates of each formulation 
were analyzed. Error bars represent standard error of mean. * indicates statistical significance 
from the protein only control with p ≤ 0.0167. 
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Figure 7.4. Relative antigenicity of H53 released from polyanhydride nanoparticles. An 
ELISA was used to determine the antigenicity of H53 released from various polyanhydride 
nanoparticle formulations. Relative antigenicity was calculated by dividing the optical density 
(OD) of samples by the OD obtained using a control H53 as the antigen. Three replicates of 
released H53 were evaluated for each formulation. Error bars represent standard error of mean. 
No statistical significance was found in comparing each treatment group to the protein only 
control (p ≤ 0.4656).  
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Figure 7.5. Neutralizing inhibition of H53 released from polyanhydride nanoparticles. A 
neutralization inhibition assay was used to evaluate expression of neutralizing epitopes on H53 
released from various polyanhydride nanoparticle formulations. The IC50 was calculated as the 
concentration of H53 that inhibited 50% of neutralizing activity of convalescent pig sera. Three 
replicates of each formulation were analyzed. Error bars represent standard error of mean. No 
statistical significance was found comparing each treatment group to the protein only control (p 
≤ 0.4907). 
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Abstract 
 H5N1 avian influenza is a significant concern throughout the globe, having the potential 
to become the next pandemic threat. Recombinant subunit vaccines are an attractive alternative 
for pandemic vaccines compared to traditional technologies. Additionally, polyanhydride 
nanoparticles encapsulating subunit proteins have been shown to enhance humoral and cell-
mediated immunity. In this work, a H5 hemagglutinin trimer (H53) was expressed and 
encapsulated into polyanhydride nanovaccines. The studies performed indicate that the 
expressed H53 antigen is a robust immunogen. Encapsulation into polyanhydride nanoparticles 
also induced high neutralizing antibody titers as well as enhanced CD4+ T cell memory 
responses. Finally, the H53-based nanovaccines were protective against a low pathogenic, 
H5N1 viral challenge. 
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8.1. INTRODUCTION 
Influenza virus is a major cause of serious respiratory illness and has been responsible 
for significant morbidity and mortality in humans worldwide. The major strains of influenza A 
virus circulating in human populations are H3N2 and H1N1, which are associated with seasonal 
flu epidemics. In addition, avian strains H5N1 and H7N9 have been found to infect humans;1 
however, they do not appear capable of sustained human-to-human spread. Should these 
highly pathogenic avian viruses develop such capability, the disease could rapidly spread 
resulting in a global influenza pandemic. Vaccination represents a critical control measure 
against yearly seasonal influenza viruses and is an essential component of pandemic 
preparedness plans.2 Nearly all of the current influenza vaccine technologies are based on the 
use of embryonated eggs and require a relatively long production cycle and limited 
manufacturing capacity.2 The response to the 2009 H1N1 pandemic clearly demonstrated the 
limitations of these methods of vaccine production with respect to rapid deployment in response 
to an emerging influenza pandemic, which can lead to vaccine shortages. Consequently, there 
is great interest in developing new technologies for rapid, large scale, and safe and efficacious 
influenza vaccine production. 
Recombinant hemagglutinin (rHA)-based vaccines produced in mammalian or insect cell 
culture systems are considered attractive alternatives to egg-based vaccine technologies.3 
Production and purification of rHA protein can effectively limit the production time, and 
mammalian and insect cell culture systems will glycosylate proteins important for neutralizing 
epitope generation.4 Recent studies demonstrated that rHA engineered to form a stable trimeric 
configuration elicited a protective immune response in vaccinated animals.5-10 Neutralizing 
antibody levels and protection from disease were enhanced in mice vaccinated with soluble rHA 
trimers as compared to animals vaccinated with rHA monomers,5,8 indicating the importance of 
immunogens that mimic a natural infection. Along those lines, the composition and/or number of 
N-linked glycans on sHA trimers has been shown to modify the level of the protective antibody 
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response.10,11 These data suggest that recombinant soluble HA trimers could be an important 
component of a subunit vaccine strategy against influenza. 
HA-specific serum antibody titers correlate with protection from disease; however, 
recombinant proteins are often weak immunogens and often require multiple immunizations with 
high doses to achieve protection.6,7,12 Polyanhydride nanoparticles have been shown to be a 
versatile vaccine adjuvant/delivery platform capable of enhancing the immune response to 
recombinant proteins.13-15 Polyanhydrides are a class of surface erodible, biodegradable 
materials that provide sustained release kinetics of encapsulated antigen, resulting in long lived, 
high avidity antibody titers even with suboptimal doses of antigen.13,15 Aside from amplifying 
humoral immunity, polyanhydride nanovaccines have also been known to be 
immunomodulatory16 and are capable of promoting cell-mediated immunity. Previous work with 
polyanhydride nanovaccines has observed higher frequencies of both antigen-specific CD8+ 
and CD4+ T cells following nanovaccine immunization, resulting in greater memory T cell 
populations that responded to challenge (CD8+ T cells)17 and increased germinal center B cells 
(CD4+ T cells).18 This broad repertoire of immune responses produced by polyanhydride 
nanovaccines may provide a large advantage in influenza vaccines as robust cell-mediated 
responses are often associated with broader protective immunity and directed at conserved 
epitopes.19,20 
In this study, soluble H5 HA trimers (sH53) from H5N1 influenza virus A/Whooper 
Swan/244/Mongolia/05 were produced using a baculovirus insect cell expression system. After 
characterizing the oligomeric structure of the protein and examining its immunogenicity in vivo, 
the protein was subsequently encapsulated into polyanhydride nanoparticles. The virus-
neutralizing antibody titer in response to nanoparticle immunization was observed for 
approximately two months and concluded with an analysis of the memory T cell responses 
generated. Finally, the efficacy of lead nanoparticle formulations was examined using a low-
pathogenic, live viral challenge. The data demonstrate that polyanhydride nanoparticles 
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encapsulating an immunogenic hemagglutinin trimer represent a potentially viable platform for 
pandemic influenza vaccines. 
 
8.2. MATERIALS AND METHODS 
8.2.1. Plasmids and antibody 
Plasmid pHW500 (Genbank DQ659326), obtained from Dr. Bruce Janke of Iowa State 
University, contains the full length HA gene from HPAI H5N1 influenza virus A/whooper 
swan/244/Mongolia/05 (H5N1). The pHW500 HA gene was modified by replacement of the 
cognate polybasic cleavage site with that from a low pathogenic H6N1 avian influenza virus.21 
The FDA-VN plasmid, obtained from Dr. Carol Weiss of U.S. FDA, contains the full length HA 
from A/Vietnam/1203/2004 (H5N1) (Genbank EF541403) in pCMV/R. The pWS-HA was 
constructed by replacing the H5 Vietnam HA gene in FDA-VN with the HA gene from pHW500. 
The low pathogenic cleavage site in pWS-HA was replaced with the polybasic cleavage site 
from A/whooper swan/3/Mongolia/05 (H5N1) (Genbank AB233320.1). The equine infectious 
anemia lentivirus vector plasmids pEV53B and pSIN6.1ClucW were obtained from John 
Olsen.22 Hyperimmune swine sera containing high-titers of H5 neutralizing antibody was 
obtained from Dr. Bruce Janke. H5-specific polyclonal rabbit antisera was obtained from Dr. 
Carol Weiss.19  
 
8.2.2. Cloning and expression of soluble H5 trimer (sH53) 
The HA ectodomain (nucleotides 1-1723) was amplified from pHW500 and modified at 
the 3’ end by addition of linker sequences, a GCN4pII trimerization domain and His-tag 
sequences at the 3’ end (Figure 8.1A). The modified gene was cloned into pFastBac I, 
transformed into DH10Bac cells, and recombinant baculoviruses were generated using Bac-to 
Bac Baculovirus Expression System (Invitrogen, Grand Island, NY). Sf9 cells (Invitrogen) were 
infected with recombinant baculovirus and supernatants collected 96 h after infection were 
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clarified by centrifugation, dialyzed against 10 mM Tris buffer (10 mM Tris, 50 mM NaCl pH 8.0), 
and incubated with Ni-NTA beads (Thermo Scientific, Waltham, MA) overnight at 4°C. The 
beads were washed with 10 mM Tris buffer containing 10 mM imidazole and recombinant sH53 
was eluted in 10 mM Tris buffer containing 250 mM imidazole. The eluted proteins were 
dialyzed against 10 mM Tris buffer to remove imidazole, concentrated and stored at 4°C for up 
to a month or at -80°C for long term storage. 
 
8.2.3. HA-pseudotyped reporter virus 
HA pseudotyped viruses were produced in HEK293T cells as previously described.23,24 
Briefly, HEK293T cells were co-transfected with 5 μg of pEV-53B encoding the lentiviral core 
proteins of equine infectious anemia virus, 5.5 μg of the luciferase reporter plasmid 
plgSIN6.1Luc and 1 μg of pFDA-VN or pWS-HA plasmid DNA expressing HA from 
A/Vietnam/1203/2004 (clade1) or A/Whooper Swan/244/Mongolia/05 (clade 2.2), respectively. 
At 18 h post-transfection, cells were incubated with fresh medium containing 7 mU/mL of Vibrio 
cholera Type II neuraminidase (Sigma) and 1M NaB to induce the release of H5-pseudovirions 
from the surface of the producer cells. Supernatants were collected 48 h post-transfection, 
clarified by centrifugation, and stored at −80°C.  
Reporter virus pseudotyped with HA from A/Vietnam/1203/2004 (H5-VN-Luc) or 
A/Whooper Swan/244/Mongolia/ 05 (H5-WS-Luc) were titered on HEK293T cells. Cells were 
seeded in 96-well plates at 2 x 104 cells/well in Dulbecco’s modified Eagle medium 
supplemented with antibiotics and heat-inactivated fetal bovine serum. The following day, cells 
were inoculated in triplicate with 10-fold serial dilutions of pseudovirus stock in the presence of 8 
μg/mL polybrene. At 48 h post-transduction, cells were lysed and assayed for luciferase activity 
using the ONE-Glo Luciferase assay system (Promega). Luciferase activity was quantified using 
a Centro XS3 LB960 illuminometer (Berthold Technologies) and results reported as relative light 
units (RLU)/mL supernatant. 
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8.2.4. Electrophoresis and Immunoblot 
For protein analyses in denaturing conditions, 1 μg of purified sH53 protein was boiled 
for 5 min in SDS loading buffer in (50mM Tris, 1% β-mecaptoethanol, 2% SDS, 0.005% 
bromophenol blue, and 10% glycerol) and electrophoresed in 10% SDS-PAGE. For analyses in 
non-denaturing gels, 1 μg of purified sH53 protein was mixed with Blue native loading buffer (2 
mM EDTA, 20 mM NaCl, 20 mM Bis-Tris, 10% glycerol, 0.08% coomassie blue G-250) and 
separated on 10% Blue native PAGE gel containing Bis-Tris, glycerol and acrylamide in Bis-Tris 
buffer in the outer chamber and Tricine, Bis-Tris with Coomassie blue G250 in the inner 
chamber. Following electrophoresis, gels were stained with coomassie blue and imaged with a 
GelDoc XR+ imaging system (BioRad). 
For immunoblot, 200 ng of protein was electrophoresed in SDS-PAGE and Blue native 
gels as described above. Proteins were transferred to PVDF membrane (GE Healthcare), 
blocked overnight in blocking buffer (5% Nonfat dried milk in Tris-buffered saline with 0.1% 
Tween 20) and incubated with 1:2000 of anti-H5 Vietnam 03/04. Blots were washed 3X, and 
incubated with 1:5000 dilution of HRP-conjugated donkey anti-rabbit antibody (Jackson 
ImmunoResearch). Blots were developed with ECL substrate (Thermo Scientific) and bands 
were visualized by FOTODYNE imaging system (Fotodyne Inc.).  
 
8.2.5. Polymer and nanoparticle synthesis 
Diacids based on 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) diacids were synthesized as previously described25,26 using: 
1,6-dibromohexane, 1-methyl-2-pyrrolidinone, hydroxybenzoic acid, N,N-dimethylacetamide, 
and tri-ethylene glycol (Sigma, Aldrich, St. Louis, MO); acetic acid, acetone, acetonitrile, 
dimethyl formamide, potassium carbonate, sulfuric acid, and toluene (Fisher Scientific, Fairlawn, 
NJ); 4-p-fluorobenzonitrile (Apollo Scientific, Cheshire, UK). Following diacid synthesis, 20:80 
CPTEG:CPH copolymer was synthesized by melt polycondensation.26 The final composition of 
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the polymer (23:77 CPTEG:CPH), molecular weight (6055 Da), and purity were determined with 
1H nuclear magnetic resonance spectroscopy (VXR 300 MHz, Varian, Palo Alto, CA). H53-
loaded nanoparticles were synthesized using a water-oil-oil (w/o/o) double emulsion process27. 
First, 4.5 mg of sH53 was concentrated into 100 μL of nanopure water. The solution of sH53 was 
then added to 45 mg of 20:80 CPTEG:CPH dissolved in 2.25 mL of methylene chloride and 
homogenized for 90 s. The H53-loaded nanoparticles were precipitated by pouring into 562.5 
mL of chilled pentane and collected via vacuum filtration. Blank nanoparticles, 1% poly I:C 
(InvivoGen, San Diego, CA)-loaded nanoparticles, and 1% poly dA:dT (InvivoGen)-loaded 
nanoparticles were synthesized similarly without water. Scanning electron microscopy (FEI 
Quanta 250, FEI, Hillsboro, OR) was used to characterize the size and morphology of the 
nanoparticles, which were found to be consistent with previous work.13 The encapsulation 
efficiency of protein was determined by degrading 10 mg of nanoparticles in 250 µL of 40 mM 
sodium hydroxide and quantifying the total protein released using a microBCA protein kit 
(Pierce, Rockford, IL).13 
 
8.2.6. Mice 
Female BALB/c mice were purchased from Harlan Laboratories (Indianapolis, IN). All 
mice were housed under specific pathogen-free conditions where all bedding, caging, water, 
and feed were sterilized prior to use. Animal procedures were conducted with the approval of 
the Iowa State University and University of Nebraska Medical Center Institutional Animal Care 
and Use Committees. 
  
8.2.7. Immunizations 
 Mice were administered 10 µg of sH53 alone or in conjunction with 10 µg of 
monophosphoryl lipid A (MPLA) from Salmonella enterica (Sigma) as outlined in Table 8.1. In 
studies testing the efficacy of sH53-loaded nanoparticles, blank nanoparticles were used to bring 
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the total amount of nanoparticles to 300 μg in all the groups tested (Table 8.1). All nanoparticle 
formulations were suspended in 250 μL (subcutaneous immunization) or 50 μL (intranasal 
immunization) sterile saline. Subcutaneous (SC) immunizations were administered at the nape 
of the neck; intranasal (IN) immunizations were carried out using droplet admission via pipettor 
after ketamine/xylazine chemical anesthetic. Boost immunizations were prepared and 
administered the same way as primary immunizations. Serum samples were obtained at the 
time points indicated via saphenous vein bleeding.  
 
8.2.8. Neutralization Assay 
Neutralizing antibody assays were carried out using HA-pseudotyped reporter virus as 
described previously.23,24 HEK293T cells were seeded in 96-well plate at 2 x 104 cells/well and 
grown for 24 h. Sera samples were serially diluted threefold in culture medium containing 8 
μg/mL of polybrene (Sigma), and mixed with an equal volume of diluted pseudoviruses 
containing 5 x 104 RLU/mL. After incubation at 37°C for 1 h, virus and serum mixtures were 
added to the cells. Infectivity was evaluated 48 h after transduction using One-glo Luciferase 
assay system (Promega). The percent neutralization was calculated as (1-[virus+sera RLU/virus 
only RLU]) x100. The percent neutralizations for each sera dilution were plotted and neutralizing 
titers reported as ID50, calculated as the reciprocal of the serum dilution that neutralized 50% of 
the virus.  
A neutralization inhibition assay was used to evaluate the immunogenic properties of 
sH53 protein. Ten-fold serial dilutions of sH5 trimer or monomer were incubated 37°C for 30 min 
with a 1:5,000 dilution of pig H5-antiserum, which neutralizes 90% of 50,000 RLU of H5-WS-Luc 
(Dr. Bruce Janke, Iowa State University). Following pre-incubation with H5 protein, 50,000 RLU 
of H5-WS-Luc were added and the samples incubated an additional 1 h at 37°C and inoculated 
onto HEK293T cells in 96 well plates. At 48 h after transduction, the levels of the luciferase in 
the transfected cells were evaluated using One-glo Luciferase assay system (Promega) and 
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percent neutralization was calculated as described above. The percent neutralization at each 
protein concentration was plotted and the IC50 was calculated as the concentration of soluble H5 
protein that inhibited 50% of the neutralizing activity of the diluted pig sera. 
 
8.2.9. Flow cytometry for T cell memory populations  
Brachial and axillary draining lymph nodes were harvested 63 days post-immunization 
and homogenized into single cell suspensions in complete tissue culture medium. Single cell 
populations were labeled with 2.5 µM 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester 
(5(6)-CFDA, SE) (CFSE) (Life Technologies, Grand Island, NY). Cells (2.5 x 105) were 
incubated in 96 well U-bottom plates with 0.5 µg of sH53 antigen for 96 h. Cells were aspirated 
and quantified using flow cytometry (BD FACScanto). Cell suspensions were blocked for non-
specific antibody binding using 0.1 mg/mL Rat IgG (Sigma Aldrich, St. Louis, MO) and mouse 
anti-CD16/32 (eBioscience, San Diego, CA) 10 µg/mL. Fluorescently conjugated antibodies for 
CD4 and CD8 (eBioscience) were used to stain in FACS buffer, gate, and quantify specific cell 
populations. 
 
8.2.10. Low-pathogenic viral challenge and clinical evaluation 
The efficacy of sH53-based nanoparticle vaccines were evaluated in mice challenged at 
63 days post-immunization with the low pathogenicity influenza virus A/H5N1 VNH5N1-
PR8CDC-RG, obtained from the Centers for Disease Control and Prevention (Atlanta, GA). This 
is a PR-8-based reassortant virus that contains the HA and NA genes of H5N1 
A/VietNam/1203/04, a clade 1 virus. Mice were anesthetized with 20 mg/ml of xylazine and 100 
mg/ml of ketamine (1:4 ratio) and inoculated intranasally with 2.7 x 103 TCID50 virus in 30 μL 
PBS. Three days after challenge, half of the mice were euthanized with 600 μL of 20 mg/mL 
xylazine and 100 mg/mL ketamine delivered via intraperitoneal injection. Bronchoalveolar 
lavage (BAL) fluid was collected as described previously28 and lung tissue was collected for 
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inflammatory cytokine and viral load quantitation (described below). The remaining mice were 
monitored for weight loss for two weeks post-challenge before being removed from study. 
 
8.2.11. Virus load quantitation 
Following the procedure of Alsharifi and co-workers, lung tissue was preserved in 3 mL 
of RNAlater Stabilizing Reagent (Qiagen).29 Tissue was held submerged in the RNAlater for 
three days at 4°C. Tissues were then removed from the RNAlater, weighed and cut into 30 mg 
pieces and individually frozen at -80°C in 1.5 mL microcentrifuge tubes. For the extraction 
process (total RNA), individual 30 mg tissue pieces were homogenized in 200 μL Buffer RLT 
(Qiagen RNEasy Mini Kit) using a disposable pellet pestle (Fisher Scientific) in conjunction with 
a cordless motor (Fisher Scientific). An additional 400 μL of RLT buffer was added to each tube 
after homogenization was completed. Tissue was extracted into 60 μL final volume in sterile, 
RNAse-free H20 (Qiagen) and frozen at -80°C until PCR was performed. Samples containing 
the extracted RNA were thawed, mixed well, and the total RNA concentration was determined, 
in duplicate measurements, using the Nanodrop method for RNA content. Total RNA 
concentration for each sample was adjusted to 40 μg/μL and 5 μL was used as the template for 
the PCR reaction. PCR was performed on an Applied Biosystems 7500 Fast Real-Time PCR 
System, on the standard mode, using the AgPath-ID One-Step RT-PCR Reagents (Life 
Technologies, Grand Island, NY) in conjunction with the Fast-Track Diagnostics FTD-21-96/12 
Kit (Junglinster, Luxembourg) which contains Brome Mosaic Virus (BMV) internal PCR 
extraction control, positive control and primer/probes for universal influenza A antigen. For the 
standard curve, normal, non-influenza challenged mice lungs (naive controls) were 
homogenized using the procedure outlined above. RNA from stock influenza A H5 virus was 
extracted using the Qiagen QiAmp Viral RNA Kit Mini Kit (Qiagen). Extracted RNA was 
quantified using the Nanodrop procedure. For the standard curve, ten-fold dilutions of the H5 
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extracted viral RNA were mixed with extracted RNA from the normal mouse lungs that had been 
standardized to 40 ng/μL. Standard curves were obtained with each set of PCR reactions. 
 
8.2.12. Cytokine quantitation 
BAL fluid samples collected three days post-viral challenge were analyzed for the 
inflammatory cytokines IL-6, IP-10, MIG, G-CSF, IFN-g, MCP-1, KC, and MIP-2 using a 
MILLIPLEX® MAP assay kit (EMD Millipore Corporation, Billerica, MA). The assay was 
performed according to manufacturer instructions. Briefly, 25 μL of BAL fluid, 25 μL assay 
buffer, and 25 μL MILLIPLEX® MAP beads were added to each well of a 96- well plate. After 
shaking overnight at 4°C, the plate was washed and incubated with 25μL/well detection 
antibody for 1 h at room temperature. Following, 25μL/well streptavidin-phycoerythrin was 
added for an additional 30 min. The plate was washed once more before measuring 
fluorescence intensity on a Bio-Plex 200 system (Bio-Rad). 
 
8.2.13. Statistics 
Statistical significance among formulations (p ≤ 0.05) was determined by a one-way 
analysis of variance followed by Tukey’s post text using Graph Pad Prism (Version 6.01, Graph 
Pad Software, Inc., La Jolla, CA).  
 
8.3. RESULTS 
8.3.1. Characterization of soluble H5 trimer protein (sH53)  
A recombinant baculovirus containing a GCN-modified ectodomain of HA from A/Whooper 
Swan/244/Mongolia/ 05 (Figure 8.1A) was expressed in Sf21 insect cells and the secreted 
soluble H5 trimer (sH53) protein was purified from culture supernatant by affinity 
chromatography using nickel-agarose beads. Analyses of the purified protein by electrophoresis 
in SDS-PAGE blue native gels indicated the predominant form of sH53 protein was trimeric 
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(Figure 8.1B). A neutralization inhibition assay was used to determine whether the sH53 retained 
neutralizing epitopes of native virus (Figure 8.1C). In this assay, convalescent pig sera 
containing high titers of H5-neutralizing antibody was incubated with serial dilutions of sH53 or 
sH5 monomer and tested for neutralizing activity against H5-WS-Luc pseudotyped reporter 
virus. Both the monomeric and trimeric forms of sH5 inhibited neutralizing antibody at fmol 
concentrations; however, the inhibitory activity of the sH53 trimer was about 2.5 fold higher than 
the monomer. 
 
8.3.2. Immunogenicity of soluble recombinant H5 HA trimer 
BALB/c mice (6-8 weeks) were immunized either subcutaneously or intranasally with 10 
µg of soluble protein at 0, 21 and 42 days and sera collected at 21, 42, and 63 days post-
immunization were tested for neutralizing antibody against the homologous H5-WS-Luc 
pseudovirus.  No neutralizing antibody was detected at day 21 following primary immunization 
(Figure 8.2A). By day 42, the majority of mice in both immunization groups had detectable 
neutralizing antibody to the homologous challenge virus. However, the response was highly 
variable among individual mice, with ID50 titers ranging from undetectable to greater than 1,000. 
Neutralization titers significantly increased following a second boost, with mean neutralization 
antibody titers of greater than 10,000. In addition, there was less variability in in the neutralizing 
antibody titers among individual mice, especially those immunized subcutaneously.   
As highly pathogenic H5N1 has continued to spread in avian and mammalian hosts, 
different lineages have emerged that are now classified into distinct, but phylogenetically related 
clades.1 To examine the cross-clade breadth of the neutralizing antibody response elicited with 
A/Whooper Swan/244/Mongolia/2005-based sH53 (Clade 2.2), day 63 sera was tested for 
neutralizing activity against H5-VN-Luc, a luciferase reporter virus pseudotyped with HA from 
the A/Vietnam/1203/2004 HA, an H5 clade 1 strain. Although the cross-clade neutralization 
titers were 2-10 fold lower than titers to homologous virus, all mice were able to neutralize 
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Vietnam/1203 pseudotyped virus, with mean neutralizing antibody titers of 103 (Figure 8.2B). 
Together, these data indicate that non-adjuvanted sH53 antigen is able to elicit high titers of H5 
cross-clade neutralizing antibody when administered using a prime-boost-boost regimen. 
However, consistent with previous reports,6,7,12 multiple immunizations of sH53 recombinant 
protein were required to generate consistently high neutralizing antibody titers. 
 
8.3.3. Neutralizing antibody response in mice vaccinated with H53-based nanovaccines 
Our previous studies indicate that polyanhydride nanovaccines can enhance the immune 
response to recombinant proteins.13-15 Therefore, we examined the immune response of sH53 
delivered with and/or encapsulated into polyanhydride nanoparticles (Table 8.1). Mice were 
immunized subcutaneously with either a single dose regimen or a prime/boost regimen of three 
immunizations 21 days apart. Serum was collected via saphenous vein at 42 and 63 days post-
immunization and tested for neutralizing antibody titers against H5-WS-Luc. As we observed 
above, sH53 alone elicited low neutralizing titers in the absence of booster immunizations with 
most mice having ID50 titers of less than 100 through 63 days post-immunization (Figure 8.3). 
Higher titers were observed using a single dose immunization regimen with sH53 in the 
presence of adjuvant, with MPLA eliciting higher neutralizing antibody titers than any of the 
nanovaccine formulations or sH53 alone. In the absence of booster immunizations, the 
neutralizing antibody response in groups vaccinated with nanoparticle formulations was lower 
than the MPLA adjuvant group at 42 days with the exception of the formulation including poly 
I:C; however, there were a greater number of nanoparticle vaccinated mice with detectable 
neutralizing antibodies than in mice vaccinated with sH53 alone.  
The prime/boost vaccination regimen resulted in enhanced neutralizing antibody titers in 
all vaccine formulations, with most groups showing a 10-20 fold increase in mean neutralizing 
antibody titer over groups receiving a single booster immunization (Figure 8.3). In almost all 
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groups, the highest and most consistent titers were observed after receiving three 
immunizations, with little difference observed among the different formulations.   
 
8.3.4. Cell-mediated immune response 
Cell-mediated immune responses are often associated with broader protective immunity 
and can play an important role in protection against antigenically diverse strains of influenza.19,20 
Therefore, we examined the proliferative T cell populations 63 days post-immunization in mice 
receiving the prime/boost/boost regimen (Figure 8.4). Draining lymph nodes were removed and 
homogenized to single cell suspensions and labeled with CFSE to observe proliferating cell 
populations. After 96 h of ex vivo stimulation with sH53, CD4
+ and CD8+ T cells were quantified 
via flow cytometry. A significant expansion of CD4+ T cells, but not CD8+ T cells, was observed 
in all groups of vaccinated mice as compared to mice receiving saline alone as shown in Figure 
8.4. In addition, the inclusion of poly I:C within the nanovaccine formulation resulted in 
significantly higher numbers of both CD4+ and CD8+ T cells as compared to other vaccinated 
groups. These data suggest that inclusion of nanoparticles encapsulating poly I:C to induce an 
appropriate innate immune response may enhance antigen-specific adaptive immune 
responses. 
 
8.3.5. H53 vaccination protects against live viral challenge 
To examine the efficacy of sH53-loaded nanoparticles in protection from clinical disease, 
mice were vaccinated with various nanovaccine formulations (Table 8.1) using a prime/boost 
regimen and challenged at 63 days post-immunization with the low pathogenic VNH5N1-
PR8/CDC-RG, a reverse genetics-derived influenza virus containing the HA and neuraminidase 
(NA) genes of A/Vietnam/1203/04 (H5N1) virus in the genetic background of the high-growth 
master strain A/Puerto Rico/8/34 (H1N1). Pre-challenge antibody response to the various 
vaccine regimens was evaluated in serum collected one week before challenge. All vaccinated 
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groups had high levels of total anti-H53 IgG, with no significant difference among the groups 
(data not shown). Similar to our earlier studies, all vaccinated mice had detectable neutralizing 
antibody titers of greater than 100 to the clade 2.2 H5-WS-Luc pseudotyped reporter virus, with 
mean titers among the group ranging between 3000-4000 (Figure 8.5).  
The body weight of each mouse was observed over the course of 14 days post-
challenge. All of the vaccine formulations protected mice from challenge with body weight 
increasing post-challenge similar to naïve mice that were not challenged (Figure 8.6A). In 
contrast, mice receiving saline immunizations began to lose a significant portion of body weight 
approximately five days post-challenge. Saline-administered mice continued to lose 
approximately 20% of their total by eight days post-challenge before recovering. Based on 
clinical response, as measured by weight loss following virus challenge, all vaccine regimens 
resulted in a protective immune response and there was no significant difference among the 
various vaccine regimens. 
At three days post-challenge, half of the mice in each group were sacrificed and lung 
homogenates were assayed for virus load using quantitative RT-PCR.30 All vaccinated mice 
showed significant reduction in virus load upon challenge as compared to the virus load in the 
saline-administered mice (Figure 8.6B).  There was wide mouse-to-mouse variability in virus 
load observed in all vaccine regimens, with no significant differences among the groups in mean 
virus loads. 
Finally, a multiplex assay was used to quantitate the concentrations of inflammatory 
cytokines (IL-6, IP-10, G-CSF, IFN-γ, MCP-1, KC, and MIP-2) present in BAL fluid. Consistent 
with virus load, vaccinated mice produced very little inflammatory cytokines similar to the naïve 
control (Figure 8.6C). Mice receiving saline had significantly greater concentrations of 
inflammatory cytokines with the exception of IFN-γ (data not shown). 
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8.4. DISCUSSION 
Subunit vaccines comprised of recombinant hemagglutinin are a viable alternative to 
traditional vaccine technologies against influenza. However, recombinant proteins are typically 
weak immunogens and require large doses as well as adjuvants to induce an immune 
response.6,7,12 In this work, the cloned and expressed recombinant protein was found to be 
highly immunogenic. It is known that hemagglutinin presented in its native trimeric state is often 
more immunogenic than the monomeric form5,8 and this was confirmed with a neutralization 
inhibition assay as shown in Figure 8.1. The trimeric oligomer of the H5 protein required 
significantly less protein in comparison with monomeric forms to inhibit neutralizing antibodies. 
Additionally, subcutaneous and intranasal immunizations with 10 μg soluble H5 trimer (sH53) 
elicited neutralizing antibody titers greater than protective titers reported in the literature (Figure 
8.2).7,8 
While sH53 may be immunogenic it requires refrigeration and/or freezing at low 
concentrations to maintain stability, and therefore, function. Previous work has demonstrated 
that the encapsulation of H53 into polyanhydride nanoparticles preserved the stability of the 
protein while simultaneously providing sustained release.31 Polyanhydride nanoparticles have 
also been shown to provide adjuvant properties, enhancing both cellular and humoral 
immunity.13,15,16 Other excipients known to enhance the immune response against viral 
pathogens include poly I:C, a synthetic analog of dsRNA interacting with TLR3, and poly dA:dT, 
a synthetic analog of dsDNA interacting with RIG-I.32,33,34 To understand the immune response 
to polyanhydride nanovaccines encapsulating H53, mice were immunized subcutaneously with 
nanovaccine formulations (Table 8.1) with and without excipients (i.e., poly I:C and poly dA:dT) 
and compared to sH53 alone or MPLA (positive control).  
The neutralizing antibody titers were examined at 42 and 63 days after the initial 
immunization. In mice receiving the single dose immunization regimen, the formulation including 
poly I:C enhanced neutralizing antibody titers at 42 days similar to the MPLA positive control 
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(Figure 8.3). It is known that poly I:C confers protection in influenza vaccines through the 
activation of dendritic cells early resulting in marked antibody responses.32 The remaining 
formulations, while resulting in low titers at 42 days, were able to exhibit equivalent antibody 
titers at 63 days with the exception of the poly dA:dT formulation. The polyanhydride 
nanovaccine formulations release antigen slowly, which may explain the delayed antibody 
kinetics of nanovaccines delivered without excipients.15  
The mice administered a prime/boost immunization regimen (three immunizations, 21 
days apart) generally displayed increased neutralizing titers in comparison with the single dose 
regimen at 42 days (i.e., after the first boost) (Figure 8.3). All formulations using a prime/boost 
regimen were found to have antibody titers similar to the positive control. While the mean 
antibody titer for each prime/boost formulation was similar at both 42 and 63 days, the addition 
of a second booster immunization enhanced almost all the treatments in comparison to the 
single dose regimen with less mouse-to-mouse variability at 63 days. 
Although humoral immunity is often enough to provide protection against homologous 
strains of influenza, cell-mediated immunity is necessary when confronting heterologous 
variants.19 CD8+ T cells secrete antiviral cytokines and often have a broader epitope spectrum 
than that of the humoral response.19,20 While not fully understood, CD4+ T cells also play a role 
in protection against heterologous influenza infection by producing cytokines to restrict viral 
replication and even providing some lytic activity as well.19,20,35 Likewise, vaccines that can 
stimulate both humoral and cell-mediated immunity would likely have an advantage in cross-
clade protection. As shown in Figure 8.4, polyanhydride nanovaccines enhanced T cell 
proliferation upon ex vivo stimulation with antigen. While all the formulations studied increased 
CD4+ T cell proliferation, only the nanovaccine formulation containing poly I:C induced the 
greatest proliferation of both CD4+ and CD8+ T cells. It is known that poly I:C signaling through 
TLR3 induces the production of several Th1 and Th2 cytokines as well as type I interferons,32 
which may explain the T cell expansion observed in Figure 8.4. 
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To examine whether the immune responses to H53 vaccination led to protection, mice 
administered a prime/boost immunization regimen were challenged intranasally with a low 
pathogenic virus. As expected, mice receiving saline injections were not protected from viral 
challenge. Saline-administered mice began to lose weight 4-5 days post-challenge and 
continued to lose up to 20% of their body weight by eight days post-challenge, confirming that 
the viral challenge was successful (Figure 8.6A). In contrast, all the mice receiving H53 
immunizations maintained or gained body weight post-challenge similar to naïve, non-infected 
mice.  
At three days post-challenge, half of the mice were euthanized to further characterize 
the viral load and inflammatory cytokines present in the lungs. Saline-administered mice 
displayed significantly increased viral load compared to immunized mice (Figure 8.6B). All mice 
receiving H53 immunizations displayed at least a 10-fold reduction in viral load with some 
individual mice completely clearing the virus. Upon examining the presence of inflammatory 
cytokines within BAL fluid, saline mice had significantly increased levels of all cytokines 
examined (Figure 8.6C), which correlated with the increased viral load observed in Figure 8.6B. 
Consistent with the reduction of viral load, and therefore a reduction in antigen and 
inflammation, all vaccinated mice showed little to no inflammatory cytokines present in the 
lungs. 
While no significant advantages of polyanhydride nanovaccines were found in terms of 
neutralizing antibody responses or reduction of clinical signs, the inclusion of nanoparticles in 
the vaccine formulations did not adversely affect the immune response. Noting that the H53 
immunogenicity was relatively high, it is likely that the dose of antigen was greater than optimal. 
Polyanhydride nanovaccines have been shown to induce equivalent antibody titers with 
suboptimal (i.e., 64 times less) doses than that induced by soluble antigen.15 Likewise, 
previously observed enhancements of T cell memory after immunization with polyanhydride 
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nanovaccines17,18 will play an important role in future studies with high pathogenic and/or cross-
clade influenza viral challenges. 
 
8.5. CONCLUSIONS 
The studies presented herein demonstrated the strong immunogenic properties of the 
H53 antigen as well as the immune responses to H53 containing polyanhydride nanovacciness. 
All formulations were able to achieve detectable neutralizing antibody titers 42 days post-
vaccination even with a single dose regimen. The formulation including poly I:C also conferred 
the additional advantages of enhanced antibody titers at earlier time points and proliferative T 
cell responses. All vaccine formulations were able to induce protection against a low 
pathogenic, live viral challenge. The current studies lay a platform to further exploit the 
advantages of encapsulation into polyanhydride nanoparticles in future studies. 
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8.6. TABLES 
Table 8.1. Immunization Formulations 
Group 
Encapsulated 
H5
3
 
Soluble 
H5
3
 
Total 20:80 
CPTEG:CPH 
Nanoparticles 
Additional 
Excipients 
H5
3
 NP 2 μg 8 μg 300 μg - 
H5
3
 & 
Poly I:C NP 
2 μg 8 μg 300 μg 2.5 μg Poly I:C 
H5
3
 & 
Poly dA:dT NP 
2 μg 8 μg 300 μg 2.5 μg Poly dA:dT 
Blank NP - 10 μg 300 μg - 
MPLA - 10 μg - 10 μg MPLA 
sH5
3
 - 10 μg - - 
Saline - - - - 
 
  
169 
 
 
 
8.7. FIGURES 
 
 
Figure 8.1. Expression and characterization of H53. The HA ectodomain (nucleotides 1-
1723) was amplified from pHW500 and modified at the 3’ end by addition of linker sequences, a 
GCN4pII trimerization domain and His-tag sequences at the 3’ end (A). SDS-PAGE (Lane 1), 
blue native gel electrophoresis (Lane 3), and their subsequent immunoblots (Lane 2 and 4, 
respectively) confirmed the expression of the H5 antigen as well as its trimeric form (B). A 
neutralization assay demonstrated that the immunogenicity of trimeric H5 was significantly 
greater than that of monomeric forms, requiring a lower concentration of protein to inhibit 50% of 
the neutralizing sera (IC50). (C) Error bars represent the standard error of mean. p ≤ 0.0243. 
 
 
 
A 
B C 
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Figure 8.2. Immunogenicity of soluble H53 antigen. Mice were immunized subcutaneously or 
intranasally with 10 μg soluble H53 on day 0, 21, and 42. Neutralizing antibody titers were not 
detected until after the second immunization, however, titer generated by days 42 and 63 were 
robust (A). The neutralizing antibodies demonstrated cross-clade protection at 63 days with both 
immunization routes (B). ID50 = dose that inhibits 50% pseudovirus neutralization. Error bars 
represent standard error of mean. 
 
 
 
A B 
171 
 
 
 
 
Figure 8.3. Prime/boost polyanhydride nanovaccines induced robust neutralizing 
antibodies 42 days post-immunization. The neutralizing antibody responses to H53-
polyanhydride nanovaccines were examined 42 and 63 days post-primary immunization. Single 
dose vaccination regimens utilizing poly I:C encapsulated with H53 demonstrated neutralization 
titers similar to a MPLA-adjuvanted control at day 42, with most of the remaining formulations 
reaching equivalency at day 63. The use of a prime/boost immunization regimen enhanced the 
production of neutralizing antibodies and reduced mouse-to-mouse variability. ID50 = dose that 
inhibits 50% pseudovirus neutralization. Error bars represent standard error of mean. Different 
42 Days  
Post-Immunization 
63 Days  
Post-Immunization 
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letters indicate statistical significant among treatments of the same regimen (i.e., single dose or 
prime/boost) at each time point. * indicates statistical significance between the different 
regimens for each treatment. No statistical significance was found comparing among 
prime/boost formulations. p ≤ 0.0434. 
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Figure 8.4. Enhanced CD4+ T cell memory with poly I:C polyanhydride nanovaccine. 
Draining lymph nodes were harvested for prime/boost immunized mice 63 days after the 
primary immunization. Ex vivo antigen stimulation and CFSE-labeling demonstrated enhanced 
CD4+ T cell proliferation of mice immunized with poly I:C nanovaccines. Error bars represent 
standard error of mean. p ≤ 0.0147. 
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Figure 8.5. Prime/boost immunized mice induced protective neutralizing antibody titers. 
Mice immunized with the lead nanovaccine formulations were challenged with a low pathogenic 
influenza virus 63 days after initial vaccination. One week before challenge, all vaccine 
formulations induced high neutralizing antibody titers consistent with previous work and 
suggested by literature to be protective. ID50 = dose that inhibits 50% pseudovirus 
neutralization. Error bars represent standard error of mean. p ≤ 0.0001. 
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Figure 8.6. Mice protected upon challenge with low, pathogenic viral strain. Body weight 
was observed for two weeks post-infection. All vaccinated mice maintained or gained weight 
similar to naïve, non-infected mice (A). Additionally, all mice demonstrated a reduction of viral 
load three days post-infection (B), which correlated with a significant reduction in inflammatory 
cytokines in comparison with saline immunized mice (C). 
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CHAPTER 9: 
Conclusions and Ongoing/Future Research 
 
9.1. CONCLUSIONS 
 Mucosal immunization is paramount for protection against respiratory pathogens 
because other routes of vaccination may not elicit mucosal immunity.1-3 Intranasal vaccination is 
an advantageous yet challenging strategy for advancing vaccine development against 
respiratory pathogens. Intranasal administration of vaccines can increase the availability of 
antigens due to the large, permeable surface area of the lung and can avoid the harsh 
environments of the gastrointestinal tract.2-5 Despite these advantages, antigen delivered alone 
is often not immunogenic and requires the use of an adjuvant.4 Polyanhydride nanoparticles 
have been shown to be a promising platform for intranasal immunization with many beneficial 
properties including sustained release, cell internalization, and immunomodulation which may 
be suitable for vaccines against respiratory pathogens such as H5N1 avian influenza.6-9 
 To understand the early deposition kinetics of intranasal vaccination in vivo, 
fluorescently tagged antigen was encapsulated in polyanhydride nanoparticles and administered 
to mice (Chapter 4). By utilizing flow cytometry and high throughput microscopy, polyanhydride 
nanoparticles were shown to deposit uniformly within the lungs, prolong antigen presence within 
the lungs, and increase internalization by antigen presenting cells. The prolonged persistence of 
antigen after the initial deposition and the nanoparticle chemistry were found to play important 
roles in controlling antigen release kinetics and the kinetics of the antibody response (Chapter 
5). Finally, by utilizing an adoptive transfer model with ovalbumin-specific T cells, it was found 
that amphiphilic CPTEG:CPH nanovaccine formulations enhanced early CD8+ T cell expansion 
and differentiation into effector memory phenotypes (Chapter 6). 
 The ability of polyanhydride nanoparticles to release stable trimeric hemagglutinin 
antigen (H53) was investigated in Chapter 7. These studies showed the preservation of protein 
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structure as well as antigenicity upon release from three polyanhydride nanoparticle 
formulations, which demonstrated that these particles can serve as suitable adjuvants/carriers 
for influenza vaccination. In addition, the immune responses to H53 encapsulated in 20:80 
CPTEG:CPH nanoparticles was examined over a period of 9 weeks (Chapter 8). All 
formulations were found to achieve robust neutralizing antibody titers that were protective 
against a low pathogenic, live viral challenge demonstrating that polyanhydride nanovaccines 
represent a promising platform for H5N1 influenza vaccines.  
 
9.2.  ONGOING/FUTURE WORK 
 While polyanhydride nanoparticles have so far been shown to be a promising platform 
for the delivery of H53, further studies are necessary to optimize an efficacious vaccine for H5N1 
avian influenza. The H53 antigen was found to be highly immunogenic and a dose titration was 
performed for subsequent studies. Further in vivo experiments included the addition of different 
polyanhydride chemistries with or without additional excipients such as poly I:C. These 
optimized formulations will be examined for efficacy against a cross-clade, high pathogenic viral 
challenge (i.e., pandemic influenza) in contrast to the low pathogenic challenge described in 
Chapter 8. Finally, the inclusion of other viral components (such as matrix or nucleoproteins) as 
well as development of dry powder, intranasal formulations may lead to an efficacious and 
broadly protective influenza vaccine suitable for pandemics. 
 
9.2.1.  Dose titration of H53 antigen in vivo 
 Vaccine shortages can occur for a wide variety of reasons; however, in a pandemic 
scenario, a limited supply of immunizations could have a large impact on the spread, morbidity, 
and mortality of the disease. The initial in vivo studies presented in Chapter 8 demonstrated that 
H53 is a potent immunogen against influenza. It is possible that a lower dose of antigen would 
be within the therapeutic window and provide similar efficacy to previous immune responses, 
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and therefore, enhance vaccine availability and cost effectiveness. Polyanhydride nanovaccines 
have also been demonstrated to possess dose-sparing capabilities.10 In a recent study (see 
Appendix A), immunization with 25 μg of polyanhydride particle-encapsulated antigen elicited 
similar antibody titers and avidity in comparison with a 1600 μg dose of antigen alone, 
demonstrating a 64-fold dose sparing.10  
  To identify an optimal dose of H53 antigen, BALB/c mice were immunized 
subcutaneously with 2, 4, or 8 μg of protein (in comparison with the 10 μg administered in 
Chapter 8). Each mouse received a total of three immunizations three weeks apart and was 
monitored for serum antibody over the course of 9 weeks. Consistent with previous work, little 
antibody was present 21 days post-immunization. The lowest antigen dose (2 μg) demonstrated 
fewer antibodies at 42 days post-initial immunization compared to the larger doses (Figure 9.1). 
However, with the addition of a third immunization, equivalent and robust antibody responses 
were demonstrated with all three doses at 63 days post-initial immunization.  
 
9.2.2. Optimization of polyanhydride nanoparticle chemistry in vivo 
 Chapter 8 demonstrated the immune response to and efficacy of 20:80 CPTEG:CPH 
nanovaccines encapsulating H53. However, the data presented in Chapter 4 indicates that other 
polyanhydride nanoparticle chemistries also released stable H53. The chemistry of individual 
polyanhydride copolymers has been demonstrated previously to have immunomodulatory 
capabilities that may play an important role in the in vivo response to H53 immunization.
8 To this 
end, the immune response to H53 encapsulated in 20:80 CPH:SA nanoparticles was evaluated. 
 BALB/c mice were immunized subcutaneously with H53-loaded nanovaccine + sH53 (H53 
NP) blank (i.e., no protein) nanoparticles + sH53 (Blank NP), sH53 alone, or saline (Table 9.1). 
Similar to the experiments performed in Chapter 8, two immunization regimens were used: 
single dose (Day 0 immunization) and prime/boost (Day 0 and 21 immunizations). While the 
single dose regimen generally displayed low levels of antigen-specific IgG, the addition of a 
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booster immunization led to an approximate 50-fold increase in antibody production at day 42 
(Figure 9.2). Consistent with previous work, each formulation displayed similar levels of 
antibodies demonstrated in the dose titration experiment (Figure 9.1). 
 Additionally, all mice received a 5 μg intranasal dose of H53 co-delivered with 20 μg of 
poly I:C to mimic an antigenic challenge at day 42. After administering bromodeoxyuridine 
(BrdU) to detect proliferating cells, mice were euthanized 5 days post-challenge to examine T 
cell recall responses via flow cytometry. While all immunization formulations were not able to 
elicit proliferative CD8+ T cell responses (Figure 9.3), mice receiving the prime/boost regimen of 
the H53 NP formulation demonstrated significant and robust CD4
+ T cell proliferation (Figure 
9.3). It is important to note that immunization with H53-loaded nanovaccine displayed similar 
levels of T cell proliferation to the results presented in Chapter 8 despite a 2.5-fold reduction in 
antigen dose. In contrast, the reduced dose of sH53 antigen delivered alone did not induce any 
significant T cell proliferation in comparison to saline-administered mice.  
 Finally, examination of neutralizing antibody titers will aid in the identification of 
formulations with the most robust immune responses. These key formulations will move forward 
to protection studies against a highly pathogenic H5N1 influenza live viral challenge. Protection 
will be ascertained using a combination of survival, viral load, and cytokine analyses, as 
described in Chapter 8. These experiments will be performed in collaboration with Dr. Richard 
Webby at St. Jude Children’s Research Hospital in Memphis, TN. 
 
9.2.3. Development of intranasal influenza vaccines with broad protection 
 The development of a single dose, intranasal vaccine that can elicit broad protection 
against several influenza strains is of paramount importance. The need for multiple doses or 
prime/boost immunization regimens to achieve protection is a large drawback, especially in 
pandemic or post-exposure situations.11 A single dose, intranasal vaccine is also easier to 
administer without significant training allowing for rapid deployment of vaccines during a 
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pandemic and permitting healthcare professionals to focus on responding to critical patients.12 
In addition, intranasal delivery is advantageous in that it enables both mucosal and systemic 
immunity.1-3 
 A unique aspect of the polyanhydride nanovaccine platform is the ability to create dry 
powder vaccines. Dry powder vaccines are useful in that they can be delivered via several 
different routes, including intranasal, and can generally maintain antigen stability better than 
liquid formulations.13 Lyophilization of influenza vaccines has been explored in the literature; 
however, these vaccines often require stabilizers and additives to maintain the potency of the 
antigen upon reconstitution.13 In contrast, polyanhydride nanovaccines have shown that antigen 
stability can be preserved without additional components for up to ten months at room 
temperature.14 The optimization of dry powder polyanhydride nanovaccines could provide 
effective single dose, intranasal vaccines that can be stockpiled in anticipation of an influenza 
pandemic. 
 Finally, influenza vaccines that are broadly protective would be valuable against both 
seasonal and pandemic strains. Neutralizing antibodies have been shown to be fully protective 
against antigenically matched viruses, however, the hemagglutinin protein (H53) typically is the 
most variable or mutation-prone of the virus.15 Thus, incorrect predictions of seasonal strains or 
rapid changes of epitope presentation in pandemic circumstances could render neutralizing 
antibodies against H53 useless. Although not usually protective on their own, the addition of 
conserved viral antigens to hemagglutinin vaccines have been shown to induce cross-protective 
immunity.13,15 Inclusion of conserved viral antigens, such as the surface protein neuraminidase 
(NA), ion channel matrix proteins (MP), and the internal nucleoprotein (NP), in subunit vaccines 
have been noted to enhance the expansion of CD8+ T cells leading to cross-protection.16 The 
addition of these conserved antigens to H53 polyanhydride nanovaccines could provide great 
benefit in terms of complementing the humoral (Chapter 8) and enhancing the cell-mediated 
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(Chapters 6 and 8) immune responses previously discussed, leading to the development of an 
efficacious, universal influenza vaccine. 
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9.3.  TABLES 
 
Table 9.1: H53 20:80 CPH:SA Nanovaccine Immunization Regimen 
 
Group Treatment 
H53 NP 
(μg) 
Blank NP 
(μg) 
Total H53 Encap 
(μg) 
Total Soluble 
H53 (μg) 
1 H53 NP 300 0 2 2 
2 Blank NP 0 300 0 4 
3 sH53 0 0 0 4 
4 Saline 0 0 0 0 
 
 
 
9.4.  FIGURES 
 
Figure 9.1. Antibody response to H53 dose titration. Mice (n = 6) were immunized 
subcutaneously with 2, 4, or 8 μg H53 at days 0, 21, and 42. Total anti-H53 IgG of a 1:1000 
serum dilution was quantified using a fluorescent multiplex method. Error bars represent 
standard error of mean.  
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Figure 9.2. H53-specific IgG antibody responses to 20:80 CPH:SA nanovaccine. Mice (n = 
8) were immunized subcutaneously with a single dose or prime/boost immunization regimen. 
Antibody responses at 42 days post-immunization demonstrated an approximate 50-fold 
increase of antibody production with the prime/boost regimen. Error bars represent standard 
error of mean. 
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Figure 9.3. T cell responses to intranasal H53 antigenic challenge of prime/boost 
immunized mice. All mice received at 5 μg H53 + 20 μg poly I:C intranasal challenge 42 days 
post-initial immunization. Mice (n = 8) immunized with H53-loaded polyanhydride nanovaccine 
displayed robust CD4+ T cell proliferation five days post-challenge. Different letters indicate 
statistical significance. Error bars represent standard error of mean. p ≤ 0.0052.  
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APPENDIX A: 
Single Immunization with a Suboptimal Antigen Dose Encapsulated 
into Polyanhydride Microparticles Promotes High Titer and Avid 
Antibody Responses 
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Abstract 
 Microparticle adjuvants based on biodegradable polyanhydrides were used to provide 
controlled delivery of a model antigen, ovalbumin (Ova), to mice. Ova was encapsulated into 
two different polyanhydride microparticle formulations to evaluate the influence of polymer 
chemistry on the nature and magnitude of the humoral immune response after administration of 
a suboptimal dose. Subcutaneous administration of a single dose of polyanhydride 
microparticles containing 25 μg of Ova elicited humoral immune responses that comparable in 
magnitude to that induced by soluble doses of 400–1600 μg Ova. In contrast, the avidity of the 
Ova-specific antibodies was greater in mice administered the microparticle formulations in 
comparison to the higher soluble doses. Finally, the microparticle delivery system primed an 
anamnestic immune response as evidenced by the significant increases in Ova-specific 
antibody when mice were administered an antigenic challenge of 25 μg of Ova at 12 weeks 
post-vaccination. Together, these results indicate that encapsulation of antigens into 
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polyanhydride microparticles facilitates isotype switching, establishes immunologic memory, and 
the humoral response was characterized by a higher quality antibody response. 
 
1. INTRODUCTION 
 Many current subunit vaccine formulations consist of poorly immunogenic recombinant 
proteins that require adjuvants to induce humoral and cellular immune responses. Although 
beneficial, vaccine adjuvants do pose a risk of adverse reactions, which may, in part, explain 
why only three formulations (the aluminum salts Al(OH)3 and AlPO4, oil-in-water emulsion, and 
monophosphoryl lipid A) are currently licensed for human use in the United States.1 
Recombinant proteins are also often costly to produce. Reducing the amount of antigen needed 
to elicit protective immune responses could help eliminate vaccine production shortages similar 
to those observed during the 2009 H1N1 influenza pandemic.2 Immunization with subunit 
vaccines can also fail to induce robust humoral immune responses in which naïve 
B cells differentiate into antigen-specific, long-lived plasma cells and memory B cells. Although 
these vaccines elicit measurable antibody titers, the quality (i.e., avidity) and kinetics of the 
antibody response may be less than optimal. Successful vaccines must induce antigen-specific 
memory B cells capable of rapidly proliferating upon antigen stimulation.3,4 In addition, an avid 
antibody response must be developed through somatic hypermutation and positive selection of 
high affinity B cell clones. These attributes are all essential factors in determining the quality of 
antibody-mediated protection against a subsequent pathogen challenge.  
 To overcome many of the limitations associated with traditional vaccine regimens, 
antigens have been encapsulated into synthetic, biodegradable polymer micro- and 
nanoparticles.5-8 The most extensively studied formulations include the polyesters poly(glycolic 
acid), poly(lactic acid), and their copolymers (i.e., poly(lactide-co-glycolide) or PLGA). 
Unfortunately, particles made of PLGA degrade by a bulk erosion mechanism that may 
negatively affect the stability of proteins susceptible to moisture-induced aggregation.9,10 In 
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addition, the acidic microenvironment created by PLGA degradation products (i.e., lactic or 
glycolic acids) can lead to protein instabilities.11,12 Polyanhydrides, another class of well-studied 
biodegradable polymers, present an alternative for drug and vaccine delivery.13 These materials 
exhibit surface erosion characteristics and possess hydrolytically labile anhydride bonds.14 The 
most commonly studied polyanhydrides are based on the aliphatic sebacic acid (SA) and the 
aromatic 1,6-bis(p-carboxyphenoxy)hexane (CPH). Encapsulation of proteins into CPH:SA 
copolymers has been shown to preserve protein and antigenic epitope stability.9,15,16 These 
surface-erodible polymers also provide sustained protein release15-17 and possess immune-
modulatory capabilities.18-21  
 In this work, we extend our studies of polyanhydride particle-based vaccines by 
exploring the ability of this platform to enhance the immunogenicity of ovalbumin (Ova), a model 
vaccine antigen. We found that a single subcutaneous (SC) administration of a suboptimal dose 
of Ova encapsulated into polyanhydride microparticles induced an antibody response that was 
comparable in magnitude to that induced by 16-fold higher doses of soluble Ova or that induced 
by multiple doses of Alum-adjuvanted Ova.22 Moreover, this microparticle vaccine regimen 
successfully primed the humoral immune response for an anamnestic immune response. 
Together, these results indicate that encapsulation of vaccine antigens into polyanhydride 
microparticles provides a platform delivery system that can elicit a mature humoral memory 
response after a single administration. 
 
2. MATERIALS AND METHODS 
2.1. Materials and polymer synthesis 
 The chemicals needed for CPH monomer synthesis, 4-p-hydroxybenzoic acid, 1,6-
dibromohexane, 1-methyl-2-pyrrolidinone, and SA (99%), were purchased from Sigma Aldrich 
(St Louis, MO); acetic anhydride, methylene chloride, and ethanol were purchased from Fisher 
Scientific (Fairlawn, NJ). CPH diacid was synthesized as described previously.23,24 Pre-polymers 
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of SA and CPH were synthesized by the methods described by Shen et al.25 and Conix.23 
CPH:SA copolymers were synthesized by melt polycondensation as described previously.14 The 
purity and degree of polymerization of the copolymers was analyzed using 1H nuclear magnetic 
resonance(NMR) spectroscopy obtained from a Varian VXR-300 MHz NMR spectrometer 
(Varian, Palo Alto, CA). NMR spectra were consistent with previously published data and 
confirmed the synthesis of the desired copolymer compositions.24 In addition, polymer molecular 
weight was determined using gel permeation chromatography (GPC, Waters HPLC System, 
Milford, MA) using Varian, GPC columns. 
 
2.2. Microparticle fabrication 
 To eliminate the endotoxin contamination of the Ova (Sigma Aldrich) and to prevent 
unintended enhancement of the immune response caused by contaminating endotoxin, 
affinityPak Detoxi-Gel endotoxin removal columns (Thermo Scientific, Rockford, IL) were used 
according to manufacturer’s instructions. The recovered Ova contained <10 EU/mg protein and 
was lyophilized and stored at -20°C. Ova-loaded microparticles were fabricated using cryogenic 
atomization.5,9,26 The parameters used for each copolymer chemistry were previously specified 
by Torres et al.16 and Lopac et al.17 The obtained microparticles were collected by vacuum 
filtration and dried under vacuum. Using four replicative samples for each microparticle 
preparation, microparticle morphology and size distribution were analyzed by using images 
obtained by scanning electron microscopy (SEM) (JEOL 840 A, JEOL, Peabody, MA), and 
ImageJ image analysis software (National Institutes of Health, Bethesda, MD). An average of 
200 particles per image was analyzed. 
 
2.3. In vitro antigen release 
 In vitro Ova release kinetics were measured by suspending 15 mg of the Ova-loaded 
microparticles in 1 mL of phosphate buffered saline (0.1 M, pH 7.4) with 0.01% (w/v) sodium 
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azide, and incubating at 37°C on a shaker platform at 100 rpm. Aliquots of 750 μL were taken at 
prescribed time intervals and replaced with fresh buffer. Aliquots were stored at 4°C to measure 
protein concentration using micro-bicinchoninic acid (BCA) analysis at an absorbance of 570 
nm. At least three replicates of each sample were analyzed. After 25 days, the remaining 
encapsulated protein was extracted by degrading the remaining particles in 17 mM NaOH. 
Protein concentration was determined with a micro-BCA assay. Total protein encapsulated in 
the particles was determined by calculating the protein released at each time point as described 
by Torres et al.16 
 
2.4. Mice and immunization procedures 
 Female C3H/HeNHsd (C3H) mice were purchased from Harlan Sprague Dawley 
(Frederick, MD). All animal procedures were conducted with the approval of the Iowa State 
University Institutional Animal Care and Use Committee. To evaluate the serum antibody 
response to nonadjuvanted Ova, 20 mg of endotoxin-free Ova was suspended in pyrogen-free 
saline and diluted to the indicated concentrations. Mice were subcutaneously (SC) immunized 
with soluble Ova alone at doses of 1600, 400, 100, or 25 μg in 100 μL pyrogen- free saline with 
seven mice per treatment group (n = 7). Control animals received 100 μL saline alone (n = 6). 
Blood samples were collected from the left saphenous vein before immunization and every 4 
weeks thereafter. Serum was collected after centrifugation and stored at -20°C until assayed for 
Ova-specific antibody as described below.  
 Mice were immunized SC with 25 μg of Ova encapsulated into 0.5 mg of either 20:80 
CPH:SA or 50:50 CPH:SA microparticles suspended in pyrogen-free saline with eight mice per 
treatment group (n = 8). Before administration, microparticles were sonicated briefly to generate 
a uniform suspension. A total volume of 100 μL was administered at the injection site. For the 
antigenic challenge studies, mice that had been immunized 12 weeks prior were immunized SC 
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with 25 μg of endotoxin-free Ova suspended in pyrogen-free saline. Serum samples were 
collected 5 days later in order to measure the anamnestic antibody response. 
 
2.5. ELISA for Ova-specific antibody titer and avidity 
 ELISA plates (Costar Catalog # 3590, EIA/RIA high binding) were coated overnight with 
0.5 μg/well Ova. Plates were washed with phosphate buffered saline containing 0.5% Tween 20 
at a pH of 7.4 (PBST). Plates were blocked for 2 h with 2% gelatin (Difco) in PBST. Plates were 
washed and serial dilutions of individual serum samples in PBST with 1% heat inactivated 
normal goat serum (GIBCO) were incubated overnight at 4°C. Plates were washed again with 
PBST and alkaline phosphatase-conjugated goat anti-mouse IgG (H&L), IgG1, or IgG2a 
(Jackson ImmunoResearch Laboratories, West Grove, PA) diluted 1:1000 in 1% heat 
inactivated normal goat serum in PBST was incubated for 2 h. Plates were washed and p-
nitrophenyl phosphate (Sigma) substrate (1 mg/mL) in 50 mM Na2CO3 and 2 mM MgCl2 buffer 
(pH 9.3) was added to each well. Changes in optical density were measured at 405 nm using a 
spectrophotometer (Spectra Max 190, Molecular Devices, Sunnyvale, CA). Antibody avidity 
ELISA was performed as described previously to determine antibody binding strength in the 
presence of a chaotropic agent that disrupts antibody–antigen binding interactions.18 The molar 
concentration of NaSCN corresponding to the 50% loss of absorbance was designated as the 
relative avidity value reported. 
 
2.6. Statistical analysis 
 Longitudinal data were analyzed using repeated measure analysis of variance (ANOVA) 
models (with SAS version 9.2). Treatment and time were fixed effects in the statistical model, 
whereas mouse was the subject of repeated measures. Cross-sectional data were analyzed 
using one-way ANOVA models with treatment as the explanatory variable. Differences in mean 
responses among treatments were compared by using Tukey’s T-test. Log10 transformation was 
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applied to responses with skewed distributions before analyses. Statistical tests with p ≤ 0.05 
were regarded as significant. 
 
3. RESULTS 
3.1. Single, soluble doses of Ova require ≥100 μg to elicit significant antibody titers 
and prime the humoral response to respond to an antigenic challenge 
To demonstrate the capabilities of a single dose immunization regimen employing a 
suboptimal dose of Ova encapsulated into polyanhydride microparticles, we first examined the 
kinetics of the IgG antibody response of mice immunized subcutaneously once with varying 
doses of soluble Ova (Figure 1A). Groups of mice that were administered 1600 μg, 400 μg, or 
100 μg of Ova elicited significantly higher antibody titers in contrast to mice immunized with 25 
μg of Ova. The kinetics of the IgG response induced by a single, soluble dose of Ova 
demonstrated that the peak titer was obtained 4 weeks post-injection and then began to wane.  
Antibody avidity was also assessed as a surrogate marker of vaccine efficacy. Serum 
samples from the mice immunized with a single dose of 100 μg, 400 μg, or 1600 μg of soluble 
Ova developed a peak antibody avidity at 4 weeks post-vaccination that was stable through 12 
weeks post-immunization (Figure 1B). Serum samples from mice vaccinated with 25 μg of 
soluble Ova alone did not induce a sufficient antibody titer to measure antibody avidity. To 
ascertain the generation of antigen-specific memory responses, a 25 μg ‘‘antigenic challenge’’ 
was administered at 12 week post-vaccination. A measurable increase in the secondary 
humoral antibody response was observed in mice that had received ≥ 25 μg antigen at the initial 
vaccination (Figure 1C). A soluble dose of 25 μg of Ova was not sufficient to induce a primary 
serum antibody (Figure 1C, open bar) response but was able to prime the mice for a secondary 
immune response (Figure 1C, closed bar), indicating that 25 μg was a suboptimal dose of 
immunogen.  
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3.2. Controlled antigen release by polyanhydride microparticles in vivo results in a 
primed humoral response  
Ova-loaded 20:80 and 50:50 CPH:SA microparticles were characterized by SEM after 
fabrication (Figure 2A). Morphologies of the Ova-loaded microparticles were consistent with 
previous work describing blank microparticles.16,17 The diameter of the microparticles ranged 
between 5 and 21 μm for both 20:80 CPH:SA and 50:50 CPH:SA. Although there was a greater 
initial burst release from the 20:80 CPH:SA formulation (Figure 2B), the release profile of Ova 
from the two polyanhydride formulations was shown to be sustained and is consistent with 
previous work.9,16,17  
Using the polyanhydride microparticle vaccine delivery platform, we sought to 
demonstrate that a significant humoral response could be induced when a suboptimal dose of 
Ova (25 μg) was encapsulated into one or both of the microparticle formulations evaluated in 
this study. The IgG response induced by the administration of 500 μg of either 20:80 CPH:SA or 
50:50 CPH:SA containing 25 μg of Ova (i.e., 5%, wt/wt) was evaluated for 12 weeks after 
administration (Figure 3A). Both polyanhydride formulations tested elicited similar Ova-specific 
antibody titers. Compared to mice receiving 25 μg of soluble Ova, significant antibody titers 
were demonstrable in microparticle vaccinated groups beginning at week 4 and were 
maintained through 12 weeks post-vaccination. Mice receiving either Ova-encapsulated 
microparticle vaccine formulation developed a more avid Ova-specific antibody response than 
did mice receiving much larger doses of soluble Ova (Figure 3B). These more avid antibody 
responses were sustained over the 12 weeks of the experiment (Figure 3B). After the antigenic 
challenge (i.e., booster immunization), greater Ova-specific serum antibody responses (i.e., 
titers ≥ 100,000) were observed in mice administered the Ova-loaded microparticles as 
compared to the antibody responses (i.e., titers ≤ 10,000) induced by the soluble doses of Ova 
(Figure 3C compared to Figure 1C). Statistical comparisons of the antibody responses induced 
after the antigenic challenge (Figures1C and 3C, solid histograms) demonstrated an adjuvant 
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effect associated with the administration of the microparticles that was consistent with the 
elevated titers and avidity presented in Figure 3A, B. 
 
3.3. Isotype switching of the serum antibody responses suggests immunological 
memory 
 Characteristics of an immune response can be determined by examining the antibody 
isotype produced. For mice immunized with Ova-loaded microparticles, the secondary serum 
antibody response was characterized by the presence of both Ova-specific IgG1 and IgG2a 
(Figure 4A,B, respectively). For mice immunized with single doses of soluble Ova (100–1600 
μg), there was no demonstrable Ova-specific IgG2a detected after the antigenic challenge (data 
not shown). Together, these results indicate that a mature, antigen-specific memory response 
was obtained with a priming dose of only 25 μg when encapsulated into polyanhydride 
microparticles. 
 
4. DISCUSSION 
 Biodegradable polymers exhibit adjuvant properties, making them ideal delivery 
platforms for single dose vaccine regimens.27-29 Specifically, vaccine formulations based on 
PLGA, PLA, or PGA have been shown to induce immune responses to a variety of 
immunogens.30,31 Several of these studies incorporated monophosphoryl lipid A, a known 
adjuvant, into the polymer delivery device along with the immunogen, thereby complicating the 
ability to determine whether or not the polymer itself provides any immune enhancing 
activity.13,29,31 Other studies have included excipients and/or stabilizers to enhance the 
immunogenicity of encapsulated proteins.27 In this study, no additional immune enhancers were 
included during the fabrication of our polyanhydride microparticles loaded with endotoxin-free 
Ova or administered at the time of immunization. Therefore, any immunomodulatory properties 
observed were the direct result of the polymers themselves. 
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 Previously, we have demonstrated that polymer chemistry differentially effects in vitro 
antigen presenting cell (APC) cytokine production, particle uptake, and cell surface marker 
expression.20,32 In contrast to these differential effects demonstrated in vitro on APCs, in vivo 
administration of Ova-loaded 20:80 or 50:50 CPH:SA microparticles induced similar serum 
antibody titers (Figure 3A), avidity (Figure 3B), and recall responses (Figures 3C) and 4). This 
study was performed to demonstrate that immune responses could be induced with a single, 
suboptimal dose of an immunogen, and not to compare the adjuvant capabilities of the 
microparticles to other adjuvants. However, these studies do infer that polyanhydride delivery 
devices provide the adjuvant properties essential for effective implementation of subunit 
vaccines. Indeed, when a subimmunogenic dose (e.g., 25 μg) of Ova was encapsulated into the 
microparticles, both copolymer formulations were able to induce a robust immune response 
comparable to that induced by 400–1600 μg of soluble Ova. Furthermore, the titers of mice 
immunized with single dose microparticle formulations were similar to those reported for mice 
immunized multiple times with Alum-adjuvanted Ova over a range of doses comparable to the 
25 μg dose used in this study.22,33–38 For example, Pollock et al.22 reported mean IgG1 titers of 
40,000 after two administrations of 100 μg Ova adjuvanted with Alum. In another study, a single 
immunization with 50 μg Ova adjuvanted with Alum in C57BL/6 mice induced an IgG1 titer of 
approximately 100, which increased to approximately 10,000 after a second immunization.36 
Sun and Pan38 observed similar antigen-specific IgG titers after administration of 100 μg Ova 
adjuvanted with Alum. In this work, the titer values (approximately 1000) obtained by 
immunizing mice once with 25 μg of Ova encapsulated in polyanhydride microparticles are 
similar to those induced by multiple doses of Alum-adjuvanted Ova described in the 
literature.22,33–38  
 Recombinant protein antigens provide excellent purity and safety profiles for vaccines, 
but may sacrifice potency of the vaccine and lead to less than efficacious immune responses. In 
this regard, the avidity of the antibody response induced by the microparticle formulations was 
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greater than that induced by any of the soluble doses of Ova used in this study. These 
observations demonstrate the importance of evaluating the magnitude (i.e., titer) and the quality 
(i.e., avidity) of the antibody response in order to fully appreciate the benefits of novel vaccine 
delivery platforms. 
 Persistence of antigen is also known to be critical for inducing long-lived plasma cells 
and memory B cells.39 Companion studies from our laboratory indicate the persistence of 
polyanhydride particles at injection sites up to 12 weeks post-administration (manuscript in 
preparation). In this study, the encapsulation, controlled release and subsequent persistence of 
Ova in vivo likely contributed to the induction of long-lived plasma cells and induction of a more 
avid humoral immune response than that induced by higher doses of soluble Ova. It may be 
speculated that the increased avidity of the serum antibody response in mice vaccinated with 
the Ova-loaded microparticles results specifically from persistence of antigen in germinal 
centers, possibly mediated by follicular dendritic cells, in secondary lymphoid tissue.40 The 
single dose of 25 μg Ova encapsulated into the microparticles was sufficient to induce a 
demonstrable antibody response and to prime the host for a more robust secondary antibody 
responses after an antigenic challenge 12 weeks later (Figures 3 and 4). In contrast, there was 
little evidence of a recall response in mice initially administered 1600 μg Ova. Bioerodible 
microparticles may be performing similar actions as traditional emulsification vaccine adjuvants 
by providing an antigenic depot and creating particulate antigen that is more readily recognized 
by B cells and taken up by APCs.41 Experimental models employing micro- or nanoparticle 
vaccination regimen incorporating recombinant immunogens followed by pathogen challenge 
will demonstrate the full potential of this polymer delivery platform to induce protective immune 
responses.42 
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5. CONCLUSIONS 
 In this work, we demonstrated that robust, long-lived immune responses can be induced 
by a single, suboptimal dose of a weak immunogen by encapsulation into surface eroding 
polyanhydride microparticles. The use of these biodegradable delivery devices to immunize 
mice induced an anamnestic antibody response and generated isotype switching, as evidenced 
by the induction of antigen-specific IgG2a, an antibody isotype indicative of memory T cell 
development. Lastly, the avidity (i.e., quality) of the serum antibody induced by 25 μg of Ova 
encapsulated into microparticles was greater than that induced by 1600 μg of soluble Ova. 
Collectively, the data demonstrate that the use of surface-erodible polyanhydride microparticles 
as a vaccine delivery platform may enhance the magnitude and quality of the immune response 
to subunit or recombinant proteins, and thus broaden the arsenal of recombinant immunogens 
that can be safely, efficaciously, and cost effectively employed in vaccine formulations. 
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6. FIGURES 
 
Figure 1. Single doses of soluble 
ovalbumin (Ova) required ≥100 μg to 
elicit significant antibody titers and 
prime the humoral response to 
respond to an antigenic challenge. 
Separate groups of C3H mice were 
immunized with a titrating dosage of 
soluble Ova: 1600 μg (open diamonds), 400 μg (open squares), 100 μg (open circles), 25 μg 
(open triangles), or saline alone (x). Ova-specific serum antibody titers (A) and antibody avidity 
(B) were measured over 12 weeks. (C) At 12 weeks post-immunization, the Ova-specific serum 
antibody titer was measured before (open histograms) and 5 days after (closed histograms) an 
antigenic challenge administered subcutaneously in the form of 25 μg Ova. All data are 
presented as the mean ± SEM and are representative of three independent experiments. For 
panel A, * represents a statistically significant difference from the 25 μg group at p < 0.05. For 
panel C, * indicates a statistically significant difference from treatments before boost at p < 0.05. 
Treatments with different letters are significantly different from one another at p < 0.05. 
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Figure 2. Morphology and in vitro release kinetics of Ova-loaded polyanhydride 
microparticles. Scanning electron photomicrographs of Ova-loaded 20:80 CPH:SA (mean 
diameter ± SD, 10 ± 5 μm) and 50:50 CPH:SA (12 ± 7 μm). (A) Scale bar: 20 μm. (B) Release 
kinetics of Ova from 20:80 CPH:SA and 50:50 CPH:SA microparticles. Data are presented as 
the mean ± SEM and are representative of two independent experiments with duplicate samples 
analyzed in each experiment. 
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Figure 3. Enhanced serum antibody 
response in mice immunized with Ova-
loaded polyanhydride microparticles. Ova-
specific serum antibody titers (A) and antibody 
avidity (B) for C3H mice immunized with 20:80 
CPH:SA Ova-loaded microparticles (closed 
circles), 50:50 CPH:SA Ova-loaded 
microparticles (closed squares), 25 μg soluble 
Ova (open triangles), or saline alone (x). (C) At 12 weeks post-immunization, the anamnestic 
Ova-specific serum antibody titer was measured before (open histograms) and 5 days after 
(closed histograms) a subcutaneously administered dose of 25 μg Ova (i.e., antigenic 
challenge). All data are presented as the mean ± SEM and are representative of three 
independent experiments. For panel A, * represents a statistically significant difference from the 
25 μg soluble Ova group at p < 0.05. For panel C, * indicates a statistically significant difference 
from treatments before boost at p < 0.05. Treatments with different letters are significantly 
different from one another at p < 0.05. 
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Figure 4. Mice immunized with Ova-loaded polyanhydride microparticles develop an 
anamnestic humoral response characterized by IgG1 and IgG2a, indicating antibody 
isotype switching. Ova-specific (A) IgG1 and (B) IgG2a serum antibody titer in mice 
administered a subcutaneous antigenic challenge of 25 μg Ova in saline 12 weeks after initial 
immunization with Ova-loaded polyanhydride microparticles. Data are presented as the mean ± 
SEM and are representative of three independent experiments. Treatments with different letters 
are significantly different from one another at p < 0.05. 
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Abstract 
 Efficacy, purity, safety, and potency are important attributes of vaccines. Polyanhydride 
particles represent a novel class of vaccine adjuvants and delivery platforms that have 
demonstrated the ability to enhance the stability of protein antigens as well as elicit protective 
immunity against bacterial pathogens. This work aims to elucidate the biocompatibility, 
inflammatory reactions, and particle effects on mice injected with a 5 mg dose of polyanhydride 
nanoparticles via common parenteral routes (subcutaneous and intramuscular). Independent of 
polymer chemistry, nanoparticles more effectively disseminated away from the injection site as 
compared to microparticles, which exhibited a depot effect. Using fluorescent probes, the in vivo 
distribution of three formulations of nanoparticles, following subcutaneous administration, 
indicated migration away from the injection site. Less inflammation was observed at the injection 
sites of mice-administered nanoparticles as compared to Alum and incomplete Freund’s 
adjuvant. Furthermore, histological evaluation revealed minimal adverse injection site reactions 
and minimal toxicological effects associated with the administration of nanoparticles at 30 days 
post-administration. Collectively, these results demonstrate that polyanhydride nanoparticles do 
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not induce inflammation as a cumulative effect of particle persistence or degradation and are, 
therefore, a viable candidate for a vaccine delivery platform. 
 
1. INTRODUCTION 
 Next generation vaccine design aims to recapitulate the positive effects of enhancing 
immune responses to the immunogen of interest while avoiding the detrimental side-effects 
often caused by adjuvants.1 While efficacy is an essential outcome of vaccine design, 
biocompatibility is critical for ensuring patient compliance and ultimately developing protective 
immunity.2 Adverse injection site reactions that cause either pain or tissue damage are major 
hurdles in the development and licensure of vaccines containing immunostimulatory adjuvants. 
These adjuvants are often necessary vaccine components, as they enhance immune responses 
against poorly immunogenic antigens. Specifically, adjuvants often comprise particulate material 
that is readily taken up by antigen presenting cells, activates innate immunity, and provides an 
antigenic depot to sustain immune responses.3 The most common adjuvants used in human 
and veterinary medicine consist of aluminum salts, modified Toll-like receptor ligands, oil-water 
emulsions, or combinations thereof.4 The majority of adjuvanted vaccines approved for human 
use contain potassium aluminum sulfate (Alum), MF59 (a squalene oil-in-water emulsion), or 
ASO4 (monophosphoryl lipid A and Alum). Unfortunately, administration of vaccines containing 
these adjuvants often induces clinical signs of pain, redness, rash, swelling, and fever.5–7 
 Polyanhydrides are a class of biodegradable polymers that have been studied for more 
than three decades as carriers for drugs, proteins, and vaccines.8 The degradation products of 
polyanhydrides are metabolized and either released as carbon dioxide or excreted through urine 
and feces as carboxylic acids and were found to have no significant impact on kidney or liver 
functions.9,10 Additionally, polyanhydride wafer implants comprised of 1,3-bis-(p-
carboxyphenoxy)pentane (CPP) and sebacic acid (SA) have been successfully used in humans 
to deliver chemotherapeutic drugs to treat glioblastoma multiforme.11–14 Recently, amphiphilic 
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polyanhydride nanoparticles based upon copolymers of SA, 1,6-bis-(p-carboxyphenoxy)hexane 
(CPH), and 1,8-bis-( p -carboxyphenoxy)-3,6-dioxaoctane (CPTEG) have been explored as a 
vaccine delivery platform with inherent adjuvant and antigen stabilization properties.15,16 These 
particles provide amphiphilic environments for release of conformationally and functionally 
stable protein antigens16,17 and demonstrate a combination of bulk and surface erosion kinetics 
that create a controlled release of encapsulated payload, making them ideal candidates for 
delivery of single-dose vaccines. Recent studies have shown that these polyanhydride 
nanoparticles exhibit pathogen-mimicking properties in terms of their effect on immune 
activation, cellular uptake, and cellular persistence.18–22 Moreover, single dose vaccination with 
these particles has induced long-lasting, high titer, and avid antibody responses against multiple 
immunogens. For example, administration of a single-dose of CPH:SA microparticles 
encapsulating tetanus toxoid to mice created antibody titers that persisted for at least 26 weeks 
post-vaccination.23 Additionally, immunization of mice with a single dose of ovalbumin-loaded 
polyanhydride microparticles elicited humoral responses comparable to those induced by a 40-
fold greater dose of soluble ovalbumin.24 We have also demonstrated the ability of the 
polyanhydride nanoparticle vaccine platform to induce, in a single intranasal administration, 
long-lived protective immunity in mice for up to 280 days after an otherwise lethal challenge by 
Yersinia pestis , the causative agent of pneumonic plague.21,22  
 However, the toxicological effects of these novel polyanhydride nanoparticles, especially 
when administered via various routes, need to be determined. To complement our previous 
findings of efficacy, we demonstrate here that polyanhydride nanoparticles result in deposition 
characteristics similar to those of traditional adjuvants. However, in contrast to traditional 
adjuvants, immunization with polyanhydride nanoparticles induced minimal inflammatory 
reactions and little to no tissue damage at sites of injection. Together with previous results, 
these data demonstrate the biocompatibility and limited reactogenicity of this nanoparticle 
delivery platform. 
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2. MATERIALS AND METHODS 
2.1. Synthesis and Characterization of Copolymers 
 CPH and CPTEG monomers were synthesized using the chemicals listed: 4-p-
hydroxybenzoic acid, 1,6-dibromohexane, 1-methyl-2-pyrrolidinone, and tri-ethylene glycol. All 
these chemicals and sebacic acid (99%) were purchased from Sigma Aldrich (St. Louis, MO); 4-
p-fluorobenzonitrile was obtained from Apollo Scientific (Cheshire, UK); potassium carbonate, 
dimethyl formamide, toluene, sulfuric acid, acetic acid, acetonitrile, acetic anhydride, methylene 
chloride, and petroleum ether were purchased from Fisher Scientific (Fairlawn, NJ). Synthesis of 
CPH and CPTEG diacids was performed as previously described16,25 and prepolymers of SA 
and CPH were synthesized using previously described methods.25,26 Copolymers (20:80 and 
50:50 CPH:SA and 20:80 and 50:50 CPTEG:CPH) were synthesized using a melt 
polycondensation process as detailed by Kipper et al. and Torres et al.,16,23 respectively. The 
degree of polymerization, molecular weight, chemical structure, and polymer purity were 
determined using 1H nuclear magnetic resonance (NMR) spectroscopy (Varian VXR-300 MHz, 
Palo Alto, CA). 
 
2.2. Fabrication and Characterization of Particles 
 Microparticles were fabricated using a cryogenic atomization method as described in 
Kipper et al.23 Blank and dye-loaded (Kodak X-Sight 640 LSS Dye, NHS Ester Carestream 
Health, Rochester, NY) nanoparticles (0.5% w/w loading) were fabricated using the anti-solvent 
nanoencapsulation method outlined in Ulery et al.20 Briefly, the copolymer was dissolved in 
methylene chloride at a concentration of 25 mg/mL at 4°C. The dye was added to the dissolved 
copolymer and the solution was sonicated for uniform dispersal of the dye within the copolymer. 
The dissolved dye and copolymer (dye-loaded) or copolymer (blank) solution was rapidly 
transferred into chilled pentane ( −20°C) at a non-solvent to solvent ratio of 80:1, and this 
solution was vacuum filtered to recover the nanoparticles. Shape and size of the resulting 
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nanoparticles were characterized using scanning electron microscopy (SEM) (JEOL 840 A, 
JEOL, Peabody, MA). The particle size distribution was obtained from SEM images using Image 
J version 1.44 image analysis software.27 An average of 200 particles per image was analyzed. 
 
2.3. Mice 
 Female BALB/c mice were purchased from Harlan Laboratories (Indianapolis, IN). 
Female SKH1-E (hairless) mice were purchased from Charles River Laboratories (Wilmington, 
MA). All mice were housed under specific pathogen-free conditions where all bedding, caging, 
water, and feed were sterilized prior to use. Animal procedures were conducted with the 
approval of the Iowa State University Institutional Animal Care and Use Committee. 
 
2.4. Mouse Treatments 
2.4.1. Microparticle and Nanoparticle Biodistribution 
 Separate groups of BALB/c mice received a subcutaneous (SC) injection of either 0.5 
mg of microparticles or 0.5 mg nanoparticles loaded with LSS 640 in 250 μL of saline at the 
nape of the neck (Figure 1). 
 
2.4.2. Nanoparticle and Adjuvant In Vivo Imaging 
 To avoid the auto-fluorescence often associated with animal fur, immunocompetent, 
hairless SKH1-E mice were employed for these studies and assigned to one of six treatment 
groups: 1.5 mL of sterile saline, 5 mg of nanoparticles (of three different chemistries) loaded 
with LSS 640 suspended in 1.5 mL of sterile saline, 200 μL of 1:1 sterile saline batched with 
Imject Alum (Pierce Rockford, IL) or 200 μL of 1:1 sterile saline emulsified in incomplete 
Freund’s adjuvant (IFA). To administer the same amount of fluorescent dye as present in the 
polyanhydride particles, LSS 640 was solubilized in saline (6.25 μg/mL). Each mouse was 
injected SC at the nape of the neck with 2.5 mg of particles in 330 μL saline, 1.75 mg of 
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particles in 230 μL of saline in the left rear flank intramuscularly (IM) and 0.75 mg in 100 μL of 
saline IM in the right rear flank. The three nanoparticle formulations used for these studies were 
20:80 CPH:SA, 50:50 CPTEG:CPH, and 20:80 CPTEG:CPH. IFA and Alum injections consisted 
of 100 μL SC at the nape of the neck, 75 μL IM in the left rear flank, and 25 μL IM in the right 
rear flank. The regimen for the administration of sterile saline with LSS 640 employed the same 
volumes as the nanoparticle injections. Rotational image capture was performed daily for 7 days 
after the injection with a Multimodal Animal Rotation System (Carestream Multispectral FX, 
Rochester, NY). In vivo images were captured while mice were anesthetized with 2% isoflurane 
in 100% O2, at 2.5 L/min. Images were captured using 60-second exposures with an excitation 
filter of 630 nm and emission filter of 790 nm. Rotational images consisted of exposures taken 
every 25° from 0° to 400° to provide sufficient overlap and create a full 360° rotational image of 
each mouse. All image analysis was performed using Image J software version 1.44. 27 Raw 
images were inverted and background subtracted via a rolling ball radius of 150 pixels. The 
ImageJ lookup table “thal” was applied to the data in Figures 1 and 2. A region of interest (ROI) 
was constructed and used to analyze mean fluorescence intensity (MFI) at the injection site of 
all mice for every image. The MFI of the ROI at the injection site of mice receiving particles was 
compared to the MFI of the ROI at the injection site measured immediately after administration 
of nanoparticles and the data is expressed as percent of initial fluorescence intensity. 
 
2.4.3. Nanoparticle and Adjuvant Inflammation 
 SKH1-E mice were injected with blank nanoparticles as outlined in the treatment groups 
described above. To evaluate the in vivo inflammatory response, mice were intravenously 
administered 2 nmol of ProSense 750 (VisEn Medical, Woburn, MA) 8 h prior to imaging on 
days 3 and 7 after the administration of the nanoparticles. ProSense 750 is an activatable 
fluorescent reagent that is optically visible when the dye is cleaved by degradative enzymes, 
including cathepsin B, L, S, or plasminogen, that are common at sites of inflammation.28 After 8 
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h, in vivo images were captured while mice were kept under anesthesia with 2% isoflurane in 
100% O2, at 2.5 L/min. Images were captured using 30-second exposures with an excitation 
filter of 730 nm and an emission filter of 790 nm. All image analysis was performed using 
ImageJ version 1.44.27 Raw images were inverted and background subtracted via a rolling ball 
radius of 150 pixels. The ImageJ lookup table “smart” was applied to the data in Figure 3. ROI 
analysis of injections sites was performed and mean fluorescence intensity (MFI) was 
quantified. 
 
2.4.4. Nanoparticle and Adjuvant Histological and Biomarker Examination 
 BALB/c mice were injected with a total of 5 mg of nanoparticles as described above. 
Other treatments included mice injected with Alum, IFA, or saline. Serum samples were 
collected from all mice prior to the administration of the nanoparticles and on days 3, 7, and 28 
after administration. Serum samples were obtained via saphenous vein bleeds. Serum, tissue, 
and urine samples were collected at necropsy. 
 
2.5. Serum Cytokine Analysis 
 Serum samples obtained from BALB/c mice were analyzed using a 22-plex chemokine 
and cytokine antibody array (Millipore, Billerica, MA) measuring the following analytes: G-CSF, 
GM-CSF, IFN-γ, IL-10, IL-12p70, IL-13, IL-15, IL-17, IL-1α, IL-1β, IL-2, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-9, IP-10, KC, MCP-1, MIP-1α, RANTES, and TNF-α. Assays were performed according to the 
manufacturer’s recommendations; data were acquired and analyzed using a Bio-Plex 200 (Bio 
Rad, Hercules, CA). 
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2.6. Biomarker Analysis 
 Serum and urinary biomarkers of kidney and liver function were analyzed using Vitros 
5.1 Chemistry Analyzer. Toxicological biomarker values were compared to those reported in 
Mazzaccara et al.29 
 
2.7. Histological Evaluation 
 Formalin-fixed tissues from BALB/c mice were embedded, sectioned, stained with 
hematoxylin and eosin (H&E), and blindly evaluated by a board-certified veterinary pathologist 
(JM Hostetter) for indications of toxicity in liver and kidney and adverse injection site reactions in 
muscle as well as in the epidermal and dermal tissue. A twenty-point histopathological scoring 
system for adverse reactions at injection sites was created in which scores of 0–5 were 
assigned to four independent parameters: inflammation, distribution of inflammatory cell 
infiltrate, muscle degeneration, and fibrosis. A fifteen-point histopathological scoring system for 
toxicological damage in liver and kidneys was created in which scores of 0 to 5 were assigned 
to three independent parameters: inflammation, distribution of inflammatory cell infiltrate, and 
tissue necrosis. 
 
2.8. Statistical Analysis 
 Cytokine values were log10 transformed and analyzed using repeated measure Analysis 
of Variance (ANOVA) models. Treatment and time were fixed effects in this model, while mouse 
was the subject of repeated measures. Histological, weight, and biomarker data were analyzed 
using one-way ANOVA models with treatment as an explanatory variable. Differences in mean 
responses among treatments were tested with an overall F-test followed by a post-hoc Tukey’s 
t-test. Statistical tests with p values ≤ 0.05 were regarded as significant. 
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3. RESULTS 
3.1. Nanoparticles Disseminated Away from the Injection Site Whereas Microparticles 
Formed a Depot 
 The estimated mean diameter of the LSS 640 fluorphore-loaded microparticles was 10 
μm (±400 nm) (Figure 1A) and that of the LSS 640 fluorphore-loaded nanoparticles was 400 nm 
(±100 nm) (Figure 1B). These sizes were consistent between particles of all chemistries and 
with previously published studies.19–21,23,30–34 The polymers were characterized by 1H NMR and 
the molecular weights were determined to be within published ranges.32  
 The effect of size on particle biodistribution was investigated following SC administration 
of 50:50 CPH:SA nanoparticles or microparticles using live animal in vivo imaging. At four days 
post-administration, nanoparticles were more widely disseminated in contrast to the 
microparticles (Figure 1C). Specifically, three dimensional image analysis revealed a single, 
more intense peak of fluorescence at the injection site of mice receiving microparticles (Figure 
1C). In contrast, multiple sites of discrete fluorescence were detected at tissue sites distal to the 
site of administration for mice receiving nanoparticles. This pattern of distribution observed 
following administration of the nanoparticles is not associated with the release of the tracer dye 
because at no time point after administration of the soluble tracer dye was a discrete pattern of 
fluorescence detected. 
 
3.2. In Vivo Persistence of Nanoparticles Mimicked That of Traditional Adjuvants When 
Administered Via Parenteral Routes 
 Traditional vaccine adjuvants, including Alum, are thought to elicit immune-enhancing 
effects partly by forming antigenic depots.3 In these studies, live animal in vivo imaging was 
employed to compare the deposition and persistence of polyanhydride nanoparticle adjuvants to 
those of traditional adjuvants. SKH1-E mice were administered a total of 5 mg of nanoparticles 
at three different injection sites as outlined in the methods (Figure 2A). Control mice were 
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administered saline containing the fluorescent dye (LSS 640), and other mice were 
administered the LSS 640 dye adsorbed onto Alum or emulsified into IFA. Rotational images of 
mice were captured at 7-day intervals; a representative image of a mouse from each treatment 
group is shown in Figure 2B. Mice administered Alum or IFA exhibited depot effects as 
demonstrated by the focal fluorescence present at the injection site after 7 days (Figure 2B). 
Each of the nanoparticle formulations provide a depot, however, there were lower amounts of 
fluorescence emanating from the injection sites, suggesting dissemination and/or erosion of the 
nanoparticles. Image analysis of injection site regions of interest (ROI) revealed chemistry-
dependent effects on particle persistence (Figure 2C). Fluorescence intensity diminished most 
rapidly (by 2 weeks post-injection) for 20:80 CPH:SA nanoparticles. Based on the fluorescence 
intensity, 50:50 CPTEG:CPH nanoparticles persisted for 6 weeks post-injection, while the 
fluorescent signal was detectable at the injection site for 12 weeks post-administration for the 
20:80 CPTEG:CPH nanoparticle formulation. 
 
3.3. Polyanhydride Nanoparticle Formulations Did Not Induce Deleterious Injection 
Site Reactions 
 To assess the biocompatibility and phlogistic properties of polyanhydride nanoparticles, 
the magnitude of the host inflammatory response to each nanoparticle formulation was 
compared to that induced by Alum or IFA. Local tissue inflammation was visualized in SKH1-E 
mice using ProSense 750, a fluorescent probe activated by enzymes released by inflammatory 
cells.35 At 3 days post-injection, the magnitude of the inflammation induced at the SC (nape of 
the neck) site of administration was significantly greater in IFA treated mice than in mice 
administered Alum or any formulation of polyanhydride nanoparticles (Figure 3). The IM 
injection of Alum (left flank) induced a more severe inflammatory reaction than that induced by 
nanoparticles or IFA. At 7 days post-injection, the relative intensity of the local inflammatory 
reactions at sites of nanoparticle administration was significantly lower (p ≤ 0.05) than that 
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observed in mice receiving Alum or IFA. These results indicate that the nanoparticles did not 
induce inflammation as a cumulative effect of particle persistence or degradation (see 
Supporting Information (SI), Figure S2). Furthermore, there was little to no evidence of local 
inflammation at 30 days post- injection for any of the treatment groups, even though the 
nanoparticles persisted in vivo for up to twelve weeks post-injection (data not shown).  
 The systemic inflammatory response of mice administered Alum, IFA, or nanoparticles 
was examined by assaying for inflammatory chemokines and cytokines in the serum at 3, 7, and 
30 days post-injection. At 3 days post-injection, levels of the monocyte-recruiting chemokines 
IP-10 and MCP-1 were elevated in the serum of mice administered CPTEG:CPH nanoparticles, 
Alum, or IFA compared to saline controls (Figure 4A–B). Of note, the MCP-1 and IP-10 levels 
remained elevated in mice administered Alum on day 7 post-injection while the levels for mice 
receiving other treatments were similar to the saline controls (Figure 4C-D). At 30 days post-
immunization, all cytokine levels were basal (data not shown).  
 Because polyanhydride nanoparticles persist in vivo, tissues from SC and IM injection 
sites were harvested at 30 days post-injection and evaluated for microscopic evidence of tissue 
damage and inflammation. The highest dosages of adjuvant were administered at the SC 
immunization site, and it was observed that the tissue response induced by Alum was 
histopathologically more severe than that induced by the nanoparticles or IFA (Figure 5A). 
Statistical differences were observed in only the 20:80 CPH:SA groups for both IM tissues sites 
indicating more inflammation associated with CPTEG:CPH chemistries (Figure 5B–C). Mice 
immunized with Alum had marked injection site reactions, characterized by muscle 
degeneration, inflammatory cell infiltrate, and fibrosis. Macrophage infiltrate was observed in all 
groups at the SC injection site; however, polymorphonuclear cell infiltrate was only noted in 
tissue recovered from mice treated with Alum, IFA, or 50:50 CPTEG:CPH nanoparticles. 
Granuloma formation was recorded in five of the six Alum treated mice at the SC injection site. 
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In contrast, only one mouse (50:50 CPTEG:CPH) was found to have granuloma formation 
across all the nanoparticle-treated mice. 
 
3.4. Minimal Toxicological Effects on Kidney and Liver Function Following 
Immunization with Polyanhydride Nanoparticles 
 Although enhanced tissue distribution of polyanhydride nanoparticles may provide 
immunological benefits, accumulation of CPTEG:CPH or CPH:SA nanoparticles in the liver or 
kidney could prove detrimental to normal physiological processes. Therefore, separate groups 
of mice were administered one of the three nanoparticle formulations, Alum or IFA and the 
appearance of serological biomarkers of liver or kidney damage was subsequently evaluated. 
 To measure liver function, total bilirubin, alanine aminotransferase (ALT) aspartate 
aminotransferase (AST) ratios, albumin, and lactate dehydrogenase were assayed using serum 
from mice at seven and 30 days post-treatment. Kidney function was evaluated by measuring 
changes in blood urea nitrogen (BUN), serum creatinine, and albumin in serum samples. For all 
parameters evaluated, no statistical differences were observed between nanoparticle treated 
mice in comparison to saline controls (Table 1). Similar results were observed at both 7 and 30 
days post-injection, indicating that there was no evidence of adverse responses at acute or 
chronic times post-treatment (see SI, Table S1).  
 Liver and kidney tissues were also examined both macroscopically and microscopically 
to identify structural or histological damage. No statistical differences in liver and kidney weights 
were observed for any adjuvant-treated mice as compared to controls (Figure 6A and B). 
Histopathological analysis revealed no significant indications of toxicity, inflammation, or 
necrosis in livers and kidneys from nanoparticle-treated mice (Figure 6C and D). While one 
mouse administered 20:80 CPTEG:CPH particles did present with focal signs of hepatic 
necrosis, the pathologist interpreted this lesion as being consistent with commonly observed 
tissue changes within the liver of BALB/c mice. Altogether, tissues analyzed from all mice, 
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regardless of treatment group, revealed normal histological features similar to those observed in 
the saline treated controls. 
 
4. DISCUSSION 
 Vaccine adjuvants must maintain a delicate balance between eliciting a robust antigen-
specific immune response and inducing an adverse reaction at the site of administration.3,4,36–39 
When administered subcutaneously, polyanhydride nanoparticles persisted at the injection site, 
providing an antigenic depot similar to that provided by Alum and IFA (Figure 2). However, 
unlike the traditional adjuvants, the nanoparticles provided the added advantage of 
disseminating throughout the body (Figure 1 and 2). Based on companion studies and the 
injection of soluble tracer dye, the distinct biodistribution observed was not a result of detecting 
tracer dye released from the nanoparticles but the dissemination of the nanoparticles 
themselves. Similar to the systemic spread of a pathogen, the capacity to distribute or 
disseminate throughout the body further supports the pathogen-mimicking potential of the 
polyanhydride nanoparticles.18,22 Measuring the presence of the dye-loaded nanoparticles over 
time demonstrated that polyanhydride nanoparticles persisted for up to 12 weeks in vivo , with 
polymer chemistry influencing the degree of persistence (Figure 2). Additional analyses 
evaluated the biocompatibility of the polyanhydride nanoparticle platform by comparing the 
inflammatory responses, injection site tissue responses, and liver and kidney functions from 
nanoparticle-treated mice to those of mice administered Alum or IFA (Figures 3 to 6). No 
indications of inflammation or adverse reactions associated with administration or degradation 
of the nanoparticles were observed.  
 In combination with our previous reports of nanoparticle-based vaccine potency and 
efficacy,19–21,23,32 the reactogenicity profile presented in this work further supports the in vivo use 
of polyanhydride nanoparticle adjuvants in vaccine formulations. Independent of chemistry, the 
nanoparticles presented unique biodistribution characteristics not observed with the 
222 
 
 
 
microparticles, including their ability to disperse from the injection site. We hypothesize that 
particle size and chemistry influences both dissemination to distal tissues and more efficient 
uptake by phagocytic cells that would contribute to tissue distribution and/or persistence of the 
nanoparticles.20,40 The observed persistence of the nanoparticles at injection sites resembles 
that of Alum and IFA; however, CPTEG:CPH nanoparticle chemistries appear to more readily 
disperse throughout the body and mimic the distribution patterns of pathogens.41–43  
 To date, the majority of in vivo immunization studies in murine models performed in our 
laboratories have employed a single 0.5 mg dose of the polyanhydride nanoparticles.21,23 The 
data presented herein demonstrated negligible inflammatory and adverse biological responses 
in mice subsequent to the administration of 5.0 mg (i.e., 10-fold higher amount) of polyanhydride 
nanoparticles as compared to Alum or IFA. IP-10, thought to be the chemokine primarily 
responsible for the efficacy of the yellow fever vaccine,44 was elevated in the nanoparticle-
treated mice, indicating monocytic recruitment. Collectively, our results indicate that although 
polyanhydride nanoparticles may mimic pathogens with respect to tissue distribution and 
phagocytic uptake,18–20 they do not, however, induce detrimental tissue destruction caused by 
extensive inflammatory cell infiltration.  
 The surface erosion characteristics of the polyanhydride nano particles enables them to 
persist in vivo as long or longer than other vaccine formulations. It is, therefore, critical that 
polyanhydride delivery systems be evaluated for the induction of both acute and chronic 
adverse toxicological reactions. In the present study, we observed no significant elevation of 
physiological biomarkers of liver or kidney damage in mice administered a 5 mg dose of 
nanoparticles (Table 1), suggesting that neither the nanoparticles nor their degradation products 
were adversely accumulating or altering liver or kidney functions. This finding is in agreement 
with previous studies where liver and kidney functions were fully preserved after implantation of 
a poly anhydride wafer used to treat human brain cancer.10,45 Together, these results 
demonstrate the non-toxic and biocompatible characteristics of polyanhydride nanoparticle-
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based vaccine carriers and support the hypothesis that their inherent physicochemical 
properties (e.g., degradation kinetics and pathogen-mimicking ability, leading to dissemination 
and persistence) positively affect the immune response by inducing long-lived, protective 
immunity.22 
 
5. CONCLUSIONS 
 Developing adjuvants that balance enhancing innate and adaptive immune responses 
while simultaneously limiting the induction of non-specific adverse events are a challenge for 
vaccinology. The results of this study indicate that administration of larger doses of 
polyanhydride nanoparticles are more biocompatible than nominal doses of traditional adjuvants 
such as Alum and IFA. The nanoparticles disseminated rapidly into tisssues distal to the 
administration site, and persisted for as long as 12 weeks, potentially providing a basis for the 
induction of long-lived immunity. Furthermore, administration of a 5 mg dose of polyanhydride 
particles resulted in no adverse effects as evidenced by the lack of biomarkers of liver and 
kidney damage and/or dysfunction, affirming the biocompatibility of these materials. The data 
herein also outline the inherent adjuvant activity of polyanhydride nanoparticles that stimulates 
immune responses with minimal lesion development at the site of administration. These data 
offer an initial standard for translating polyanhydride nanomaterials into use as a vaccine 
delivery platform for humans and animals. 
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6. TABLES 
 
Table 1. No elevated biomarkers of liver or kidney damage in serum of mice 30 days after 
injections with polyanhydride nanoparticles. Enzymatic tests, synopsis of test, and normal 
ranges are indicated in the first three columns. Values are presented as the mean ± SEM. 
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7. FIGURES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Nanoparticles disseminated away from the injection site, whereas 
microparticles formed a depot. Scanning electron photomicrographs of 50:50 CPH:SA (A) 
micro- (scale bar 20 μm) or (B) nanoparticles (scale bar 2 μm). C) Representative 3D surface 
plot for a BALB/c mouse 4 days after SC administration of 500 μg of 50:50 CPH:SA micro- (left) 
or nanoparticles (right) graphed as a function of platform location ( x - and y -axes) and 
fluorescent intensity ( z -axis). x - and y -axes represent size (in millimeters) of field of view; z -
axis represents fluorescence intensity. 
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Figure 2. In vivo persistence of nanoparticles mimicked that of traditional adjuvants 
when administered via parenteral routes. A) Schematic of dosing regimen for mice injected 
with either polyanhydride nanoparticles or traditional adjuvants. B) In vivo imaging of mice 
injected with a total of 5 mg of 20:80 CPH:SA, 20:80 CPTEG:CPH, or 50:50 CPTEG:CPH 
nanoparticles loaded with fluorescent dye or administered with the fluorescent dye adsorbed 
onto Alum or emulsified into incomplete Freund’s adjuvant (IFA). Images were captured at 7 
days post-injection. Fluorescence intensity calibration bar is located in bottom right corner. C) 
Fluorescence extinction of dye at injection sites. Data depict the percent of fluorescence 
intensity of the SC region of interest (ROI) at the nape of the neck as compared to the 
fluorescence intensity of the initial image taken immediately after administration. n = 2 mice per 
group. 
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Figure 3. Polyanhydride nanoparticles induced less inflammation-associated enzymatic 
activity than traditional adjuvants. At 3 days post-injection, mice were administered 
ProSense 750, a protease activatable fluorescent imaging agent activated by cathepsins B, L, 
S, and Plasmin at sites of inflammation. ProSense 750 is optically silent in its inactivated state 
and becomes highly fluorescent following protease-mediated activation. A) Images were 
captured 8 hours after ProSense 750 administration. B) Data depict the mean of the 
fluorescence intensity of the ROI’s of the three injection sites. n = 2 mice per group. 
 
 
228 
 
 
 
 
 
 
Figure 4. Increased levels of the monocyte-recruiting chemokines IP-10 and MCP-1 in the 
serum of mice administered either nanoparticles, Alum, or IFA. Concentrations of (A–B) IP-
10 and (C–D) MCP-1 in the serum of mice administered a 5.0 mg dose of 20:80 CPH:SA, 20:80 
CPTEG:CPH, or 50:50 CPTEG:CPH nanoparticles, Alum, IFA, or saline at 3 (A and C) or 7 
days post-injection (B and D). Treatment groups marked with # are significantly different from 
the Alum treatment group at p < 0.05. n = 6–7 mice per group. 
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Figure 5. Polyanhydride nanoparticle 
formulations did not induce 
deleterious injection site reactions. 
Composite histopathological scores of 
injection site subcutaneous tissue (A), 
left muscle (B), and right muscle (C) 
from mice administered 20:80 CPH:SA, 
20:80 CPTEG:CPH, 50:50 CPTEG:CPH 
nanoparticles, Alum, IFA, or saline at 30 
days post-administration. Treatment 
groups marked with # are significantly 
different from the Alum treatment group 
at p < 0.05. n = 6–13 mice per group. 
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Figure 6. Minimal toxicological effects on kidney and liver function following 
immunization with polyanhydride nanoparticles. A,B) Livers and kidneys from immunized 
mice were weighed at 30 days post-injection; no significant differences among treatments were 
observed. C,D) Composite histopathological scores of liver and kidney tissues from mice 
administered 20:80 CPH:SA, 20:80 CPTEG:CPH, 50:50 CPTEG:CPH nanoparticles, Alum, IFA, 
or saline at 30 days post-administration; no significant differences from healthy controls were 
observed. n = 6–13 mice per group. 
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